Guide rna with chemical modifications

ABSTRACT

The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/757,204, filed Dec. 3, 2015, allowed, which claims the benefit of U.S. Provisional Application No. 62/256,095, filed Nov. 16, 2015, U.S. Provisional Application No. 62/146,189, filed Apr. 10, 2015, and U.S. Provisional Application No. 62/087,211, filed Dec. 3, 2014, the contents of each of which is incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 19, 2020, is named 20150013_13_SL.txt and is 114,989 bytes in size.

FIELD OF THE INVENTION

The present invention relates to the field of molecular biology. In particular, the present invention relates to the clusters of regularly interspaced short palindromic repeats (CRISPR) technology.

BACKGROUND OF THE INVENTION

The native prokaryotic CRISPR-Cas system comprises an array of short repeats with intervening variable sequences of constant length (i.e., clusters of regularly interspaced short palindromic repeats, or “CRISPR”), and CRISPR-associated (“Cas”) proteins. The RNA of the transcribed CRISPR array is processed by a subset of the Cas proteins into small guide RNAs, which generally have two components as discussed below. There are at least three different systems: Type I, Type II and Type III. The enzymes involved in the processing of the RNA into mature crRNA are different in the 3 systems. In the native prokaryotic system, the guide RNA (“gRNA”) comprises two short, non-coding RNA species referred to as CRISPR RNA (“crRNA”) and trans-acting RNA (“tracrRNA”). In an exemplary system, the gRNA forms a complex with a Cas nuclease. The gRNA:Cas nuclease complex binds a target polynucleotide sequence having a protospacer adjacent motif (“PAM”) and a protospacer, which is a sequence complementary to a portion of the gRNA. The recognition and binding of the target polynucleotide by the gRNA:Cas nuclease complex induces cleavage of the target polynucleotide. The native CRISPR-Cas system functions as an immune system in prokaryotes, where gRNA:Cas nuclease complexes recognize and silence exogenous genetic elements in a manner analogous to RNAi in eukaryotic organisms, thereby conferring resistance to exogenous genetic elements such as plasmids and phages.

It has been demonstrated that a single-guide RNA (“sgRNA”) can replace the complex formed between the naturally-existing crRNA and tracrRNA.

Considerations relevant to developing a gRNA, including a sgRNA, include specificity, stability, and functionality. Specificity refers to the ability of a particular gRNA:Cas nuclease complex to bind to and/or cleave a desired target sequence, whereas little or no binding and/or cleavage of polynucleotides different in sequence and/or location from the desired target occurs. Thus, specificity refers to minimizing off-target effects of the gRNA:Cas nuclease complex. Stability refers to the ability of the gRNA to resist degradation by enzymes, such as nucleases, and other substances that exist in intra-cellular and extra-cellular environments. Thus, there is a need for providing gRNA, including sgRNA, having increased resistance to nucleolytic degradation, increased binding affinity for the target polynucleotide, and/or reduced off-target effects while, nonetheless, having gRNA functionality. Further considerations relevant to developing a gRNA include transfectability and immunostimulatory properties. Thus, there is a need for providing gRNA, including sgRNA, having efficient and titratable transfectability into cells, especially into the nuclei of eukaryotic cells, and having minimal or no immunostimulatory properties in the transfected cells. Another important consideration for gRNA is to provide an effective means for delivering it into and maintaining it in the intended cell, tissue, bodily fluid or organism for a duration sufficient to allow the desired gRNA functionality.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a set of diagrams showing a schematic model of an exemplary CRISPR-Cas system. The exemplary system shown here is a Type II system having a Cas nuclease. In this particular example, the Cas nuclease is the Cas9 nuclease. The Cas9 nuclease recognizes a PAM sequence (here, the PAM sequence is a 3-nt sequence of NGG, where N is A, G, C or T, but other PAM sequences are known to exist). The sgRNA includes a guide sequence, a crRNA sequence or segment, and tracrRNA sequence or segment. The guide sequence of the sgRNA hybridizes with the DNA target directly upstream of the PAM sequence. In the example shown here, Cas9 mediates a double-stranded break upstream of the PAM sequence (arrows).

FIG. 2A is a diagram showing an exemplary CRISPR-Cas9-mediated cleavage assay.

FIG. 2B is a table showing components and their concentrations for a biochemical cleavage assay used to generate the data in FIG. 4.

FIG. 2C is a diagram showing titration of Streptococcus pyogenes Cas9 nuclease for the biochemical cleavage assay.

FIG. 2D is a diagram showing titration of an exemplary sgRNA for the biochemical cleavage assay. In this example a sgRNA named kanC1 is targeted to a complementary sequence in the kanamycin resistance gene.

FIG. 3 shows exemplary conditions and procedures for the biochemical cleavage assay which uses purified components in vitro.

FIG. 4 is a table showing the data obtained using exemplary modified guide RNAs in the cleavage assay.

FIG. 5A shows an exemplary guide RNA disclosed in the application.

FIG. 5B shows an exemplary single guide RNA (sgRNA) disclosed in the application.

FIG. 6 is a table showing exemplary guide RNAs having at least two chemical modifications (e.g., a first modification and a second modification). Each number represents a modification as indicated and each “x” indicates the combination of modifications in a guide RNA. In certain embodiments, the first and second modifications are present on a single nucleotide. In certain embodiments, the first and second modifications are present on separate nucleotides.

FIG. 7 shows exemplary types of guide RNAs having at least three chemical modifications. The lower part of FIG. 7 lists several types of modifications. The table in the upper part of FIG. 7 indicates how a double modification (“double mod,” a combination of two types of modifications) can be combined with a single modification (“single mod,” one type of modification). An “x” indicates the presence of the corresponding double mod and single mod in a guide RNA.

FIGS. 8A and 8B show fluorophore-modified CLTA1 sgRNAs for in vitro testing. In FIG. 8A, the RNA sequence (SEQ ID NO: 135) of a sgRNA for CLTA1 is shown, including a position where a fluorescent dye or a label could be attached to the sgRNA. Target DNA is SEQ ID NO: 134. FIG. 8B shows a structure determined by Xray crystallography of a Cas9:sgRNA complex, as reported in Nishimasu et al., Cell (2014) 156, 1-15.

FIG. 9A shows CLTA1 sgRNAs modified with 2-thiouridine at certain locations (positions 3, 9 and 11) in an effort to improve specificity for the target CTLA1. Top strand and bottom strand sequences (respectively) of the CTLA1 targets are: ON1 (SEQ ID NOs: 136 and 137); OFF1 (SEQ ID NOs: 138 and 139); OFF2 (SEQ ID NOs: 140 and 141); and OFF3 (SEQ ID NOs: 142 and 143). FIG. 9B shows that gRNA modified with 2-thioU (SEQ ID NO: ###) can increase target specificity of the gRNAs when off-target sites involve U-G wobble pairing. In particular, the CTLA1_2thioU+11 had much lower cleavage of the off-target sequence CLTA1 OFF3, which has a T to C mutation at the 11 position in the 5′ strand. Top strand and bottom strand sequences (respectively) of the CTLA1 targets are: ON1 (SEQ ID NOs: 136 and 137); OFF1 (SEQ ID NOs: 138 and 139); and OFF3 (SEQ ID NOs: 142 and 143).

FIG. 10 shows the guide RNA scaffold secondary structure, displaying noncovalent binding interactions with amino acids of Cas9, as reported in Jiang et al., Science (2015) 348:6242, 1477-81.

FIGS. 11A and 11B illustrate experimental results showing that gene disruption in human cell lines, with high frequencies of indels and homologous recombination (HR), can be achieved using synthesized and chemically modified sgRNAs disclosed herein, as reported in Hendel et al., Nat. Biotechnol. (2015) 33:9, 985-9.

FIGS. 12A, 12B, 12C and 12D illustrate experimental results showing that chemically modified sgRNAs as described herein can be used to achieve high frequencies of gene disruption or targeted genome editing in stimulated primary human T cells as well as in CD34+ hematopoietic stem and progenitor cells (HSPCs), as reported in Hendel et al., Nat. Biotechnol. (2015) 33:9, 985-9.

DETAILED DESCRIPTION OF THE INVENTION

This invention is based, at least in part, on an unexpected discovery that certain chemical modifications to gRNA are tolerated by the CRISPR-Cas system. In particular, certain chemical modifications believed to increase the stability of the gRNA, to alter the thermostability of a gRNA hybridization interaction, and/or to decrease the off-target effects of Cas:gRNA complexation do not substantially compromise the efficacy of Cas:gRNA binding to, nicking of, and/or cleavage of the target polynucleotide. Furthermore, certain chemical modifications are believed to provide gRNA, including sgRNA, having efficient and titratable transfectability into cells, especially into the nuclei of eukaryotic cells, and/or having minimal or no immunostimulatory properties in the transfected cells. Certain chemical modifications are believed to provide gRNA, including sgRNA, which can be effectively delivered into and maintained in the intended cell, tissue, bodily fluid or organism for a duration sufficient to allow the desired gRNA functionality.

I. Definitions

As used herein, the term “guide RNA” generally refers to an RNA molecule (or a group of RNA molecules collectively) that can bind to a Cas protein and aid in targeting the Cas protein to a specific location within a target polynucleotide (e.g., a DNA). A guide RNA can comprise a crRNA segment and a tracrRNA segment. As used herein, the term “crRNA” or “crRNA segment” refers to an RNA molecule or portion thereof that includes a polynucleotide-targeting guide sequence, a stem sequence, and, optionally, a 5′-overhang sequence. As used herein, the term “tracrRNA” or “tracrRNA segment” refers to an RNA molecule or portion thereof that includes a protein-binding segment (e.g., the protein-binding segment is capable of interacting with a CRISPR-associated protein, such as a Cas9). The term “guide RNA” encompasses a single guide RNA (sgRNA), where the crRNA segment and the tracrRNA segment are located in the same RNA molecule. The term “guide RNA” also encompasses, collectively, a group of two or more RNA molecules, where the crRNA segment and the tracrRNA segment are located in separate RNA molecules.

The term “scaffold” refers to the portions of guide RNA molecules comprising sequences which are substantially identical or are highly conserved across natural biological species. Scaffolds include the tracrRNA segment and the portion of the crRNA segment other than the polynucleotide-targeting guide sequence at or near the 5′ end of the crRNA segment, excluding any unnatural portions comprising sequences not conserved in native crRNAs and tracrRNAs.

The term “nucleic acid”, “polynucleotide” or “oligonucleotide” refers to a DNA molecule, an RNA molecule, or analogs thereof. As used herein, the terms “nucleic acid”, “polynucleotide” and “oligonucleotide” include, but are not limited to DNA molecules such as cDNA, genomic DNA or synthetic DNA and RNA molecules such as a guide RNA, messenger RNA or synthetic RNA. Moreover, as used herein, the terms “nucleic acid” and “polynucleotide” include single-stranded and double-stranded forms.

The term “modification” in the context of an oligonucleotide or polynucleotide includes but is not limited to (a) end modifications, e.g., 5′ end modifications or 3′ end modifications, (b) nucleobase (or “base”) modifications, including replacement or removal of bases, (c) sugar modifications, including modifications at the 2′, 3′, and/or 4′ positions, and (d) backbone modifications, including modification or replacement of the phosphodiester linkages. The term “modified nucleotide” generally refers to a nucleotide having a modification to the chemical structure of one or more of the base, the sugar, and the phosphodiester linkage or backbone portions, including nucleotide phosphates.

The terms “Z” and “P” refer to the nucleotides, nucleobases, or nucleobase analogs developed by Steven Benner and colleagues as described for example in “Artificially expanded genetic information system: a new base pair with an alternative hydrogen bonding pattern” Yang, Z., Hutter, D., Sheng, P., Sismour, A. M. and Benner, S. A. (2006) Nucleic Acids Res., 34, 6095-101, the contents of which is hereby incorporated by reference in its entirety.

The terms “xA”, “xG”, “xC”, “xT”, or “x(A,G,C,T)” and “yA”, “yG”, “yC”, “yT”, or “y(A,G,C,T)” refer to nucleotides, nucleobases, or nucleobase analogs as described by Krueger et al in “Synthesis and Properties of Size-Expanded DNAs: Toward Designed, Functional Genetic Systems”; Andrew T. Krueger, Haige Lu, Alex H. F. Lee, and Eric T. Kool (2007) Acc. Chem. Res., 40, 141-50, the contents of which is hereby incorporated by reference in its entirety.

The term “Unstructured Nucleic Acid” or “UNA” refers to nucleotides, nucleobases, or nucleobase analogs as described in U.S. Pat. No. 7,371,580, the contents of which is hereby incorporated by reference in its entirety. An unstructured nucleic acid, or UNA, modification is also referred to as a “pseudo-complementary” nucleotide, nucleobase or nucleobase analog (see e.g., Lahoud et al. (1991) Nucl. Acids Res., 36:10, 3409-19).

The terms “PACE” and “thioPACE” refer to internucleotide phosphodiester linkage analogs containing phosphonoacetate or thiophosphonoacetate groups, respectively. These modifications belong to a broad class of compounds comprising phosphonocarboxylate moiety, phosphonocarboxylate ester moiety, thiophosphonocarboxylate moiety and thiophosphonocarboxylate ester moiety. These linkages can be described respectively by the general formulae P(CR1R2)nCOOR and (S)—P(CR1R2)nCOOR wherein n is an integer from 0 to 6 and each of R1 and R2 is independently selected from the group consisting of H, an alkyl and substituted alkyl. Some of these modifications are described by Yamada et al. in “Synthesis and Biochemical Evaluation of Phosphonoformate Oligodeoxyribonucleotides” Christina M. Yamada, Douglas J. Dellinger and Marvin H. Caruthers (2006) J. Am. Chem. Soc. 128:15, 5251-61, the contents of which is hereby incorporated by reference in its entirety.

As used herein, “modification” refers to a chemical moiety, or portion of a chemical structure, which differs from that found in unmodified ribonucleotides, namely adenosine, guanosine, cytidine, and uridine ribonucleotides. The term “modification” may refer to type of modification. For example, “same modification” means same type of modification, and “the modified nucleotides are the same” means the modified nucleotides have the same type(s) of modification while the base (A, G, C, U, etc.) may be different. Similarly, a guide RNA with “two modifications” is a guide RNA with two types of modifications, which may or may not be in the same nucleotide, and each type may appear in multiple nucleotides in the guide RNA. Similarly, a guide RNA with “three modifications” is a guide RNA with three types of modifications, which may or may not be in the same nucleotide, and each type may appear in multiple nucleotides.

As used herein, the term “target polynucleotide” or “target” refers to a polynucleotide containing a target nucleic acid sequence. A target polynucleotide may be single-stranded or double-stranded, and, in certain embodiments, is double-stranded DNA. In certain embodiments, the target polynucleotide is single-stranded RNA. A “target nucleic acid sequence” or “target sequence,” as used herein, means a specific sequence or the complement thereof that one wishes to bind to, nick, or cleave using a CRISPR system.

The term “hybridization” or “hybridizing” refers to a process where completely or partially complementary polynucleotide strands come together under suitable hybridization conditions to form a double-stranded structure or region in which the two constituent strands are joined by hydrogen bonds. As used herein, the term “partial hybridization” includes where the double-stranded structure or region contains one or more bulges or mismatches. Although hydrogen bonds typically form between adenine and thymine or adenine and uracil (A and T or A and U) or cytosine and guanine (C and G), other noncanonical base pairs may form (See e.g., Adams et al., “The Biochemistry of the Nucleic Acids,” 11th ed., 1992). It is contemplated that modified nucleotides may form hydrogen bonds that allow or promote hybridization.

The term “cleavage” or “cleaving” refers to breaking of the covalent phosphodiester linkage in the ribosylphosphodiester backbone of a polynucleotide. The terms “cleavage” or “cleaving” encompass both single-stranded breaks and double-stranded breaks. Double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Cleavage can result in the production of either blunt ends or staggered ends.

The term “CRISPR-associated protein” or “Cas protein” refers to a wild type Cas protein, a fragment thereof, or a mutant or variant thereof. The term “Cas mutant” or “Cas variant” refers to a protein or polypeptide derivative of a wild type Cas protein, e.g., a protein having one or more point mutations, insertions, deletions, truncations, a fusion protein, or a combination thereof. In certain embodiments, the “Cas mutant” or “Cas variant” substantially retains the nuclease activity of the Cas protein. In certain embodiments, the “Cas mutant” or “Cas variant” is mutated such that one or both nuclease domains are inactive. In certain embodiments, the “Cas mutant” or “Cas variant” has nuclease activity. In certain embodiments, the “Cas mutant” or “Cas variant” lacks some or all of the nuclease activity of its wild-type counterpart.

The term “nuclease domain” of a Cas protein refers to the polypeptide sequence or domain within the protein which possesses the catalytic activity for DNA cleavage. A nuclease domain can be contained in a single polypeptide chain, or cleavage activity can result from the association of two (or more) polypeptides. A single nuclease domain may consist of more than one isolated stretch of amino acids within a given polypeptide. Examples of these domains include RuvC-like motifs (amino acids 7-22, 759-766 and 982-989 in SEQ ID NO: 1) and HNH motif (aa 837-863). See Gasiunas et al. (2012) Proc. Natl. Acad. Sci. USA, 109:39, E2579-E2586 and WO2013176772.

A synthetic guide RNA that has “gRNA functionality” is one that has one or more of the functions of naturally occurring guide RNA, such as associating with a Cas protein, or a function performed by the guide RNA in association with a Cas protein. In certain embodiments, the functionality includes binding a target polynucleotide. In certain embodiments, the functionality includes targeting a Cas protein or a gRNA:Cas protein complex to a target polynucleotide. In certain embodiments, the functionality includes nicking a target polynucleotide. In certain embodiments, the functionality includes cleaving a target polynucleotide. In certain embodiments, the functionality includes associating with or binding to a Cas protein. In certain embodiments, the functionality is any other known function of a guide RNA in a CRISPR-Cas system with a Cas protein, including an artificial CRISPR-Cas system with an engineered Cas protein. In certain embodiments, the functionality is any other function of natural guide RNA. The synthetic guide RNA may have gRNA functionality to a greater or lesser extent than a naturally occurring guide RNA. In certain embodiments, a synthetic guide RNA may have greater functionality as to one property and lesser functionality as to another property in comparison to a similar naturally occurring guide RNA.

A “Cas protein having a single-strand nicking activity” refers to a Cas protein, including a Cas mutant or Cas variant, that has reduced ability to cleave one of two strands of a dsDNA as compared to a wild type Cas protein. For example, in certain embodiments, a Cas protein having a single-strand nicking activity has a mutation (e.g., amino acid substitution) that reduces the function of the RuvC domain (or the HNH domain) and as a result reduces the ability to cleave one strand of the target DNA. Examples of such variants include the D10A, H839A/H840A, and/or N863A substitutions in S. pyogenes Cas9, and also include the same or similar substitutions at equivalent sites in Cas9 enzymes of other species.

As used herein, the term “portion” or “fragment” of a sequence refers to any portion of the sequence (e.g., a nucleotide subsequence or an amino acid subsequence) that is smaller than the complete sequence. Portions of polynucleotides can be any length, for example, at least 5, 10, 15, 20, 25, 30, 40, 50, 75, 100, 150, 200, 300 or 500 or more nucleotides in length. A portion of a guide sequence can be about 50%, 40%, 30%, 20%, 10% of the guide sequence, e.g., one-third of the guide sequence or shorter, e.g., 7, 6, 5, 4, 3, or 2 nucleotides in length.

The term “derived from” in the context of a molecule refers to a molecule isolated or made using a parent molecule or information from that parent molecule. For example, a Cas9 single mutant nickase and a Cas9 double mutant null-nuclease are derived from a wild-type Cas9 protein.

The term “substantially identical” in the context of two or more polynucleotides (or two or more polypeptides) refers to sequences or subsequences that have at least about 60%, at least about 70%, at least about 80%, at least about 90%, about 90-95%, at least about 95%, at least about 98%, at least about 99% or more nucleotide (or amino acid) sequence identity, when compared and aligned for maximum correspondence using a sequence comparison algorithm or by visual inspection. Preferably, the “substantial identity” between polynucleotides exists over a region of the polynucleotide at least about 50 nucleotides in length, at least about 100 nucleotides in length, at least about 200 nucleotides in length, at least about 300 nucleotides in length, at least about 500 nucleotides in length, or over the entire length of the polynucleotide. Preferably, the “substantial identity” between polypeptides exists over a region of the polypeptide at least about 50 amino acid residues in length, at least about 100 amino acid residues in length, or over the entire length of the polypeptide.

As disclosed herein, a number of ranges of values are provided. It is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range is also specifically contemplated. Each smaller range or intervening value encompassed by a stated range is also specifically contemplated. The term “about” generally refers to plus or minus 10% of the indicated number. For example, “about 10%” may indicate a range of 9% to 11%, and “about 20” may mean from 18-22. Other meanings of “about” may be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.

II. CRISPR-Mediated Sequence-Specific Binding and/or Cleavage

Shown in FIG. 1 is a diagram of CRISPR-Cas9-mediated sequence-specific cleavage of DNA. The guide RNA is depicted as sgRNA with an exemplary 20-nucleotide (20-nt) guide sequence (other guide sequences may be, for example, from about 15 to about 30 nts in length) within the 5′ domain, an internally positioned base-paired stem, and a 3′ domain. The guide sequence is complementary to an exemplary 20-nt target sequence in a DNA target. The stem corresponds to a repeat sequence in crRNA and is complementary to a sequence in the tracrRNA. The 3′ domain of the guide RNA corresponds to the 3′ domain of the tracrRNA that binds a Cas9 nuclease. The Cas9:guide RNA complex binds and cleaves a target DNA sequence or protospacer directly upstream of a PAM sequence recognized by Cas9. In FIG. 1, a 3-nt PAM sequence is exemplified; however other PAM sequences, including 4-nt and 5-nt PAM sequences are known. In the system exemplified in FIG. 1, both strands of the target sequence in DNA are cleaved by Cas9 at the sites indicated by arrows.

III. Guide RNAs

In at least one aspect, the present invention comprises a chemically modified guide RNA that has guide RNA functionality. A guide RNA that comprises any nucleotide other than the four canonical ribonucleotides, namely A, C, G, and U, whether unnatural or natural (e.g., a pseudouridine, inosine or a deoxynucleotide), is a chemically modified guide RNA. Likewise a guide RNA that comprises any backbone or internucleotide linkage other than a natural phosphodiester internucleotide linkage possesses a chemical modification and therefore is a chemically modified guide RNA. In certain embodiments, the retained functionality includes binding a Cas protein. In certain embodiments, the retained functionality includes binding a target polynucleotide. In certain embodiments, the retained functionality includes targeting a Cas protein or a gRNA:Cas protein complex to a target polynucleotide. In certain embodiments, the retained functionality includes nicking a target polynucleotide by a gRNA:Cas protein complex. In certain embodiments, the retained functionality includes cleaving a target polynucleotide by a gRNA:Cas protein complex. In certain embodiments, the retained functionality is any other known function of a guide RNA in a CRISPR-Cas system with a Cas protein, including an artificial CRISPR-Cas system with an engineered Cas protein. In certain embodiments, the retained functionality is any other function of a natural guide RNA.

A. Exemplary Modifications

In certain embodiments, a nucleotide sugar modification incorporated into the guide RNA is selected from the group consisting of 2′-O—C1-4alkyl such as 2′-O-methyl (2′-OMe), 2′-deoxy (2-H), 2′-O—C1-3alkyl-O—C1-3alkyl such as 2′-methoxyethyl (“2′-MOE”), 2′-fluoro (“2-F”),2′-amino (“2′-NH2”), 2′-arabinosyl (“2′-arabino”) nucleotide, 2′-F-arabinosyl (“2′-F-arabino”) nucleotide, 2′-locked nucleic acid (“LNA”) nucleotide, 2′-unlocked nucleic acid (“ULNA”) nucleotide, a sugar in L form (“L-sugar”), and 4′-thioribosyl nucleotide. In certain embodiments, an internucleotide linkage modification incorporated into the guide RNA is selected from the group consisting of: phosphorothioate “P(S)” (P(S)), phosphonocarboxylate (P(CH2)nCOOR) such as phosphonoacetate “PACE” (P(CH2COO—)), thiophosphonocarboxylate ((S)P(CH2)nCOOR) such as thiophosphonoacetate “thioPACE” ((S)P(CH2COO—)), alkylphosphonate (P(C1-3alkyl) such as methylphosphonate —P(CH3), boranophosphonate (P(BH3)), and phosphorodithioate (P(S)2).

In certain embodiments, a nucleobase (“base”) modification incorporated into the guide RNA is selected from the group consisting of: 2-thiouracil (“2-thioU”), 2-thiocytosine (“2-thioC”), 4-thiouracil (“4-thioU”), 6-thioguanine (“6-thioG”), 2-aminoadenine (“2-aminoA”), 2-aminopurine, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylcytosine (“5-methylC”), 5-methyluracil (“5-methylU”), 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allyluracil (“5-allylU”), 5-allylcytosine (“5-allylC”), 5-aminoallyluracil (“5-aminoallylU”), 5-aminoallyl-cytosine (“5-aminoallylC”), an abasic nucleotide, Z base, P base, Unstructured Nucleic Acid (“UNA”), isoguanine (“isoG”), isocytosine (“isoC”) [as described in “Enzymatic Incorporation of a New Base pair into DNA and RNA Extends the Genetic Alphabet.” Piccirilli, J. A.; Krauch, T.; Moroney, S. E.; Benner, S. A. (1990) Nature, 343, 33], 5-methyl-2-pyrimidine [as described in Rappaport, H. P. (1993) Biochemistry, 32, 3047], x(A,G,C,T) and y(A,G,C,T).

In certain embodiments, one or more isotopic modifications are introduced on the nucleotide sugar, the nucleobase, the phosphodiester linkage and/or the nucleotide phosphates. Such modifications include nucleotides comprising one or more 15N, 13C, 14C, Deuterium, 3H, 32P, 125I, 131I atoms or other atoms or elements used as tracers.

In certain embodiments, an “end” modification incorporated into the guide RNA is selected from the group consisting of: PEG (polyethyleneglycol), hydrocarbon linkers (including: heteroatom (O,S,N)-substituted hydrocarbon spacers; halo-substituted hydrocarbon spacers; keto-, carboxyl-, amido-, thionyl-, carbamoyl-, thionocarbamaoyl-containing hydrocarbon spacers), spermine linkers, dyes including fluorescent dyes (for example fluoresceins, rhodamines, cyanines) attached to linkers such as for example 6-fluorescein-hexyl, quenchers (for example dabcyl, BHQ) and other labels (for example biotin, digoxigenin, acridine, streptavidin, avidin, peptides and/or proteins). In certain embodiments, an “end” modification comprises a conjugation (or ligation) of the guide RNA to another molecule comprising an oligonucleotide (comprising deoxynucleotides and/or ribonucleotides), a peptide, a protein, a sugar, an oligosaccharide, a steroid, a lipid, a folic acid, a vitamin and/or other molecule. In certain embodiments, an “end” modification incorporated into the guide RNA is located internally in the guide RNA sequence via a linker such as for example 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker (depicted below), which is incorporated as a phosphodiester linkage and can be incorporated anywhere between two nucleotides in the guide RNA.

2-(4-butylamidorescein)propane-1,3-diol bis(phosphodiester) linker

Other linkers include for example by way of illustration, but are not limited to:

2-(3-dye-amido)propanamido)propane-1,3-diol bis(phosphodiester) linker

In certain embodiments, the end modification comprises a terminal functional group such as an amine, a thiol (or sulfhydryl), a hydroxyl, a carboxyl, carbonyl, thionyl, thiocarbonyl, a carbamoyl, a thiocarbamoyl, a phoshoryl, an alkene, an alkyne, an halogen or a functional group-terminated linker, either of which can be subsequently conjugated to a desired moiety, for example a fluorescent dye or a non-fluorescent label or tag or any other molecule such as for example an oligonucleotide (comprising deoxynucleotides and/or ribonucleotides, including an aptamer), an amino acid, a peptide, a protein, a sugar, an oligosaccharide, a steroid, a lipid, a folic acid, a vitamin. The conjugation employs standard chemistry well-known in the art, including but not limited to coupling via N-hydroxysuccinimide, isothiocyanate, DCC (or DCI), and/or any other standard method as described in “Bioconjugate Techniques” by Greg T. Hermanson, Publisher Eslsevier Science, 3rd ed. (2013), the contents of which are incorporated herein by reference in their entireties.

In certain embodiments, the label or dye is attached or conjugated to a modified nucleotide in the gRNA. The conjugation of a fluorescent dye or other moiety such as a non-fluorescent label or tag (for example biotin, avidin, streptavidin, or moiety containing an isotopic label such as 15N, 13C, 14C, Deuterium, 3H, 32P, 125I and the like) or any other molecule such as for example an oligonucleotide (comprising deoxynucleotides and/or ribonucleotides including an aptamer), an amino acid, a peptide, a protein, a sugar, an oligosaccharide, a steroid, a lipid, a folic acid, a vitamin or other molecule can be effectuated using the so-called “click” chemistry or the so-called “squarate” conjugation chemistry. The “click” chemistry refers to the [3+2] cycloaddition of an alkyne moiety with an azide moiety, leading to a triazolo linkage between the two moieties as shown in the following scheme:

as described for example in El-Sagheer, A. H and Brown, T. “Click chemistry with DNA”, Chem. Soc. Rev., 2010, 39, 1388-1405 and Mojibul, H. M. and XiaoHua, P., DNA-associated click chemistry, Sci. China Chem., 2014, 57:2, 215-31, the contents of which are hereby incorporated by reference in their entirety.

In certain embodiments, the conjugation can be effectuated by alternative cycloaddition such as Diels-Alder [4+2] cycloaddition of a Q-conjugated diene moiety with an alkene moiety.

The “squarate” conjugation chemistry links two moieties each having an amine via a squarate derivative to result in a squarate conjugate that contains a squarate moiety (see e.g., Tietze et al. (1991) Chem. Ber., 124, 1215-21, the contents of which are hereby incorporated by reference in their entirety). For example, a fluorescein containing a linker amine is conjugated to an oligoribonucleotide containing an amine through a squarate linker as described in the scheme below. An example of the squarate linker is depicted in the following scheme:

In certain embodiments, a chemical modification incorporated into the guide RNA is selected from the group consisting of 2′-O—C1-4alkyl, 2′-H, 2′-O—C1-3alkyl-O—C1-3alkyl, 2′-F, 2′-NH2, 2′-arabino, 2′-F-arabino, 4′-thioribosyl, 2-thioU, 2-thioC, 4-thioU, 6-thioG, 2-aminoA, 2-aminopurine, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylC, 5-methylU, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allylU, 5-allyC, 5-aminoallyl-uracil, 5-aminoallyl-cytosine, an abasic nucleotide (“abN”), Z, P, UNA, isoC, isoG, 5-methyl-pyrimidine, x(A,G,C,T) and y(A,G,C,T), a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a thiophosphonoacetate internucleotide linkage, a methylphosphonate internucleotide linkage, a boranophosphonate internucleotide linkage, a phosphorodithioate internucleotide linkage, 4′-thioribosyl nucleotide, a locked nucleic acid (“LNA”) nucleotide, an unlocked nucleic acid (“ULNA”) nucleotide, an alkyl spacer, a heteroalkyl (N, O, S) spacer, a 5′- and/or 3′-alkyl terminated nucleotide, a Unicap, a 5′-terminal cap known from nature, an xRNA base (analogous to “xDNA” base), an yRNA base (analogous to “yDNA” base), a PEG substituent, or a conjugated linker to a dye or non-fluorescent label (or tag) or other moiety as described above. Exemplary modified nucleotides are also depicted in Table 2.

TABLE 2 Exemplary modified nucleotides contained in a synthetic guide sequence.

R₁ = OH or 2′modificiation R₂ = OH or internucleotide linkage B = base # R₁ R₂ B A1 OH OH uridine A2 OMe OH uridine A3 F OH uridine A4 Cl OH uridine A5 Br OH uridine A6 I OH uridine A7 NH₂ OH uridine A8 H OH uridine A9 OH phosphodiester uridine A10 OMe phosphodiester uridine A11 F phosphodiester uridine A12 Cl phosphodiester uridine A13 Br phosphodiester uridine A14 I phosphodiester uridine A15 NH₂ phosphodiester uridine A16 H phosphodiester uridine A17 OH phosphonoacetate uridine A18 OMe phosphonoacetate uridine A19 F phosphonoacetate uridine A20 Cl phosphonoacetate uridine A21 Br phosphonoacetate uridine A22 I phosphonoacetate uridine A23 NH₂ phosphonoacetate uridine A24 H phosphonoacetate uridine A25 OH thiophosphonoacetate uridine A26 OMe thiophosphonoacetate uridine A27 F thiophosphonoacetate uridine A28 Cl thiophosphonoacetate uridine A29 Br thiophosphonoacetate uridine A30 I thiophosphonoacetate uridine A31 NH₂ thiophosphonoacetate uridine A32 H thiophosphonoacetate uridine A33 OH phosphorothioate uridine A34 OMe phosphorothioate uridine A35 F phosphorothioate uridine A36 Cl phosphorothioate uridine A37 Br phosphorothioate uridine A38 I phosphorothioate uridine A39 NH₂ phosphorothioate uridine A40 H phosphorothioate uridine A41 OH phosphorodithioate uridine A42 OMe phosphorodithioate uridine A43 F phosphorodithioate uridine A44 Cl phosphorodithioate uridine A45 Br phosphorodithioate uridine A46 I phosphorodithioate uridine A47 NH₂ phosphorodithioate uridine A48 H phosphorodithioate uridine A49 OH methylphosphonate uridine A50 OMe methylphosphonate uridine A51 F methylphosphonate uridine A52 Cl methylphosphonate uridine A53 Br methylphosphonate uridine A54 I methylphosphonate uridine A55 NH₂ methylphosphonate uridine A56 H methylphosphonate uridine A57 OH boranophosphonate uridine A58 OMe boranophosphonate uridine A59 F boranophosphonate uridine A60 Cl boranophosphonate uridine A61 Br boranophosphonate uridine A62 I boranophosphonate uridine A63 NH₂ boranophosphonate uridine A64 H boranophosphonate uridine B1 OH OH adenosine B2 OMe OH adenosine B3 F OH adenosine B4 Cl OH adenosine B5 Br OH adenosine B6 I OH adenosine B7 NH₂ OH adenosine B8 H OH adenosine B9 OH phosphodiester adenosine B10 OMe phosphodiester adenosine B11 F phosphodiester adenosine B12 Cl phosphodiester adenosine B13 Br phosphodiester adenosine B14 I phosphodiester adenosine B15 NH₂ phosphodiester adenosine B16 H phosphodiester adenosine B17 OH phosphonoacetate adenosine B18 OMe phosphonoacetate adenosine B19 F phosphonoacetate adenosine B20 Cl phosphonoacetate adenosine B21 Br phosphonoacetate adenosine B22 I phosphonoacetate adenosine B23 NH₂ phosphonoacetate adenosine B24 H phosphonoacetate adenosine B25 OH thiophosphonoacetate adenosine B26 OMe thiophosphonoacetate adenosine B27 F thiophosphonoacetate adenosine B28 Cl thiophosphonoacetate adenosine B29 Br thiophosphonoacetate adenosine B30 I thiophosphonoacetate adenosine B31 NH₂ thiophosphonoacetate adenosine B32 H thiophosphonoacetate adenosine B33 OH phosphorothioate adenosine B34 OMe phosphorothioate adenosine B35 F phosphorothioate adenosine B36 Cl phosphorothioate adenosine B37 Br phosphorothioate adenosine B38 I phosphorothioate adenosine B39 NH₂ phosphorothioate adenosine B40 H phosphorothioate adenosine B41 OH phosphorodithioate adenosine B42 OMe phosphorodithioate adenosine B43 F phosphorodithioate adenosine B44 Cl phosphorodithioate adenosine B45 Br phosphorodithioate adenosine B46 I phosphorodithioate adenosine B47 NH₂ phosphorodithioate adenosine B48 H phosphorodithioate adenosine B49 OH methylphosphonate adenosine B50 OMe methylphosphonate adenosine B51 F methylphosphonate adenosine B52 Cl methylphosphonate adenosine B53 Br methylphosphonate adenosine B54 I methylphosphonate adenosine B55 NH₂ methylphosphonate adenosine B56 H methylphosphonate adenosine B57 OH boranophosphonate adenosine B58 OMe boranophosphonate adenosine B59 F boranophosphonate adenosine B60 Cl boranophosphonate adenosine B61 Br boranophosphonate adenosine B62 I boranophosphonate adenosine B63 NH₂ boranophosphonate adenosine B64 H boranophosphonate adenosine C1 OH OH cytidine C2 OMe OH cytidine C3 F OH cytidine C4 Cl OH cytidine C5 Br OH cytidine C6 I OH cytidine C7 NH₂ OH cytidine C8 H OH cytidine C9 OH phosphodiester cytidine C10 OMe phosphodiester cytidine C11 F phosphodiester cytidine C12 Cl phosphodiester cytidine C13 Br phosphodiester cytidine C14 I phosphodiester cytidine C15 NH₂ phosphodiester cytidine C16 H phosphodiester cytidine C17 OH phosphonoacetate cytidine C18 OMe phosphonoacetate cytidine C19 F phosphonoacetate cytidine C20 Cl phosphonoacetate cytidine C21 Br phosphonoacetate cytidine C22 I phosphonoacetate cytidine C23 NH₂ phosphonoacetate cytidine C24 H phosphonoacetate cytidine C25 OH thiophosphonoacetate cytidine C26 OMe thiophosphonoacetate cytidine C27 F thiophosphonoacetate cytidine C28 Cl thiophosphonoacetate cytidine C29 Br thiophosphonoacetate cytidine C30 I thiophosphonoacetate cytidine C31 NH₂ thiophosphonoacetate cytidine C32 H thiophosphonoacetate cytidine C33 OH phosphorothioate cytidine C34 OMe phosphorothioate cytidine C35 F phosphorothioate cytidine C36 Cl phosphorothioate cytidine C37 Br phosphorothioate cytidine C38 I phosphorothioate cytidine C39 NH₂ phosphorothioate cytidine C40 H phosphorothioate cytidine C41 OH phosphorodithioate cytidine C42 OMe phosphorodithioate cytidine C43 F phosphorodithioate cytidine C44 Cl phosphorodithioate cytidine C45 Br phosphorodithioate cytidine C46 I phosphorodithioate cytidine C47 NH₂ phosphorodithioate cytidine C48 H phosphorodithioate cytidine C49 OH methylphosphonate cytidine C50 OMe methylphosphonate cytidine C51 F methylphosphonate cytidine C52 Cl methylphosphonate cytidine C53 Br methylphosphonate cytidine C54 I methylphosphonate cytidine C55 NH₂ methylphosphonate cytidine C56 H methylphosphonate cytidine C57 OH boranophosphonate cytidine C58 OMe boranophosphonate cytidine C59 F boranophosphonate cytidine C60 Cl boranophosphonate cytidine C61 Br boranophosphonate cytidine C62 I boranophosphonate cytidine C63 NH₂ boranophosphonate cytidine C64 H boranophosphonate cytidine D1 OH OH guanosine D2 OMe OH guanosine D3 F OH guanosine D4 Cl OH guanosine D5 Br OH guanosine D6 I OH guanosine D7 NH₂ OH guanosine D8 H OH guanosine D9 OH phosphodiester guanosine D10 OMe phosphodiester guanosine D11 F phosphodiester guanosine D12 Cl phosphodiester guanosine D13 Br phosphodiester guanosine D14 I phosphodiester guanosine D15 NH₂ phosphodiester guanosine D16 H phosphodiester guanosine D17 OH phosphonoacetate guanosine D18 OMe phosphonoacetate guanosine D19 F phosphonoacetate guanosine D20 Cl phosphonoacetate guanosine D21 Br phosphonoacetate guanosine D22 I phosphonoacetate guanosine D23 NH₂ phosphonoacetate guanosine D24 H phosphonoacetate guanosine D25 OH thiophosphonoacetate guanosine D26 OMe thiophosphonoacetate guanosine D27 F thiophosphonoacetate guanosine D28 Cl thiophosphonoacetate guanosine D29 Br thiophosphonoacetate guanosine D30 I thiophosphonoacetate guanosine D31 NH₂ thiophosphonoacetate guanosine D32 H thiophosphonoacetate guanosine D33 OH phosphorothioate guanosine D34 OMe phosphorothioate guanosine D35 F phosphorothioate guanosine D36 Cl phosphorothioate guanosine D37 Br phosphorothioate guanosine D38 I phosphorothioate guanosine D39 NH₂ phosphorothioate guanosine D40 H phosphorothioate guanosine D41 OH phosphorodithioate guanosine D42 OMe phosphorodithioate guanosine D43 F phosphorodithioate guanosine D44 Cl phosphorodithioate guanosine D45 Br phosphorodithioate guanosine D46 I phosphorodithioate guanosine D47 NH₂ phosphorodithioate guanosine D48 H phosphorodithioate guanosine D49 OH methylphosphonate guanosine D50 OMe methylphosphonate guanosine D51 F methylphosphonate guanosine D52 Cl methylphosphonate guanosine D53 Br methylphosphonate guanosine D54 I methylphosphonate guanosine D55 NH₂ methylphosphonate guanosine D56 H methylphosphonate guanosine D57 OH boranophosphonate guanosine D58 OMe boranophosphonate guanosine D59 F boranophosphonate guanosine D60 Cl boranophosphonate guanosine D61 Br boranophosphonate guanosine D62 I boranophosphonate guanosine D63 NH₂ boranophosphonate guanosine D64 H boranophosphonate guanosine E1 OH OH 2-thiouridine E2 OMe OH 2-thiouridine E3 F OH 2-thiouridine E4 Cl OH 2-thiouridine E5 Br OH 2-thiouridine E6 I OH 2-thiouridine E7 NH₂ OH 2-thiouridine E8 H OH 2-thiouridine E9 OH phosphodiester 2-thiouridine E10 OMe phosphodiester 2-thiouridine E11 F phosphodiester 2-thiouridine E12 Cl phosphodiester 2-thiouridine E13 Br phosphodiester 2-thiouridine E14 I phosphodiester 2-thiouridine E15 NH₂ phosphodiester 2-thiouridine E16 H phosphodiester 2-thiouridine E17 OH phosphonoacetate 2-thiouridine E18 OMe phosphonoacetate 2-thiouridine E19 F phosphonoacetate 2-thiouridine E20 Cl phosphonoacetate 2-thiouridine E21 Br phosphonoacetate 2-thiouridine E22 I phosphonoacetate 2-thiouridine E23 NH₂ phosphonoacetate 2-thiouridine E24 H phosphonoacetate 2-thiouridine E25 OH thiophosphonoacetate 2-thiouridine E26 OMe thiophosphonoacetate 2-thiouridine E27 F thiophosphonoacetate 2-thiouridine E28 Cl thiophosphonoacetate 2-thiouridine E29 Br thiophosphonoacetate 2-thiouridine E30 I thiophosphonoacetate 2-thiouridine E31 NH₂ thiophosphonoacetate 2-thiouridine E32 H thiophosphonoacetate 2-thiouridine E33 OH phosphorothioate 2-thiouridine E34 OMe phosphorothioate 2-thiouridine E35 F phosphorothioate 2-thiouridine E36 Cl phosphorothioate 2-thiouridine E37 Br phosphorothioate 2-thiouridine E38 I phosphorothioate 2-thiouridine E39 NH₂ phosphorothioate 2-thiouridine E40 H phosphorothioate 2-thiouridine E41 OH phosphorodithioate 2-thiouridine E42 OMe phosphorodithioate 2-thiouridine E43 F phosphorodithioate 2-thiouridine E44 Cl phosphorodithioate 2-thiouridine E45 Br phosphorodithioate 2-thiouridine E46 I phosphorodithioate 2-thiouridine E47 NH₂ phosphorodithioate 2-thiouridine E48 H phosphorodithioate 2-thiouridine E49 OH methylphosphonate 2-thiouridine E50 OMe methylphosphonate 2-thiouridine E51 F methylphosphonate 2-thiouridine E52 Cl methylphosphonate 2-thiouridine E53 Br methylphosphonate 2-thiouridine E54 I methylphosphonate 2-thiouridine E55 NH₂ methylphosphonate 2-thiouridine E56 H methylphosphonate 2-thiouridine E57 OH boranophosphonate 2-thiouridine E58 OMe boranophosphonate 2-thiouridine E59 F boranophosphonate 2-thiouridine E60 Cl boranophosphonate 2-thiouridine E61 Br boranophosphonate 2-thiouridine E62 I boranophosphonate 2-thiouridine E63 NH₂ boranophosphonate 2-thiouridine E64 H boranophosphonate 2-thiouridine F1 OH OH 4-thiouridine F2 OMe OH 4-thiouridine F3 F OH 4-thiouridine F4 Cl OH 4-thiouridine F5 Br OH 4-thiouridine F6 I OH 4-thiouridine F7 NH₂ OH 4-thiouridine F8 H OH 4-thiouridine F9 OH phosphodiester 4-thiouridine F10 OMe phosphodiester 4-thiouridine F11 F phosphodiester 4-thiouridine F12 Cl phosphodiester 4-thiouridine F13 Br phosphodiester 4-thiouridine F14 I phosphodiester 4-thiouridine F15 NH₂ phosphodiester 4-thiouridine F16 H phosphodiester 4-thiouridine F17 OH phosphonoacetate 4-thiouridine F18 OMe phosphonoacetate 4-thiouridine F19 F phosphonoacetate 4-thiouridine F20 Cl phosphonoacetate 4-thiouridine F21 Br phosphonoacetate 4-thiouridine F22 I phosphonoacetate 4-thiouridine F23 NH₂ phosphonoacetate 4-thiouridine F24 H phosphonoacetate 4-thiouridine F25 OH thiophosphonoacetate 4-thiouridine F26 OMe thiophosphonoacetate 4-thiouridine F27 F thiophosphonoacetate 4-thiouridine F28 Cl thiophosphonoacetate 4-thiouridine F29 Br thiophosphonoacetate 4-thiouridine F30 I thiophosphonoacetate 4-thiouridine F31 NH₂ thiophosphonoacetate 4-thiouridine F32 H thiophosphonoacetate 4-thiouridine F33 OH phosphorothioate 4-thiouridine F34 OMe phosphorothioate 4-thiouridine F35 F phosphorothioate 4-thiouridine F36 Cl phosphorothioate 4-thiouridine F37 Br phosphorothioate 4-thiouridine F38 I phosphorothioate 4-thiouridine F39 NH₂ phosphorothioate 4-thiouridine F40 H phosphorothioate 4-thiouridine F41 OH phosphorodithioate 4-thiouridine F42 OMe phosphorodithioate 4-thiouridine F43 F phosphorodithioate 4-thiouridine F44 Cl phosphorodithioate 4-thiouridine F45 Br phosphorodithioate 4-thiouridine F46 I phosphorodithioate 4-thiouridine F47 NH₂ phosphorodithioate 4-thiouridine F48 H phosphorodithioate 4-thiouridine F49 OH methylphosphonate 4-thiouridine F50 OMe methylphosphonate 4-thiouridine F51 F methylphosphonate 4-thiouridine F52 Cl methylphosphonate 4-thiouridine F53 Br methylphosphonate 4-thiouridine F54 I methylphosphonate 4-thiouridine F55 NH₂ methylphosphonate 4-thiouridine F56 H methylphosphonate 4-thiouridine F57 OH boranophosphonate 4-thiouridine F58 OMe boranophosphonate 4-thiouridine F59 F boranophosphonate 4-thiouridine F60 Cl boranophosphonate 4-thiouridine F61 Br boranophosphonate 4-thiouridine F62 I boranophosphonate 4-thiouridine F63 NH₂ boranophosphonate 4-thiouridine F64 H boranophosphonate 4-thiouridine G1 OH OH 2-aminoadenosine G2 OMe OH 2-aminoadenosine G3 F OH 2-aminoadenosine G4 Cl OH 2-aminoadenosine G5 Br OH 2-aminoadenosine G6 I OH 2-aminoadenosine G7 NH₂ OH 2-aminoadenosine G8 H OH 2-aminoadenosine G9 OH phosphodiester 2-aminoadenosine G10 OMe phosphodiester 2-aminoadenosine G11 F phosphodiester 2-aminoadenosine G12 Cl phosphodiester 2-aminoadenosine G13 Br phosphodiester 2-aminoadenosine G14 I phosphodiester 2-aminoadenosine G15 NH₂ phosphodiester 2-aminoadenosine G16 H phosphodiester 2-aminoadenosine G17 OH phosphonoacetate 2-aminoadenosine G18 OMe phosphonoacetate 2-aminoadenosine G19 F phosphonoacetate 2-aminoadenosine G20 Cl phosphonoacetate 2-aminoadenosine G21 Br phosphonoacetate 2-aminoadenosine G22 I phosphonoacetate 2-aminoadenosine G23 NH₂ phosphonoacetate 2-aminoadenosine G24 H phosphonoacetate 2-aminoadenosine G25 OH thiophosphonoacetate 2-aminoadenosine G26 OMe thiophosphonoacetate 2-aminoadenosine G27 F thiophosphonoacetate 2-aminoadenosine G28 Cl thiophosphonoacetate 2-aminoadenosine G29 Br thiophosphonoacetate 2-aminoadenosine G30 I thiophosphonoacetate 2-aminoadenosine G31 NH₂ thiophosphonoacetate 2-aminoadenosine G32 H thiophosphonoacetate 2-aminoadenosine G33 OH phosphorothioate 2-aminoadenosine G34 OMe phosphorothioate 2-aminoadenosine G35 F phosphorothioate 2-aminoadenosine G36 Cl phosphorothioate 2-aminoadenosine G37 Br phosphorothioate 2-aminoadenosine G38 I phosphorothioate 2-aminoadenosine G39 NH₂ phosphorothioate 2-aminoadenosine G40 H phosphorothioate 2-aminoadenosine G41 OH phosphorodithioate 2-aminoadenosine G42 OMe phosphorodithioate 2-aminoadenosine G43 F phosphorodithioate 2-aminoadenosine G44 Cl phosphorodithioate 2-aminoadenosine G45 Br phosphorodithioate 2-aminoadenosine G46 I phosphorodithioate 2-aminoadenosine G47 NH₂ phosphorodithioate 2-aminoadenosine G48 H phosphorodithioate 2-aminoadenosine G49 OH methylphosphonate 2-aminoadenosine G50 OMe methylphosphonate 2-aminoadenosine G51 F methylphosphonate 2-aminoadenosine G52 Cl methylphosphonate 2-aminoadenosine G53 Br methylphosphonate 2-aminoadenosine G54 I methylphosphonate 2-aminoadenosine G55 NH₂ methylphosphonate 2-aminoadenosine G56 H methylphosphonate 2-aminoadenosine G57 OH boranophosphonate 2-aminoadenosine G58 OMe boranophosphonate 2-aminoadenosine G59 F boranophosphonate 2-aminoadenosine G60 Cl boranophosphonate 2-aminoadenosine G61 Br boranophosphonate 2-aminoadenosine G62 I boranophosphonate 2-aminoadenosine G63 NH₂ boranophosphonate 2-aminoadenosine G64 H boranophosphonate 2-aminoadenosine H1 OH OH 7-deazaguanosine H2 OMe OH 7-deazaguanosine H3 F OH 7-deazaguanosine H4 Cl OH 7-deazaguanosine H5 Br OH 7-deazaguanosine H6 I OH 7-deazaguanosine H7 NH₂ OH 7-deazaguanosine H8 H OH 7-deazaguanosine H9 OH phosphodiester 7-deazaguanosine H10 OMe phosphodiester 7-deazaguanosine H11 F phosphodiester 7-deazaguanosine H12 Cl phosphodiester 7-deazaguanosine H13 Br phosphodiester 7-deazaguanosine H14 I phosphodiester 7-deazaguanosine H15 NH₂ phosphodiester 7-deazaguanosine H16 H phosphodiester 7-deazaguanosine H17 OH phosphonoacetate 7-deazaguanosine H18 OMe phosphonoacetate 7-deazaguanosine H19 F phosphonoacetate 7-deazaguanosine H20 Cl phosphonoacetate 7-deazaguanosine H21 Br phosphonoacetate 7-deazaguanosine H22 I phosphonoacetate 7-deazaguanosine H23 NH₂ phosphonoacetate 7-deazaguanosine H24 H phosphonoacetate 7-deazaguanosine H25 OH thiophosphonoacetate 7-deazaguanosine H26 OMe thiophosphonoacetate 7-deazaguanosine H27 F thiophosphonoacetate 7-deazaguanosine H28 Cl thiophosphonoacetate 7-deazaguanosine H29 Br thiophosphonoacetate 7-deazaguanosine H30 I thiophosphonoacetate 7-deazaguanosine H31 NH₂ thiophosphonoacetate 7-deazaguanosine H32 H thiophosphonoacetate 7-deazaguanosine H33 OH phosphorothioate 7-deazaguanosine H34 OMe phosphorothioate 7-deazaguanosine H35 F phosphorothioate 7-deazaguanosine H36 Cl phosphorothioate 7-deazaguanosine H37 Br phosphorothioate 7-deazaguanosine H38 I phosphorothioate 7-deazaguanosine H39 NH₂ phosphorothioate 7-deazaguanosine H40 H phosphorothioate 7-deazaguanosine H41 OH phosphorodithioate 7-deazaguanosine H42 OMe phosphorodithioate 7-deazaguanosine H43 F phosphorodithioate 7-deazaguanosine H44 Cl phosphorodithioate 7-deazaguanosine H45 Br phosphorodithioate 7-deazaguanosine H46 I phosphorodithioate 7-deazaguanosine H47 NH₂ phosphorodithioate 7-deazaguanosine H48 H phosphorodithioate 7-deazaguanosine H49 OH methylphosphonate 7-deazaguanosine H50 OMe methylphosphonate 7-deazaguanosine H51 F methylphosphonate 7-deazaguanosine H52 Cl methylphosphonate 7-deazaguanosine H53 Br methylphosphonate 7-deazaguanosine H54 I methylphosphonate 7-deazaguanosine H55 NH₂ methylphosphonate 7-deazaguanosine H56 H methylphosphonate 7-deazaguanosine H57 OH boranophosphonate 7-deazaguanosine H58 OMe boranophosphonate 7-deazaguanosine H59 F boranophosphonate 7-deazaguanosine H60 Cl boranophosphonate 7-deazaguanosine H61 Br boranophosphonate 7-deazaguanosine H62 I boranophosphonate 7-deazaguanosine H63 NH₂ boranophosphonate 7-deazaguanosine H64 H boranophosphonate 7-deazaguanosine I1 OH OH inosine I2 OMe OH inosine I3 F OH inosine I4 Cl OH inosine I5 Br OH inosine I6 I OH inosine I7 NH₂ OH inosine I8 H OH inosine I9 OH phosphodiester inosine I10 OMe phosphodiester inosine I11 F phosphodiester inosine I12 Cl phosphodiester inosine I13 Br phosphodiester inosine I14 I phosphodiester inosine I15 NH₂ phosphodiester inosine I16 H phosphodiester inosine I17 OH phosphonoacetate inosine I18 OMe phosphonoacetate inosine I19 F phosphonoacetate inosine I20 Cl phosphonoacetate inosine I21 Br phosphonoacetate inosine I22 I phosphonoacetate inosine I23 NH₂ phosphonoacetate inosine I24 H phosphonoacetate inosine I25 OH thiophosphonoacetate inosine I26 OMe thiophosphonoacetate inosine I27 F thiophosphonoacetate inosine I28 Cl thiophosphonoacetate inosine I29 Br thiophosphonoacetate inosine I30 I thiophosphonoacetate inosine I31 NH₂ thiophosphonoacetate inosine I32 H thiophosphonoacetate inosine I33 OH phosphorothioate inosine I34 OMe phosphorothioate inosine I35 F phosphorothioate inosine I36 Cl phosphorothioate inosine I37 Br phosphorothioate inosine I38 I phosphorothioate inosine I39 NH₂ phosphorothioate inosine I40 H phosphorothioate inosine I41 OH phosphorodithioate inosine I42 OMe phosphorodithioate inosine I43 F phosphorodithioate inosine I44 Cl phosphorodithioate inosine I45 Br phosphorodithioate inosine I46 I phosphorodithioate inosine I47 NH₂ phosphorodithioate inosine I48 H phosphorodithioate inosine I49 OH methylphosphonate inosine I50 OMe methylphosphonate inosine I51 F methylphosphonate inosine I52 Cl methylphosphonate inosine I53 Br methylphosphonate inosine I54 I methylphosphonate inosine I55 NH₂ methylphosphonate inosine I56 H methylphosphonate inosine I57 OH boranophosphonate inosine I58 OMe boranophosphonate inosine I59 F boranophosphonate inosine I60 Cl boranophosphonate inosine I61 Br boranophosphonate inosine I62 I boranophosphonate inosine I63 NH₂ boranophosphonate inosine I64 H boranophosphonate inosine J1 OH OH 5-methylcytidine J2 OMe OH 5-methylcytidine J3 F OH 5-methylcytidine J4 Cl OH 5-methylcytidine J5 Br OH 5-methylcytidine J6 I OH 5-methylcytidine J7 NH₂ OH 5-methylcytidine J8 H OH 5-methylcytidine J9 OH phosphodiester 5-methylcytidine J10 OMe phosphodiester 5-methylcytidine J11 F phosphodiester 5-methylcytidine J12 Cl phosphodiester 5-methylcytidine J13 Br phosphodiester 5-methylcytidine J14 I phosphodiester 5-methylcytidine J15 NH₂ phosphodiester 5-methylcytidine J16 H phosphodiester 5-methylcytidine J17 OH phosphonoacetate 5-methylcytidine J18 OMe phosphonoacetate 5-methylcytidine J19 F phosphonoacetate 5-methylcytidine J20 Cl phosphonoacetate 5-methylcytidine J21 Br phosphonoacetate 5-methylcytidine J22 I phosphonoacetate 5-methylcytidine J23 NH₂ phosphonoacetate 5-methylcytidine J24 H phosphonoacetate 5-methylcytidine J25 OH thiophosphonoacetate 5-methylcytidine J26 OMe thiophosphonoacetate 5-methylcytidine J27 F thiophosphonoacetate 5-methylcytidine J28 Cl thiophosphonoacetate 5-methylcytidine J29 Br thiophosphonoacetate 5-methylcytidine J30 I thiophosphonoacetate 5-methylcytidine J31 NH₂ thiophosphonoacetate 5-methylcytidine J32 H thiophosphonoacetate 5-methylcytidine J33 OH phosphorothioate 5-methylcytidine J34 OMe phosphorothioate 5-methylcytidine J35 F phosphorothioate 5-methylcytidine J36 Cl phosphorothioate 5-methylcytidine J37 Br phosphorothioate 5-methylcytidine J38 I phosphorothioate 5-methylcytidine J39 NH₂ phosphorothioate 5-methylcytidine J40 H phosphorothioate 5-methylcytidine J41 OH phosphorodithioate 5-methylcytidine J42 OMe phosphorodithioate 5-methylcytidine J43 F phosphorodithioate 5-methylcytidine J44 Cl phosphorodithioate 5-methylcytidine J45 Br phosphorodithioate 5-methylcytidine J46 I phosphorodithioate 5-methylcytidine J47 NH₂ phosphorodithioate 5-methylcytidine J48 H phosphorodithioate 5-methylcytidine J49 OH methylphosphonate 5-methylcytidine J50 OMe methylphosphonate 5-methylcytidine J51 F methylphosphonate 5-methylcytidine J52 Cl methylphosphonate 5-methylcytidine J53 Br methylphosphonate 5-methylcytidine J54 I methylphosphonate 5-methylcytidine J55 NH₂ methylphosphonate 5-methylcytidine J56 H methylphosphonate 5-methylcytidine J57 OH boranophosphonate 5-methylcytidine J58 OMe boranophosphonate 5-methylcytidine J59 F boranophosphonate 5-methylcytidine J60 Cl boranophosphonate 5-methylcytidine J61 Br boranophosphonate 5-methylcytidine J62 I boranophosphonate 5-methylcytidine J63 NH₂ boranophosphonate 5-methylcytidine J64 H boranophosphonate 5-methylcytidine K1 OH OH 5-aminoallyluridine K2 OMe OH 5-aminoallyluridine K3 F OH 5-aminoallyluridine K4 Cl OH 5-aminoallyluridine K5 Br OH 5-aminoallyluridine K6 I OH 5-aminoallyluridine K7 NH₂ OH 5-aminoallyluridine K8 H OH 5-aminoallyluridine K9 OH phosphodiester 5-aminoallyluridine K10 OMe phosphodiester 5-aminoallyluridine K11 F phosphodiester 5-aminoallyluridine K12 Cl phosphodiester 5-aminoallyluridine K13 Br phosphodiester 5-aminoallyluridine K14 I phosphodiester 5-aminoallyluridine K15 NH₂ phosphodiester 5-aminoallyluridine K16 H phosphodiester 5-aminoallyluridine K17 OH phosphonoacetate 5-aminoallyluridine K18 OMe phosphonoacetate 5-aminoallyluridine K19 F phosphonoacetate 5-aminoallyluridine K20 Cl phosphonoacetate 5-aminoallyluridine K21 Br phosphonoacetate 5-aminoallyluridine K22 I phosphonoacetate 5-aminoallyluridine K23 NH₂ phosphonoacetate 5-aminoallyluridine K24 H phosphonoacetate 5-aminoallyluridine K25 OH thiophosphonoacetate 5-aminoallyluridine K26 OMe thiophosphonoacetate 5-aminoallyluridine K27 F thiophosphonoacetate 5-aminoallyluridine K28 Cl thiophosphonoacetate 5-aminoallyluridine K29 Br thiophosphonoacetate 5-aminoallyluridine K30 I thiophosphonoacetate 5-aminoallyluridine K31 NH₂ thiophosphonoacetate 5-aminoallyluridine K32 H thiophosphonoacetate 5-aminoallyluridine K33 OH phosphorothioate 5-aminoallyluridine K34 OMe phosphorothioate 5-aminoallyluridine K35 F phosphorothioate 5-aminoallyluridine K36 Cl phosphorothioate 5-aminoallyluridine K37 Br phosphorothioate 5-aminoallyluridine K38 I phosphorothioate 5-aminoallyluridine K39 NH₂ phosphorothioate 5-aminoallyluridine K40 H phosphorothioate 5-aminoallyluridine K41 OH phosphorodithioate 5-aminoallyluridine K42 OMe phosphorodithioate 5-aminoallyluridine K43 F phosphorodithioate 5-aminoallyluridine K44 Cl phosphorodithioate 5-aminoallyluridine K45 Br phosphorodithioate 5-aminoallyluridine K46 I phosphorodithioate 5-aminoallyluridine K47 NH₂ phosphorodithioate 5-aminoallyluridine K48 H phosphorodithioate 5-aminoallyluridine K49 OH methylphosphonate 5-aminoallyluridine K50 OMe methylphosphonate 5-aminoallyluridine K51 F methylphosphonate 5-aminoallyluridine K52 Cl methylphosphonate 5-aminoallyluridine K53 Br methylphosphonate 5-aminoallyluridine K54 I methylphosphonate 5-aminoallyluridine K55 NH₂ methylphosphonate 5-aminoallyluridine K56 H methylphosphonate 5-aminoallyluridine K57 OH boranophosphonate 5-aminoallyluridine K58 OMe boranophosphonate 5-aminoallyluridine K59 F boranophosphonate 5-aminoallyluridine K60 Cl boranophosphonate 5-aminoallyluridine K61 Br boranophosphonate 5-aminoallyluridine K62 I boranophosphonate 5-aminoallyluridine K63 NH₂ boranophosphonate 5-aminoallyluridine K64 H boranophosphonate 5-aminoallyluridine L1 OH OH 5-methyluridine L2 OMe OH 5-methyluridine L3 F OH 5-methyluridine L4 Cl OH 5-methyluridine L5 Br OH 5-methyluridine L6 I OH 5-methyluridine L7 NH₂ OH 5-methyluridine L8 H OH 5-methyluridine L9 OH phosphodiester 5-methyluridine L10 OMe phosphodiester 5-methyluridine L11 F phosphodiester 5-methyluridine L12 Cl phosphodiester 5-methyluridine L13 Br phosphodiester 5-methyluridine L14 I phosphodiester 5-methyluridine L15 NH₂ phosphodiester 5-methyluridine L16 H phosphodiester 5-methyluridine L17 OH phosphonoacetate 5-methyluridine L18 OMe phosphonoacetate 5-methyluridine L19 F phosphonoacetate 5-methyluridine L20 Cl phosphonoacetate 5-methyluridine L21 Br phosphonoacetate 5-methyluridine L22 I phosphonoacetate 5-methyluridine L23 NH₂ phosphonoacetate 5-methyluridine L24 H phosphonoacetate 5-methyluridine L25 OH thiophosphonoacetate 5-methyluridine L26 OMe thiophosphonoacetate 5-methyluridine L27 F thiophosphonoacetate 5-methyluridine L28 Cl thiophosphonoacetate 5-methyluridine L29 Br thiophosphonoacetate 5-methyluridine L30 I thiophosphonoacetate 5-methyluridine L31 NH₂ thiophosphonoacetate 5-methyluridine L32 H thiophosphonoacetate 5-methyluridine L33 OH phosphorothioate 5-methyluridine L34 OMe phosphorothioate 5-methyluridine L35 F phosphorothioate 5-methyluridine L36 Cl phosphorothioate 5-methyluridine L37 Br phosphorothioate 5-methyluridine L38 I phosphorothioate 5-methyluridine L39 NH₂ phosphorothioate 5-methyluridine L40 H phosphorothioate 5-methyluridine L41 OH phosphorodithioate 5-methyluridine L42 OMe phosphorodithioate 5-methyluridine L43 F phosphorodithioate 5-methyluridine L44 Cl phosphorodithioate 5-methyluridine L45 Br phosphorodithioate 5-methyluridine L46 I phosphorodithioate 5-methyluridine L47 NH₂ phosphorodithioate 5-methyluridine L48 H phosphorodithioate 5-methyluridine L49 OH methylphosphonate 5-methyluridine L50 OMe methylphosphonate 5-methyluridine L51 F methylphosphonate 5-methyluridine L52 Cl methylphosphonate 5-methyluridine L53 Br methylphosphonate 5-methyluridine L54 I methylphosphonate 5-methyluridine L55 NH₂ methylphosphonate 5-methyluridine L56 H methylphosphonate 5-methyluridine L57 OH boranophosphonate 5-methyluridine L58 OMe boranophosphonate 5-methyluridine L59 F boranophosphonate 5-methyluridine L60 Cl boranophosphonate 5-methyluridine L61 Br boranophosphonate 5-methyluridine L62 I boranophosphonate 5-methyluridine L63 NH₂ boranophosphonate 5-methyluridine L64 H boranophosphonate 5-methyluridine

As described herein, certain unnatural base pairs (e.g., isoG and isoC, Z base and P base; see Zhang et al. (2015) J. Am. Chem. Soc.) may be advantageous for affecting the thermostability of the guide RNA secondary structure. These modifications can be used to prevent misfolding of the guide RNA scaffold with other domains of a guide RNA sequence.

Recent guide RNA:Cas9 protein structural information (FIG. 10, as reported in Jiang et al. 2015, Science,) and in vivo/in vitro functional mutation studies (see, e.g., Briner et al. 2014, Mol. Cell, 56, 333-9) indicate that the guide RNA scaffold is predominantly structurally conserved. This reinforces the importance of correct folding of the conserved domain of guide RNAs for functionality with Cas9. FIG. 10 shows the guide RNA scaffold secondary structure, displaying interactions with amino acids of Cas9. Most of the guide RNA nitrogenous bases are not involved in binding interactions with Cas9 protein.

The flanking sequences of the sgRNA scaffold increase the likelihood of misfolding and hence misfunction. The 20 nt guide targeting sequence, 5′ of the scaffold region, is user-specified for each target, thus the likelihood of misfolding is variable or target-specific. Also, many emerging CRISPR-Cas applications append functional sequences 3′ of the scaffold, such as CRISPRdisplay (Schechner et al., Nat. Methods 2015) and CRISPR-i/-a (Chen et al., Cell 2013), which are riboswitches or aptamers that also need to correctly and independently fold to function properly. To ensure that each of the functional domains (i.e. targeting guide, scaffold, aptamer) of a given sgRNA folds in a modular, independent manner, the structurally conserved scaffold base pairs can be substituted with unnatural, orthogonal base pairs (e.g., isoG and isoC; Z base and P base), and in some embodiments, substituted exclusively with unnatural, orthogonal base pairs. This ensures that the sgRNA scaffold sequences will not stably interact in a secondary structure with elements of the target-pairing guide seqeunce or other non-native domains incorporated in the guide RNA such as any aptamer sequences or any non-native 5′ or 3′ overhangs on the guide RNA. Alternatively, the unnatural, orthogonal base pairs mentioned above could be incorporated in any non-native overhangs or aptamers that may be present, thus to prevent secondary structures involving misfolding of the scaffold sequence(s).

B. Guide RNA with at Least One Modification

In one aspect, the present technology provides a guide RNA having at least one modification, constituting a modified gRNA.

In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified nucleotides. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified nucleotides. In certain embodiments, all nucleotides are modified. In certain embodiments, all the modifications are the same. In certain embodiments, all the modified nucleotides have the same type of modification. In certain embodiments, the modified gRNA comprises a combination of differently modified nucleotides. In certain embodiments, the modified gRNA comprises two or more modified nucleotides. In certain embodiments, the modified gRNA comprises three or more modified nucleotides. In certain embodiments, the modified nucleotides are arranged contiguously. In certain embodiments, the modified gRNA comprises at least one contiguous stretch of modified nucleotides. In certain embodiments, the modified gRNA comprises a contiguous stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified nucleotides. Each modified nucleotide may independently comprise one or more types of modifications. In certain embodiments, no modified nucleotides are contiguous, or some but not all are contiguous, in the sequence of the modified gRNA.

In certain embodiments, the modification is within the 5′ portion of the guide RNA. In certain embodiments, the modification is within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the modification is within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the modification is within the 3′ portion of the guide RNA. In certain embodiments, the modification is within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, the modification is within the last three (3) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, the modification is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA.

In certain embodiments, the modification is incorporated in the 5′ portion or the 3′ portion of the guide RNA, particularly within the first 5 or 10 nucleotides of the 5′ portion or within the last 5 or 10 nucleotides of the 3′ portion to, for example, protect the RNA from degradation by nucleases or for other purposes. In some other embodiments, the modification is in both the 5′ portion and the 3′ portion of the guide RNA, particularly within the first 5 or 10 nucleotides of the 5′ portion and within the last 5 or 10 nucleotides of the 3′ portion to, for example, protect the RNA from degradation by nucleases or for other purposes. In certain embodiments, more than one type of modification is present in both the 5′ portion and the 3′ portion of the guide RNA. In certain embodiments, the modifications are located at the 5′ end, at the 3′ end, and within the internal sequence of the guide RNA. In certain embodiments, a guide RNA comprises 40 or fewer, alternatively 20 or fewer, alternatively 15 or fewer, alternatively 10 or fewer, alternatively 5 or fewer, alternatively 3 or fewer deoxyribonucleotide residues in the 5′ or 3′ portion of the guide RNA.

In certain embodiments, the modification is within the crRNA segment of the guide RNA. In certain embodiments, the modification is within the guide sequence of the crRNA. In certain embodiments, the modification is within the first five (5) nucleotides of the crRNA segment. In certain embodiments, the modification is within the first three (3) nucleotides of the crRNA segment. In certain embodiments, the modification is within a 5′-overhang on the crRNA segment. In certain embodiments, the modification is within the tracrRNA segment of the guide RNA. In certain embodiments, the modification is within the last five (5) nucleotides of the tracrRNA segment of the guide RNA. In certain embodiments, the modification is within the last three (3) nucleotides of the tracrRNA segment of the guide RNA. In certain embodiments, when the guide RNA is a single guide RNA, the modification is located within the loop of the guide RNA. In certain embodiments, one or more modifications is within the loop L region. In certain embodiments, the modification comprises a dye, a non-fluorescent label, or a tag conjugated to a linker incorporated between two nucleotides as described above, for example by conjugation to a 2-(3-(dye/label/tag-amido)propanamido)propane-1,3-diol bis(phosphodiester) linker or to a modified base of a nucleotide in the loop or L region.

In certain embodiments, the modification comprises an end modification, such as a 5′ end modification or a 3′ end modification. Examples of end modifications include, but are not limited to phosphorylation (as natural phosphate or polyphosphate or as modified phosphohate groups such as for example, alkylphosphonate, phosphonocarboxylate, phosphonoacetate, boranophosphonate, phosphorothioate, phosphorodithioate and the like), biotinylation, conjugating or conjugated molecules, linkers, dyes, labels, tags, functional groups (such as for example but not limited to 5′-amino, 5′-thio, 5′-amido, 5′carboxy and the like), inverted linkages, or hydrocarbon moieties which may comprise ether, polyethylene glycol (PEG), ester, hydroxyl, aryl, halo, phosphodiester, bicyclic, heterocyclic or other organic functional group. In certain embodiments, the end modification comprises dimethoxytrityl.

In certain embodiments, the modification comprises a modified base. As used herein, “unmodified” bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Examples of modified bases include, but are not limited to, synthetic and natural bases such as 2-thioU, 2-thioC, 4-thioU, 6-thioG, 2-aminoA, 2-aminoP, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylC, 5-methylU, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allylU, 5-allylC, 5-aminoallyl-uracil, and 5-aminoallyl-cytosine. In certain embodiments, the modification comprises an abasic nucleotide. In certain embodiments, the modification comprises a nonstandard purine or pyrimidine structure, such as Z or P, isoC or isoG, UNA, 5-methylpyrymidine, x(A,G,C,T) or y(A,G,C,T). In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified bases. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified bases. In certain embodiments, all bases in a gRNA are modified.

In certain embodiments, the modification comprises a modified sugar. Examples of modified sugars include, but are not limited to, sugars having modifications at the 2′ position or modifications at the 4′ position. For example, in certain embodiments, the sugar comprises 2′-O—C1-4alkyl, such as 2′-O-methyl (2′-OMe). In certain embodiments, the sugar comprises 2′-O—C1-3alkyl-O—C1-3alkyl, such as 2′-methoxyethoxy (2′-O—CH2CH2OCH3) also known as 2′-O-(2-methoxyethyl) or 2′-MOE. In certain embodiments, the sugar comprises 2′-halo, such as 2′-F, 2′-Br, 2′-Cl, or 2′-I. In certain embodiments, the sugar comprises 2′-NH2. In certain embodiments, the sugar comprises 2′-H (e.g., a deoxynucleotide). In certain embodiments, the sugar comprises 2′-arabino or 2′-F-arabino. In certain embodiments, the sugar comprises 2′-LNA or 2′-ULNA. In certain embodiments, the sugar comprises a 4′-thioribosyl. In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified sugars. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified sugars. In certain embodiments, all sugars in a gRNA are modified.

In certain embodiments, the modification comprises a modified backbone (i.e., an internucleotide linkage other than a natural phosphodiester). Examples of modified internucleotide linkages include, but are not limited to, a phosphorothioate internucleotide linkage, a chiral phosphorothioate internucleotide linkage, a phosphorodithioate internucleotide linkage, a boranophosphonate internucleotide linkage, a C1-4alkyl phosphonate internucleotide linkage such as a methylphosphonate internucleotide linkage, a boranophosphonate internucleotide linkage, a phosphonocarboxylate internucleotide linkage such as a phosphonoacetate internucleotide linkage, a phosphonocarboxylate ester internucleotide linkage such as a phosphonoacetate ester internucleotide linkage, a thiophosphonocarboxylate internucleotide linkage such as for example a thiophosphonoacetate internucleotide linkage, a thiophosphonocarboxylate ester internucleotide linkage such as a thiophosphonoacetate ester internucleotide linkage. Various salts, mixed salts and free acid forms are also included. In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified internucleotide linkages. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified internucleotide linkages. In certain embodiments, all internucleotide linkages in a gRNA are modified.

In certain embodiments, the modification is a 2′-O—C1-4alkyl, 2′-H, 2′-O—C1-3alkyl-O—C1-3alkyl, 2′-F, 2′-NH2, 2′-arabino, 2′-F-arabino, 2′-LNA, 2′-ULNA, 4′-thioribosyl, 2-thioU, 2-thioC, 4-thioU, 6-thioG, 2-aminoA, 2-aminoP, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-MeC, 5-MeU, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allylU, 5-allylC, 5-aminoallyl-uracil, 5-aminoallyl-cytosine, an abasic nucleotide, Z, P, UNA, isoC, isoG, 5-methyl-pyrimidine, x(A,G,C,T), y(A,G,C,T), a 3′-phosphorothioate group, a 3′-phosphonoacetate group, a 3′-phosphonoacetate ester group, a 3′-thiophosphonoacetate group, a 3′-thiophosphonoacetate ester group, a 3′-methylphosphonate group, a 3′-boranophosphonate group, a 3′-phosphorodithioate group, or combinations thereof.

In certain embodiments, the modified nucleotide comprises a 2′-O-methyl-3′-phosphorothioate. In certain embodiments, the modified nucleotide comprises a 2′-O-methyl-3′-phosphonoacetate. In certain embodiments, the modified nucleotide comprises a 2′-O-methyl-3′-thiophosphonoacetate. In certain embodiments, the modified nucleotide comprises a Z base. In certain embodiments, the modified nucleotide comprises a 2′-halo-3′-phosphorothioate. In certain embodiments, the modified nucleotide comprises a 2′-halo-3′-phosphonoacetate. In certain embodiments, the modified nucleotide comprises a 2′-halo-3′-thiophosphonoacetate. In certain embodiments, the modified nucleotide comprises a 2′-fluoro-3′-phosphorothioate. In certain embodiments, the modified nucleotide comprises a 2′-fluoro-3′-phosphonoacetate. In certain embodiments, the modified nucleotide comprises a 2′-fluoro-3′-thiophosphonoacetate.

In certain embodiments, the guide RNA comprises an oligonucleotide represented by Formula (I):

W—Y or Y—W  (I)

wherein W represents a nucleotide or a stretch of nucleotides of the oligonucleotide comprising at least one modification and Y represents an unmodified portion of the oligonucleotide.

In certain embodiments, W is within the 5′ portion of the guide RNA. In certain embodiments, W is at least partially within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, W is at least partially within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, W is within the 3′ portion of the guide RNA. In certain embodiments, W is at least partially within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, W is at least partially within the last three (3) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, W is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA.

In certain embodiments, W comprises an end modification, such as a 5′ end modification or a 3′ end modification as described above. In certain embodiments, the end modification comprises dimethoxytrityl.

In certain embodiments, W comprises a modified base as described above. In certain embodiments, W comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified bases. In other embodiments, W comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified bases. In certain embodiments, all bases in a gRNA are modified.

In certain embodiments, W comprises a modified sugar as described above. In certain embodiments, W comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified sugars. In other embodiments, W comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified sugars. In certain embodiments, all sugars in a gRNA are modified.

In certain embodiments, W comprises a modified backbone (i.e., an internucleotide linkage other than a phosphodiester) as described above. In certain embodiments, W comprises more than one, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 modified internucleotide linkages. In other embodiments, W comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified internucleotide linkages. In certain embodiments, all internucleotide linkages in a gRNA are modified.

In certain embodiments, W comprises a 2′-O—C1-4alkyl, 2′-H, 2′-O—C1-3alkyl-O—C1-3alkyl, 2′-F, 2′-NH2, 2′-arabino, 2′-F-arabino, 2′-LNA, 2′-ULNA, 4′-thioribosyl, 2-thioU, 2-thioC, 4-thioU, 6-thioG, 2-aminoA, 2-aminoP, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-MeC, 5-MeU, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allylU, 5-allylC, 5-aminoallyl-uracil, 5-aminoallyl-cytosine, abasic nucleotides, Z, P, UNA, isoC, isoG, 5-methyl-pyrimidine, x(A,G,C,T), y(A,G,C,T), a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a phosphonoacetate ester internucleotide linkage, a thiophosphonoacetate internucleotide linkage, a thiophosphonoacetate ester internucleotide linkage a methylphosphonate internucleotide linkage, a boranophosphonate internucleotide linkage, a phosphorodithioate internucleotide linkage, or combinations thereof.

In certain embodiments, W comprises a 2′-O-methyl and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, W comprises a 2′-O-methyl and a 3′-phosphonoacetate group on the same nucleotide. In certain embodiments, W comprises a 2′-O-methyl and 3′-thiophosphonoacetate group on the same nucleotide. In certain embodiments, W comprises a 2′-F and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, W comprises a 2′-F and a 3′-phosphonoacetate group on the same nucleotide. In certain embodiments, W comprises a 2′-F and 3′-thiophosphonoacetate group on the same nucleotide.

In certain embodiments, W comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified nucleotides. In certain embodiments, each of the modified nucleotides comprises the same modification. In certain embodiments, W comprises a combination of variously modified nucleotides. In certain embodiments, W comprises two or more modified nucleotides. In certain embodiments, W comprises three or more modified nucleotides. In certain embodiments, the modified nucleotides are not arranged contiguously in the sequence, or at least not entirely, as one or more unmodified nucleotides may intercede. In certain embodiments, the modified nucleotides are arranged contiguously. In certain embodiments, W comprises at least one contiguous stretch of modified nucleotides. In certain embodiments, W comprises a contiguous stretch of at least three (3) modified nucleotides. In certain embodiments, W comprises a contiguous stretch of at least four (4) modified nucleotides. In certain embodiments, W comprises a contiguous stretch of at least five (5) modified nucleotides.

In certain embodiments, the guide RNA comprises an oligonucleotide represented by Formula (II):

M_(m)N_(n)  (II)

wherein each N independently represents an unmodified ribonucleotide;

wherein each M represents a modified nucleotide and is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 3′-P(S) ribonucleotide, a 3′-PACE ribonucleotide, a 3′-thioPACE ribonucleotide, a 2′-O-methyl-3′-P(S)-ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, a Z nucleotide, and a 2′-deoxynucleotide;

wherein each M is at any position of the sequence of the guide RNA;

wherein any given M is the same or different from any other M, and any given N is the same or different from any other N; and

wherein each of m and n are independently selected from an integer between 0 and 219, provided that 50<m+n≤220, and m is not 0.

In some embodiments, m+n<150.

In certain embodiments, each M is modified with one or more moieties independently selected from the group consisting of 2′-F, 2-thiouracil, 4-thiouracil, 2-aminoadenine, hypoxanthine, 5-methylcytosine, 5-methyluracil, 5-allylaminouracil, squarate linkage, a triazolo linkage, and a 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linkage. In some embodiments, M comprises a dye attached through a linker.

In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl-3′-PACE ribonucleotide and a 2′-O-methyl-3′-thioPACE ribonucleotide.

In certain embodiments, where m>1, any given M is the same or different from any other M. In certain embodiments, where m>1, each M has the same modification.

In certain embodiments, each M is a 2′-O-methyl-3′-PACE ribonucleotide, m is selected from an integer between 1 and 10, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl-3′-PACE ribonucleotide, m is selected from an integer between 1 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl-3′-PACE ribonucleotide, m is selected from an integer between 2 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 148, provided 50<m+n≤150. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5.

In certain embodiments, each M is a 2′-O-methyl-3′-thioPACE ribonucleotide, m is selected from an integer between 1 and 10, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl-3′-thioPACE ribonucleotide, m is selected from an integer between 1 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl-3′-thioPACE ribonucleotide, m is selected from an integer between 2 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 148, provided 50<m+n≤150. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5.

In certain embodiments, each M is a 2′-O-methyl ribonucleotide, m is selected from an integer between 1 and 40, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl ribonucleotide, m is selected from an integer between 1 and 25, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl ribonucleotide, m is selected from an integer between 1 and 20, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5. In certain embodiments, m is 10. In certain embodiments, m is 15. In certain embodiments, m is 20. In certain embodiments, m is 30. In certain embodiments, m is 40.

In certain embodiments, each M is a 2′-deoxynucleotide, m is selected from an integer between 1 and 30, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is 2′-deoxynucleotide, m is selected from an integer between 1 and 20, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, m is 5. In certain embodiments, m is 10. In certain embodiments, m is 15. In certain embodiments, m is 20. In certain embodiments, m is 30.

In certain embodiments, each M is a 2′-O-methyl-3′-P(S) ribonucleotide, m is selected from an integer between 1 and 10, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a 2′-O-methyl-3′-P(S) ribonucleotide, m is selected from an integer between 1 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5.

In certain embodiments, each M is a Z nucleotide, m is selected from an integer between 1 and 10, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, each M is a Z nucleotide, m is selected from an integer between 1 and 5, each N is independently selected from the group consisting of A, U, C, and G, and n is selected from an integer between 1 and 149, provided 50<m+n≤150. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5.

In certain embodiments, the modification is a stability-altering modification. In certain embodiments, the modification increases nuclease resistance of the guide RNA relative to a guide RNA without the modification, thus it enhances the guide RNA stability. In certain embodiments, the stability-altering modification is a stability-enhancing modification. For example, in certain embodiments, the stability-enhancing modification comprises a 2′-O-methyl or a 2′-O—C1-4alkyl nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-halo nucleotide, such as 2′-F, 2′-Br, 2′-Cl, or 2′-I. In certain embodiments, the stability-enhancing modification comprises a 2′MOE or a 2′-O—C1-3alkyl-O—C1-3alkyl. In certain embodiments, the stability-enhancing modification comprises a 2′-NH2 nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-H (or 2′-deoxy) nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-arabino or a 2′-F-arabino. In certain embodiments, the stability-enhancing modification comprises a 4′-thioribosyl sugar moiety. In certain embodiments, the stability-enhancing modification comprises a 3′-phosphorothioate group. In certain embodiments, the stability-enhancing modification comprises a 3′-phosphonoacetate group. In certain embodiments, the stability-enhancing modification comprises a nucleotide containing a 3′-thiophosphonoacetate group. In certain embodiments, the stability-enhancing modification comprises a nucleotide containing a 3′-methylphosphonate group. In certain embodiments, the stability-enhancing modification comprises a nucleotide containing a 3′-boranophosphate group. In certain embodiments, the stability-enhancing modification comprises a nucleotide containing a 3′-phosphorodithioate group. In certain embodiments, the stability-enhancing modification comprises a locked nucleic acid (“LNA”) nucleotide. In certain embodiments, the stability-enhancing modification comprises an unlocked nucleic acid (“ULNA”) nucleotide.

In certain embodiments, the stability-enhancing modification comprises a 2′-O-methyl and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-O-methyl and a 3′-phosphonoacetate group on the same nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-O-methyl and a 3′-thiophosphonoacetate group on the same nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-fluoro and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-fluoro and a 3′-phosphonoacetate group on the same nucleotide. In certain embodiments, the stability-enhancing modification comprises a 2′-fluoro and a 3′-thiophosphonoacetate group on the same nucleotide.

In certain embodiments, the modification is a specificity-altering modification. In some embodiments, specificity enhancement may be achieved by enhancing on-target binding and/or cleavage, or reducing off-target binding and/or cleavage, or a combination of both. In some other embodiments, specificity reduction may be achieved, for example, by reducing on-target binding and/or cleavage, or increasing off-target binding and/or cleavage, or a combination of both.

In certain embodiments, the specificity-altering modification comprises a 2′-O-methyl. In certain embodiments, the specificity-altering modification comprises a 2′-halo, such as 2′-fluoro.

In certain embodiments, the specificity-altering modification comprises a 2-thiouracil base (2-thioU). In certain embodiments, the specificity-altering modification comprises 2-thioC. In certain embodiments, the specificity-altering modification comprises 4-thioU. In certain embodiments, the specificity-altering modification comprises 6-thioG. In certain embodiments, the specificity-altering modification comprises 2-aminoA. In certain embodiments, the specificity-altering modification comprises a 2-aminopurine. In certain embodiments, the specificity-altering modification comprises pseudouracil. In certain embodiments, the specificity-altering modification comprises hypoxanthine. In certain embodiments, the specificity-altering modification comprises 7-deazaguanine. In certain embodiments, the specificity-altering modification comprises 7-deaza-8-azaguanine. In certain embodiments, the specificity-altering modification comprises 7-deazaadenine. In certain embodiments, the specificity-altering modification comprises 7-deaza-8-azaadenine. In certain embodiments, the specificity-altering modification comprises 5-methylC. In certain embodiments, the specificity-altering modification comprises 5-methylU. In certain embodiments, the specificity-altering modification comprises 5-hydroxymethylcytosine. In certain embodiments, the specificity-altering modification comprises 5-hydroxymethyluracil. In certain embodiments, the specificity-altering modification comprises 5,6-dehydrouracil. In certain embodiments, the specificity-altering modification comprises 5-propynylcytosine. In certain embodiments, the specificity-altering modification comprises 5-propynyluracil. In certain embodiments, the specificity-altering modification comprises 5-ethynylcytosine. In certain embodiments, the specificity-altering modification comprises 5-ethynyluracil. In certain embodiments, the specificity-altering modification comprises 5-allylU. In certain embodiments, the specificity-altering modification comprises 5-allylC. In certain embodiments, the specificity-altering modification comprises 5-aminoallylU. In certain embodiments, the specificity-altering modification comprises 5-aminoallylC. In certain embodiments, the specificity-altering modification comprises an abasic nucleotide. In certain embodiments, the specificity-altering modification comprises a Z base. In certain embodiments, the specificity-altering modification comprises P base. In certain embodiments, the specificity-altering modification comprises a UNA base. In certain embodiments, the specificity-altering modification comprises isoC. In certain embodiments, the specificity-altering modification comprises isoG. In certain embodiments, the specificity-altering modification comprises 5-methyl-pyrimidine. In certain embodiments, the specificity-altering modification comprises x(A,G,C,T). In certain embodiments, the specificity-altering modification comprises y(A,G,C,T).

In certain embodiments, the specificity-altering modification comprises a phosphorothioate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a phosphonoacetate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a thiophosphonoacetate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a methylphosphonate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a boranophosphate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a phosphorodithioate internucleotide linkage. In certain embodiments, the specificity-altering modification comprises a ULNA. In certain embodiments, the specificity-altering modification comprises an LNA.

In certain embodiments, the modification alters RNA base pairing by, for example, altering the melting temperature (Tm) of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification lowers the Tm of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification raises the Tm of the guide RNA relative to a guide RNA without the modification.

In certain embodiments, the specificity-altering modification lowers the Tm of a base pairing interaction. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is a 2′-deoxy, as it is well-known in the art that DNA/DNA base pairs have lower Tm than their respective counterpart in RNA/DNA duplexes. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is 2-thiouracil, which slightly lowers Tm of G-U wobble pair. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is a phosphorothioate internucleotide linkage or a phosphorodithioate internucleotide linkage, which lower the Tm by ˜0.5° C. per modification. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is a boranophosphonate internucleotide linkage, which lowers the Tm by ˜0.5-0.8° C. per modification. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is a phosphonoacetate internucleotide linkage, which lowers the Tm by ˜1.3° C. per modification. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is unlocked nucleic acid (“ULNA”), which lowers the Tm by ˜5-8° C. per modification. In certain embodiments, the modification that lowers the Tm of the base pairing interaction is 2′-O-methyl-3′-methylphosphonate.

In certain embodiments, the specificity-altering modification raises the Tm of a base pairing interaction. In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 2′-O-methyl, which raises Tm by ˜0.5-0.7° C. per modification. In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 2′-F, which raises Tm by ˜1° C. per modification. In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 2-thiouracil, which raises Tm of A-U pair (and, as noted above, slightly lowers Tm of G-U wobble pair). In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 4-thiouracil, which raises Tm of G-U wobble pair and slightly raises Tm of A-U pair. In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 2-amino-adenine, which raises Tm of its base pairing with U by ˜1° C. per modification. In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 5-methyl-uracil (5-methylU) (see, e.g., Wang & Kool (1995) Biochemistry, 34, 4125-32). In certain embodiments, the modification that raises the Tm of the base pairing interaction is a 5-methyl-cytosine (5-methylC). In certain embodiments, the modification that raises the Tm of the base pairing interaction is a locked nucleic acid (“LNA”), which raises Tm by 2-10° C. per modification.

In certain embodiments, the modification alters transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification increases transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification decreases transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification neutralizes the anionic charge on phosphate to allow passive diffusion into cells. In certain embodiments, the charge-neutralizing modification comprises a phosphonoacetate alkyl ester internucleotide linkage, such as a phosphonoacetate methyl ester internucleotide linkage.

In certain embodiments, the modification alters the immunostimulatory effect of the guide RNA relative to a guide RNA without the modification. It was initially discovered that unmethylated bacterial DNA and synthetic analogs thereof are ligands for TLR9 (see Hemmi et al. (2000) Nature, 408, 740-5). The stimulation of TLR9 can be mitigated in the dinucleotide motif for example by modifying the C and G residues. The use of 5-methylcytosine, 2-aminocytosine, 2-thiocytosine, 5-methylisocytosine, P nucleobase (6-(β-D-2′-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one), and 2′-O-methylcytosine all result in loss or decrease in TLR9 stimulation. In certain embodiments, use of 6-thioguanine, 2,6-diaminopurine, 2-aminopurine, xanthosine, inosine, 7-deazaxanthosine, isoguanine, 8-oxoguanine, nebularine, 8-bromoguanine, K-nucleobase (2-amino-N-methoxyadenosine), and/or 2′-O-methylguanine can result in loss or decrease in TLR9 stimulation. In some embodiments, use of phosphodiester modifications can lower or eliminate the TLR9 response. Typically, synthetically incorporated phosphorothioates can decrease the TLR9 response to a limited extent, as is thought to result from the presence of two stereoisomers of each phosphorothioate in synthetic RNA. However, it has been shown that phosphorothioate-modified DNA lacking CpG motifs stimulate TLR9 to a rather small extent. The negative charge on the phosphorus is an important element for recognition by TLR9 and therefore removing the negative charge using alkylphosphonates can result in loss or decrease in TLR9 stimulation. The use of phosphonoacetate (PACE) internucleotide linkages between deoxynucleosides in 5′ and 3′ terminal sequences can significantly increase the TLR9 response; however, the use of thiophosphonoacetate (thioPACE) internucleotide linkages between deoxynucleosides in 5′ and 3′ terminal sequences can result in loss or decrease in TLR9 stimulation. In certain embodiments, use of sugar modifications that the favor C3′-endo conformation such as 2′-O-methyl modifications can be incorporated at 5′ and 3′ termini to decrease the TLR9 response. TLR 7 and TLR8 can be stimulated by molecules containing 7-deazaguanine and by single-stranded RNA (see, e.g., Heil et al. (2004) Science, 303, 1526-9). TLR3 has been implicated in cellular immunoresponses to virus-derived double-stranded RNA. In certain embodiments, these TLR responses can be mitigated for example by using 2′-O-methyl modifications, modified phosphodiester linkages containing sulfur, or modifications that decrease internucleotide negative charge such as methylphosphonate and/or phosphonoacetate internucleotide linkages.

In certain embodiments, the modification enhances stability and specificity of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification enhances stability and transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification enhances specificity and transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, the modification enhances the overall efficacy of the guide RNA relative to a guide RNA without the modification.

C. Guide RNA with a Combination of Modifications

In one aspect, the present technology provides a guide RNA having a combination of two or more modifications.

In certain embodiments, the two modifications are on the same nucleotide (for example, one nucleotide comprises a 2′-O-methyl and a 3′-thiophosphonoacetate moiety). In other embodiments, the two modifications are on two different nucleotides (for example, one nucleotide has a 2-thioU base and another nucleotide has a 2′-O-methyl group).

In certain embodiments, each modification in the guide RNA is the same. In certain embodiments, at least one modification in the guide RNA is different from at least one other modification in the guide RNA. In certain embodiments, a single nucleotide within the guide RNA possesses two or more modifications.

In certain embodiments, the guide RNA comprises a combination of different types of modifications, and at least one type in the combination exists in multiple places in the guide RNA In certain embodiments, at least one type in the combination appears 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 times in the guide RNA.

In certain embodiments, at least one type of the modifications in the combination appears in two or more modified nucleotides. In certain embodiments, at least one type of the modifications in the combination appears in three or more modified nucleotides. In certain embodiments, the modified nucleotides are not arranged contiguously in the sequence, or at least not entirely, as one or more unmodified nucleotides may intercede. In certain embodiments, the modified nucleotides are arranged contiguously. In certain embodiments, the guide RNA comprises a stretch of contiguous modified nucleotides of the same type. In certain embodiments, the stretch has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 modified nucleotides.

In certain embodiments, at least one type of the modifications in the combination is within the 5′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the 3′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the last three (3) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA.

In certain embodiments, at least one type of the modifications in the combination is incorporated in the 5′ portion or 3′ portion of the guide RNA, particularly within the first 5 or 10 nucleotides of the 5′ portion or within the last 5 or 10 nucleotides of the 3′ portion to, for example, protect the RNA from degradation by nucleases or for other purposes. In certain embodiments, at least one type of the modifications in the combination is in the 5′ portion and at least one type of the modifications in the combination is in the 3′ portion of the guide RNA, particularly within the first 5 or 10 nucleotides of the 5′ portion and within the last 5 or 10 nucleotides of the 3′ portion to, for example, protect the RNA from degradation by nucleases or for other purposes. In certain embodiments, a guide RNA comprises 20 or fewer, alternatively 15 or fewer, alternatively 15 or fewer, alternatively 10 or fewer, alternatively 5 or fewer, alternatively 3 or fewer deoxyribonucleotide residues in the 5′ portion of the guide RNA.

In certain embodiments, at least one type of the modifications in the combination is within the crRNA segment of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the guide sequence of the crRNA. In certain embodiments, at least one type of the modifications in the combination is within the first five (5) nucleotides of the crRNA segment. In certain embodiments, at least one type of the modifications in the combination is within the first three (3) nucleotides of the crRNA segment. In certain embodiments, at least one type of the modifications in the combination is within the tracrRNA segment of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the last five (5) nucleotides of the tracrRNA segment of the guide RNA. In certain embodiments, at least one type of the modifications in the combination is within the last three (3) nucleotides of the tracrRNA segment of the guide RNA.

In certain embodiments, a first type of modification in the combination is within the 5′ portion of the guide RNA and a second type of modification in the combination is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the 5′ portion of the guide RNA.

In certain embodiments, a first type of modification in the combination is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA and a second type of modification in the combination is within the 3′ portion of the guide RNA. In certain embodiments, the second type of modification is within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, the second type of modification is within the last three (3) nucleotides of the 3′ portion of the guide RNA.

In certain embodiments, a first type of modification in the combination is within the 5′ portion of the guide RNA and a second type of modification in the combination is within the 3′ portion of the guide RNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the second type of modification is within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, the second type of modification is within the last three (3) nucleotides of the 3′ portion of the guide RNA.

In certain embodiments, a first type of modification in the combination is within the 5′ portion of the guide RNA, a second type of modification in the combination is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA, and a third type of modification in the combination is within the 3′ portion of the guide RNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, the third type of modification is within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, the third type of modification is within the last three (3) nucleotides of the 3′ portion of the guide RNA.

In certain embodiments, a first type of modification in the combination is within the crRNA segment of the guide RNA and a second type of modification in the combination is within the tracr segment. In certain embodiments, the first type of modification is within the guide sequence of the crRNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the crRNA segment. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the crRNA segment. In certain embodiments, the second type of modification is within the last five (5) nucleotides of the tracrRNA segment of the guide RNA. In certain embodiments, the second type of modification is within the last three (3) nucleotides of the tracrRNA segment of the guide RNA.

In certain embodiments, a first type and a second type of modification in the combination are within the crRNA segment of the guide RNA. In certain embodiments, the first type of modification is within the guide sequence of the crRNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the crRNA segment. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the crRNA segment.

In certain embodiments, a first type and a second type of modification in the combination are within the crRNA segment of the guide RNA and a third type of modification in the combination is within the tracr segment. In certain embodiments, the first type of modification is within the guide sequence of the crRNA. In certain embodiments, the first type of modification is within the first five (5) nucleotides of the crRNA segment. In certain embodiments, the first type of modification is within the first three (3) nucleotides of the crRNA segment. In certain embodiments, the third type of modification is within the last five (5) nucleotides of the tracrRNA segment of the guide RNA. In certain embodiments, the third type of modification is within the last three (3) nucleotides of the tracrRNA segment of the guide RNA.

In certain embodiments, at least one of the modifications in the combination comprises an end modification, such as a 5′ end modification or a 3′ end modification as described above. In certain embodiments, the end modification comprises dimethoxytrityl.

In certain embodiments, at least one of the modifications in the combination comprises a modified base. In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 modified bases. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified bases. In certain embodiments, all bases in a gRNA are modified.

In certain embodiments, at least one of the modifications in the combination comprises a modified sugar. In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 modified sugars. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified sugars. In certain embodiments, all sugars in a gRNA are modified.

In certain embodiments, at least one of the modifications in the combination comprises a modified backbone (i.e., an internucleotide linkage other than a natural phosphodiester). In certain embodiments, the modified gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 modified internucleotide linkages. In other embodiments, the modified gRNA comprises at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130 or 140 modified internucleotide linkages. In certain embodiments, all internucleotide linkages in a gRNA are modified.

In certain embodiments, at least one of the modifications in the combination comprises a 2′-O-methyl, a 2′-fluoro, a 2-amino, a 2′-deoxy, a 2′-arabino, a 2′-F-arabino, a 2-thiouracil, a 2-aminoadenine, a 5-methylcytosine, a 5-aminoallyluracil, a Z base, a 3′-phosphorothioate, a 3′-phosphonoacetate, a 3′-phosphonoacetate ester, a 3′-thiophosphonoacetate, a 3′-thiophosphonoacetate ester, a 3′-methylphosphonate, a 3′-boranophosphonate, a 3′-phosphorodithioate, or combinations thereof. In certain embodiments, at least one of the modifications in the combination comprises a 2′-O-methyl, a 2′-deoxy, a Z base, a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a thiophosphonoacetate internucleotide linkage, or combinations thereof. In certain embodiments, at least one of the modifications in the combination comprises a 2′-F, a 2-thioU, a 4-thioU, a 2-aminoA, a 5-methylC, a 5-methylU, a 5-aminoallylU, or combinations thereof. In certain embodiments, at least one of the modifications in the combination is an “end” modification such as terminal phosphate, a PEG, a terminal amine, a terminal linker such as a hydrocarbon linker, a substituted hydrocarbon linker, a squarate linker, a triazolo linker, an internal linker such as 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker, a linker conjugated to a dye, a linker conjugated to a non-fluorescent label, a linker conjugated to a tag or a linker conjugated to a solid support such as for example a bead or microarray. In certain embodiments, at least two of the modifications in the combination comprise a 2′-O-methyl nucleotide and phosphorothioate internucleotide linkage, a 2′-O-methyl nucleotide and phosphonoacetate internucleotide linkage, or a 2′-O-methyl nucleotide and thiophosphonoacetate internucleotide linkage. In certain embodiments, at least two of the modifications in the combination comprise a 2′-O-methyl nucleotide and phosphonocarboxylate internucleotide linkage, a 2′-O-methyl nucleotide and phosphonocarboxylate ester internucleotide linkage, a 2′-O-methyl nucleotide and thiophosphonocarboxylate internucleotide linkage, a 2′-O-methyl nucleotide and thiophosphonocarboxylate ester internucleotide linkage, or combinations thereof. In other embodiments, the modifications in the combination further comprise a 2-thiouracil, 2-thiocytosine, 4-thiouracil, 6-thioguanine, 2-aminoadenine, 2-aminopurine, pseudouracil, inosine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylcytosine, 5-methyluracil, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allyluracil, 5-allylcytosine, 5-aminoallyl-uracil, 5-aminoallyl-cytosine, or an abasic nucleotide.

In certain embodiments, at least one of the modifications in the combination comprises a 2′-O-methyl-3′-phosphorothioate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-O-methyl-3′-phosphonoacetate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-O-methyl-3′-thiophosphonoacetate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-halo-3′-phosphorothioate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-halo-3′-phosphonoacetate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-halo-3′-thiophosphonoacetate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-fluoro-3′-phosphorothioate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-fluoro-3′-phosphonoacetate. In certain embodiments, at least one of the modifications in the combination comprises a 2′-fluoro-3′-thiophosphonoacetate. Possible combinations of at least two or three modifications are represented in FIG. 6 and FIG. 7 respectively and are incorporated herein by reference.

In certain embodiments, the guide RNA comprises an oligonucleotide represented by Formula (III) or Formula (IV):

W—Y-Q  (III); or

Y—W—X-Q  (IV)

wherein Q and W each independently represent a nucleotide or a stretch of nucleotides of the oligonucleotide comprising at least one modification and Y and X each independently represent an unmodified portion of the oligonucleotide.

In certain embodiments, W is within the 5′ portion of the guide RNA. In certain embodiments, W is at least partially within the first five (5) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, W is at least partially within the first three (3) nucleotides of the 5′ portion of the guide RNA. In certain embodiments, W is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA.

In certain embodiments, Q is within the 3′ portion of the guide RNA. In certain embodiments, Q is at least partially within the last five (5) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, Q is at least partially within the last three (3) nucleotides of the 3′ portion of the guide RNA. In certain embodiments, Q is within the internal region (i.e., between the 5′ end and the 3′ end) of the guide RNA.

In certain embodiments, W comprises an end modification as described above, such as a 5′ end or a 3′ end modification. In certain embodiments, the end modification comprises dimethoxytrityl.

In certain embodiments, at least one of W or Q comprises a modified base as described above. In certain embodiments, at least one of W or Q comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 modified bases. In certain embodiments, at least one of W or Q comprises more than one modified base, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified bases.

In certain embodiments, at least one of W or Q comprises a modified sugar as described above. In certain embodiments, at least one of W or Q comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 modified sugars. In certain embodiments, at least one of W or Q comprises more than one, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified sugars.

In certain embodiments, at least one of W or Q comprises a modified backbone (i.e., an internucleotide linkage other than a phosphodiester) as described above. In certain embodiments, at least one of W or Q comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 modified internucleotide linkages. In certain embodiments, at least one of W or Q comprises more than one, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified internucleotide linkages.

In certain embodiments, at least one of W or Q comprises a 2′-O-methyl nucleotide, a 2′-F nucleotide, a 2′-amino nucleotide, a 2′-deoxy nucleotide, a 2-thiouridine nucleotide, a 2-aminoadeosine nucleotide, a 6-thioguanosine nucleotide, a 5-methylcytidine nucleotide, a 5-aminoallyluridine nucleotide, a Z nucleotide, a 3′-phosphorothioate internucleotide linkage, a 3′-phosphorothioate internucleotide linkage, a 3′-phosphonoacetate internucleotide linkage, a 3′-phosphonoacetate ester internucleotide linkage, a 3′-thiophosphonoacetate internucleotide linkage, a 3′-thiophosphonoacetate ester internucleotide linkage, a 3′-methylphosphonate internucleotide linkage, a 3′-boranophosphonate internucleotide linkage, a 3′-phosphorodithioate internucleotide linkage, or combinations thereof.

In certain embodiments, at least one of W or Q comprises a 2′-O-methyl and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, at least one of W or Q comprises a 2′-O-methyl and a 3′-phosphonoacetate group linkage on the same nucleotide. In certain embodiments, at least one of W or Q comprises a 2′-O-methyl and 3′-thiophosphonoacetate group on the same nucleotide. In certain embodiments, at least one of W or Q comprises a 2′-F and a 3′-phosphorothioate group on the same nucleotide. In certain embodiments, at least one of W or Q comprises a 2′-F and a 3′-phosphonoacetate group linkage on the same nucleotide. In certain embodiments, at least one of W or Q comprises a 2′-F and 3′-thiophosphonoacetate group on the same nucleotide.

In certain embodiments, at least one of W or Q comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified nucleotides. In certain embodiments, each of the modified nucleotides within at least one of W or Q comprises the same modification or modifications. In certain embodiments, W comprises a modified nucleotide that is different than a modified nucleotide in Q. In certain embodiments, at least one of W or Q comprises two or more modified nucleotides. In certain embodiments, at least one of W or Q comprises three or more modified nucleotides. In certain embodiments, the modified nucleotides are not arranged contiguously in the sequence, or at least not entirely, as one or more unmodified nucleotides may intercede. In certain embodiments, the modified nucleotides are arranged contiguously. In certain embodiments, at least one of W or Q comprises at least one contiguous stretch of modified nucleotides. In certain embodiments, at least one of W or Q comprises a contiguous stretch of at least three (3) modified nucleotides. In certain embodiments, at least one of W or Q comprises a contiguous stretch of at least four (4) modified nucleotides. In certain embodiments, at least one of W or Q comprises a contiguous stretch of at least five (5) modified nucleotides.

In certain embodiments, the guide RNA comprises a nucleotide sequence of Formula (V) or Formula (VI):

M_(m)N_(n)M′_(m′)N′_(n),  (Formula V); or

M_(m)N_(n)M′_(m′)N′_(n),M″_(m″)  (Formula VI)

wherein each M independently represents a modified ribonucleotide;

wherein each N independently represents an unmodified ribonucleotide;

wherein each M′ independently represents a modified ribonucleotide;

wherein each N′ independently represents an unmodified ribonucleotide;

wherein each M″ independently represents a modified ribonucleotide;

wherein m is an integer between 0 and 40, n is an integer between 0 and 130, m′ is an integer between 0 and 10, n′ is an integer between 0 and 130, m″ is an integer between 0 and 10, provided that m+m′+m″ is greater than or equal to 1 and 50<m+n+m′+n′+m″≤150.

In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, and a 2′-deoxynucleotide. In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl-3′-PACE ribonucleotide and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, where m>1, any given M is the same or different from any other M. In certain embodiments, where m>1, each M comprises the same modification or modifications.

In certain embodiments, each M′ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, and a 2′-deoxynucleotide. In certain embodiments, each M′ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M′ is independently selected from the group consisting of a 2′-O-methyl-3′-PACE ribonucleotide and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, where m′>1, any given M′ is the same or different from any other M′. In certain embodiments, where m′>1, each M′ comprises the same modification or modifications.

In certain embodiments, each M″ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, and a 2′-deoxynucleotide. In certain embodiments, each M″ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M″ is independently selected from the group consisting of a 2′-O-methyl-3′-PACE ribonucleotide and a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, where m″>1, any given M″ is the same or different from any other M″. In certain embodiments, where m′>1, each M″ comprises the same modification or modifications.

In certain embodiments, each M is a 2′-O-methyl-3′-PACE ribonucleotide; m is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; n is selected from an integer between 10 and 130; each M′ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S)ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, a 2′-deoxynucleotide, and a Z nucleotide; m′ is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; and n′ is selected from an integer between 0 and 130. In certain embodiments, each M′ is a 2′-O-methyl-3′-PACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-P(S) ribonucleotide. In certain embodiments, each M′ is a Z nucleotide.

In certain embodiments, each M is a 2′-O-methyl-3′-thioPACE ribonucleotide; m is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; n is selected from an integer between 10 and 130; each M′ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, a 2′-deoxynucleotide, and a Z nucleotide; m′ is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; and n′ is selected from an integer between 0 and 130. In certain embodiments, each M′ is a 2′-O-methyl-3′-PACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-P(S) ribonucleotide. In certain embodiments, each M′ is a Z nucleotide.

In certain embodiments, each M is a 2′-O-methyl-3′-P(S) ribonucleotide; m is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; n is selected from an integer between 10 and 130; each M′ is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, a 2′-deoxynucleotide, and a Z nucleotide; m′ is selected from an integer between 1 and 10; each N is independently selected from the group consisting of A, U, C, and G; and n′ is selected from an integer between 0 and 130. In certain embodiments, each M′ is a 2′-O-methyl-3′-PACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl ribonucleotide. In certain embodiments, each M′ is a 2′-O-methyl-3′-P(S)ribonucleotide. In certain embodiments, each M′ is a Z nucleotide.

In certain embodiments, each M is independently selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, a 2′-deoxynucleotide, and a Z nucleotide; m is selected from an integer between 0 and 10; each N is independently selected from the group consisting of A, U, C, and G; n is selected from an integer between 10 and 15; each M′ is a 2′-O-methyl ribonucleotide; m is selected from an integer between 1 and 5; each N is independently selected from the group consisting of A, U, C, and G; and n′ is selected from an integer between 0 and 130. In certain embodiments, each M is a 2′-O-methyl-3′-PACE ribonucleotide. In certain embodiments, each M is a 2′-O-methyl-3′-thioPACE ribonucleotide. In certain embodiments, each M is a 2′-O-methyl ribonucleotide. In certain embodiments, each M is a 2′-O-methyl-3′-P(S)ribonucleotide. In certain embodiments, m is 0; n is selected from an integer between 10 and 15, m′ is selected from an integer between 1 and 5; and n′ is selected from an integer between 0 and 130.

In certain embodiments, at least one of the modifications in the combination is a stability-altering modification. In certain embodiments, at least one of the modifications in the combination increases nuclease resistance of the guide RNA relative to a guide RNA without the modification, thus it enhances the stability of the guide RNA.

In certain embodiments, at least one of the modifications in the combination is a stability-enhancing modification as described above.

In certain embodiments, at least one of the modifications in the combination is a specificity-altering modification as described above.

In certain embodiments, at least one of the modifications in the combination alters RNA base pairing. In certain embodiments, at least one of the modifications in the combination lowers the Tm of a base pairing interaction as described above. In certain embodiments, at least one of the modifications in the combination raises the Tm of a base pairing interaction as described above.

In certain embodiments, at least one of the modifications in the combination alters transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, at least one of the modifications in the combination increases transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, at least one of the modifications in the combination decreases transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, at least one of the transfection-increasing modifications in the combination comprises a phosphonoacetate alkyl ester internucleotide linkage, such as a phosphonoacetate methyl ester internucleotide linkage.

In certain embodiments, at least one of the modifications in the combination enhances stability and specificity of the guide RNA relative to a guide RNA without the modification. In certain embodiments, at least one of the modifications in the combination enhances stability and transfection efficiency of the guide RNA relative to a guide RNA without the modification. In certain embodiments, at least one of the modifications in the combination enhances specificity and transfection efficiency of the guide RNA relative to a guide RNA without the modification.

In certain embodiments, at least one of the modifications in the combination alters the secondary structure of the guide RNA. This modification alters the base-pairing of any of the RNA/RNA internal duplexes in the guide RNA. Some of these modifications increase the base pairing of the RNA/RNA structure or alternatively increase the Tm of the RNA/RNA duplex, whereas other modifications decrease the base pairing (or Tm) of the RNA/RNA duplex or duplexes. Such modifications include base modified nucleotides, particularly UNA nucleotides such as the 2-thiouridine and 2-aminoadenosine pair, the Z/P nucleotide pair, the isoC/isoG pair, the 6-thioG/5-methylpyrimidine pair, and nucleotides with modifications on the sugar or the internucleotide linkages as discussed before.

In certain embodiments, the combination includes at least one modification or a set of modifications that increases nucleases resistance (i.e., stability) with at least one modification or a set of modifications that increases specificity (i.e., reduces off-target effects). In certain embodiments, the combination includes at least one modification or a set of modifications that increases nucleases resistance (i.e., stability) with at least one modification or a set of modifications that raises the Tm of some bases pairing in the guide RNA. In certain embodiments, the combination includes at least one modification or a set of modifications that increases nucleases resistance (i.e., stability) with at least one modification or a set of modifications that lowers the Tm of some bases pairing of the guide RNA. In certain embodiments, the combination includes at least one modification or a set of modifications that increases nuclease resistance (i.e., stability), at least one modification or a set of modifications that increases the Tm of some bases paring in the guide RNA, and at least one modification or a set of modifications that decreases the Tm of some base paring elsewhere in the guide RNA. In certain embodiments, the combination includes at least one modification or a set of modifications that increases nuclease resistance (i.e., stability) and at least one modification or a set of modifications that increases the binding of the guide RNA to Cas protein. In certain embodiments, the combination includes at least one modification or a set of modifications that increases nuclease resistance (i.e., stability) and at least one modification or a set of modifications that decreases the binding of the guide RNA to Cas protein. In certain embodiments, the guide RNA comprises a combination of the different types of modifications.

D. Guide RNA Structure

In certain embodiments, the guide RNA is able to form a complex with a CRISPR-associated-protein. In certain embodiments, the CRISPR-associated protein is provided by or is derived from a CRISPR-Cas type II system, which has an RNA-guided polynucleotide binding and/or nuclease activity. In certain embodiments, the CRISPR-associated protein is Cas9, a Cas9 mutant, or a Cas9 variant. In certain embodiments, the CRISPR-associated protein is the Cas9 nuclease from Streptococcus pyogenes. In certain embodiments, the CRISPR-associated protein is the Cas9 nuclease from Streptococcus thermophilus. In certain embodiments, the CRISPR-associated protein is the Cas9 nuclease from Staphylococcus aureus. In certain embodiments, the synthetic guide RNA or a synthetic guide RNA:CRISPR-associated protein complex maintains functionality of natural guide RNA or a complex that does not have modified nucleotides. In certain embodiments, the functionality includes binding a target polynucleotide. In certain embodiments, the functionality includes nicking a target polynucleotide. In certain embodiments, the functionality includes cleaving a target polynucleotide. In certain embodiments, the target polynucleotide is within a nucleic acid in vitro. In certain embodiments, the target polynucleotide is within the genome of a cell in vivo or in vitro (such as in cultured cells or cells isolated from an organism). In certain embodiments, the target polynucleotide is a protospacer in DNA.

In certain embodiments, the crRNA segment comprises from 25 to 80 nucleotides. In certain embodiments, the crRNA segment comprises a guide sequence that is capable of hybridizing to a target sequence. In certain embodiments, the guide sequence is complementary to the target sequence or a portion thereof. In certain embodiments, the guide sequence comprises from 15 to 30 nucleotides. In certain embodiments, the crRNA segment comprises a stem sequence. In certain embodiments, the stem sequence comprises from 10 to 50 nucleotides. In certain embodiments, the crRNA segment comprises a 5′-overhang sequence. In certain embodiments, the 5′-overhang sequence comprises from 1 to 10 nucleotides, alternatively 1 to 5 nucleotides, alternatively 1, 2 or 3 nucleotides. In certain embodiments, the crRNA comprises both (i) a guide sequence that is capable of hybridizing to a target sequence and (ii) a stem sequence. In certain embodiments, the crRNA comprises (i) a 5′-overhang sequence, (ii) a guide sequence that is capable of hybridizing to a target sequence, and (iii) a stem sequence. In certain embodiments wherein the crRNA segment comprises a stem sequence, the tracrRNA segment comprises a nucleotide sequence that is partially or completely complementary to the stem sequence of the crRNA segment. In certain embodiments, the tracrRNA segment comprises at least one more duplex structure.

In certain embodiments, the guide RNA is a single guide RNA. In certain embodiments, the guide RNA is a single guide RNA, wherein the crRNA segment and the tracrRNA segment are linked through a loop L. In certain embodiments, the loop L comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In certain embodiments, the loop L comprises a nucleotide sequence of GNRA, wherein N represents A, C, G, or U and R represents A or G. In certain embodiments, the loop L comprises a nucleotide sequence of GAAA. In certain embodiments, the guide RNA comprises more than one loop.

The guide RNA comprises a 5′ portion (i.e., the 5′ half) and a 3′ portion (i.e., the 3′ half). In certain embodiments, the crRNA segment is 5′ (i.e., upstream) of the tracrRNA segment. In certain embodiments, the tracrRNA segment is 5′ relative to the crRNA segment.

In certain embodiments, the guide RNA comprises at least two separate RNA strands, for example, a crRNA strand and a separate tracrRNA strand. See, for example, FIG. 5A. In certain embodiments, each of the strands is a synthetic strand comprising one or more modifications. In certain embodiments, at least one of the strands is a synthetic strand comprising one or more modifications. In certain embodiments, the strands function together to guide binding, nicking, or cleaving of a target polynucleotide by a Cas protein, such as Cas9. In certain embodiments, the crRNA sequence and the tracrRNA sequence are on separate stands and hybridize to each other via two complementary sequences to form a stem or duplex.

In certain embodiments, the guide RNA is a single guide RNA comprising a crRNA sequence and a tracrRNA sequence. See, for example, FIG. 5B. In certain embodiments, the crRNA sequence and the tracrRNA sequence are connected by a loop sequence or “loop.” In certain embodiments, a single guide RNA comprises a 5′ portion and a 3′ portion, wherein the crRNA sequence is upstream of the tracrRNA sequence.

In certain embodiments, the total length of the two RNA pieces can be about 50-220 (e.g., about 55-200, 60-190, 60-180, 60-170, 60-160, 60-150, 60-140, 60-130, and 60-120) nucleotides in length, such as about 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, or 220 nucleotides in length. Similarly, the single guide RNA (e.g., FIG. 5B) can be about 50-220 (e.g., about 55-200, 60-190, 60-180, 60-170, 60-160, 60-150, 60-140, 60-130, and 60-120) nucleotides in length, such as about 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, or 220 nucleotides in length.

As shown in FIGS. 5A and 5B, the synthetic guide RNA comprises (i) a crRNA sequence that comprises (a) a guide sequence (e.g., segment G1-Gn, where each G represents a nucleotide in the guide sequence) capable of hybridizing to a target sequence in a nucleic acid, (b) a first stem sequence (e.g., segment X1-Xn, where each X represents a nucleotide in the first stem sequence) capable of hybridizing partially or completely to a second stem sequence, and, optionally (c) a 5′-overhang sequence (e.g., segment 01-On, where each O represents a nucleotide in the overhang sequence), and (ii) a tracrRNA sequence that comprises the second stem sequence (e.g., segment Y1-Yn, where each Y represents a nucleotide in the second stem sequence). The tracrRNA sequence further comprises segment T1-Tn, where each T represents a nucleotide in the tracrRNA sequence. The synthetic guide RNA shown in FIG. 5A includes one or more modifications. Likewise, the synthetic guide RNA shown in FIG. 5B includes one or more modifications. In certain embodiments, the modification is located at any point along the length of the crRNA, the tracrRNA, or the single guide RNA comprising a crRNA segment, a tracrRNA segment, and, optionally, a loop. In certain embodiments, any nucleotide represented by O, G, X, Y, or T in the synthetic guide RNA shown in FIGS. 5A and 5B may be a modified nucleotide. The guide RNA shown in FIG. 5B represents a single guide RNA (sgRNA) where the crRNA segment and the tracrRNA segment are connected by a loop having the sequence GNRA, wherein N represents A, C, G, or U, and R represents A or G.

In certain embodiments, the crRNA segment of the guide RNA is 25-70 (e.g., 30-60, 35-50, or 40-45) nucleotides in length. In certain embodiments, the guide sequence is 12-30 (e.g., 16-25, 17-20, or 15-18) nucleotides in length. In some embodiments, a 5′ portion of the crRNA does not hybridize or only partially hybridizes with the target sequence. For example, there can be a 5′-overhang on the crRNA segment.

In certain embodiments, the single guide RNA comprises a central portion including the stem sequence of the crRNA segment, the stem sequence of the tracrRNA segment, and, optionally, a loop that covalently connects the crRNA segment to the tracrRNA segment. In certain embodiments, the central segment of the single guide RNA is 8-60 (e.g., 10-55, 10-50, or 20-40) nucleotides in length.

In certain embodiments, the tracrRNA segment of the guide RNA is 10-130 (e.g., 10-125, 10-100, 10-75, 10-50, or 10-25) nucleotides in length. In certain embodiments, the tracrRNA segment includes one or more hairpin or duplex structures in addition to any hairpin or duplex structure in the central segment.

In certain embodiments, the tracrRNA is truncated compared to a reference tracrRNA, such as a naturally existing mature tracrRNA. A range of lengths has been shown to function in both the separate type (FIG. 5A) and the chimeric sgRNA type (FIG. 5B). For example, in certain embodiments, tracrRNA may be truncated from its 3′ end by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 or 40 nts. In certain embodiments, the tracrRNA molecule may be truncated from its 5′ end by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 nts. In certain embodiments, the tracrRNA molecule may be truncated from both the 5′ and 3′ end, e.g., by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 nts from the 5′ end and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 or 40 nts from the 3′ end. See, e.g., Jinek et al. (2012) Science, 337, 816-21; Mali et al. (2013) Science, 339:6121, 823-6; Cong et al. (2013) Science, 339:6121, 819-23; and Hwang et al. (2013) Nat. Biotechnol. 31:3, 227-9; Jinek et al. (2013) eLife, 2, e00471. In certain embodiments, the tracrRNA is untruncated.

In certain embodiments, the disclosed modifications are in the crRNA segment or the tracrRNA segment or both. In certain embodiments, the disclosed modifications are in the guide sequence of the crRNA segment. In certain embodiments, the disclosed modifications are in the stem sequence of the crRNA segment. In certain embodiments, the disclosed modifications are in the 5′-overhang sequence of the crRNA segment. In certain embodiments, the disclosed modifications are in the stem sequence of the tracrRNA segment. In certain embodiments, the disclosed modifications are in the loop sequence of the guide RNA. In certain embodiments, the disclosed modifications are in the 5′ portion of the guide RNA. In certain embodiments, the disclosed modifications are in the 3′ portion of the guide RNA. In certain embodiments, the disclosed modifications are in the 5′ portion of the guide RNA and the 3′ portion of the guide RNA.

E. Synthesis of Guide RNA

In certain embodiments, guide RNAs, including single guide RNAs (sgRNAs; see FIGS. 1 and 5B) are produced by chemical synthesis using the art of synthetic organic chemistry. A guide RNA that comprises any nucleotide other than the four predominant ribonucleotides, namely A, C, G, and U, whether unnatural or natural, such as a pseudouridine, inosine or a deoxynucleotide, possesses a chemical modification or substitution at the nucleotide which is chemically/structurally distinct from any of the four predominant nucleotides in RNAs.

The synthetic guide RNAs described herein can be chemically synthesized. For example, the synthetic guide RNAs can be synthesized using TC chemistry by the method described in Dellinger et al. (2011) J. Am. Chem. Soc., 133, 11540, U.S. Pat. No. 8,202,983, and US Patent Application 2010/0076183A1, the contents of which are incorporated by reference in their entireties. “TC chemistry” refers to the composition and methods of using RNA monomeric nucleotide precursors protected on the 2′-hydroxyl moiety by a thionocarbamate protecting group, to synthesize unmodified RNA or modified RNA comprising one or more modified nucleotides. The ability to chemically synthesize relatively long RNAs (as long as 200 mers or more) using TC-RNA chemistry allows one to produce guide RNAs with special features capable of outperforming those enabled by the four predominant ribonucleotides (A, C, G and U). Some synthetic guide RNAs described herein can also be made using methods known in the art that include in vitro transcription and cell-based expression. For example, 2′-fluoro NTPs can be incorporated into synthetic guide RNAs produced by cell-based expression.

Synthesis of guide RNAs can also be accomplished by chemical or enzymatic synthesis of RNA sequences that are subsequently ligated together by enzymes, or chemically ligated by chemical ligation, including but not limited to cyanogen bromide chemistry, “click” chemistry as published by R. Kumar et al. (2007) J. Am. Chem. Soc., 129, 6859-64, or squarate conjugation chemistry as described by K. Hill in WO2013176844 titled “Compositions and methods for conjugating oligonucleotides.”

As further described below, a guide RNA disclosed herein, including those comprising modified nucleotides and/or modified internucleotide linkages, can be used to perform various CRISPR-mediated functions (including but not limited to editing genes, regulating gene expression, cleaving target sequences, and binding to target sequences) in vitro or in vivo, such as in cell-free assays, in intact cells, or in whole organisms. For in vitro or in vivo applications, the RNA can be delivered into cells or whole organisms in any manner known in the art.

Libraries and Arrays

In one aspect, the present invention provides a set or library of multiple guide RNAs. In certain embodiments, the library contains two or more guide RNAs disclosed herein. The library can contain from about 10 to about 107 individual members, e.g., about 10 to about 102, about 102 to about 103, about 103 to about 105, from about 105 to about 107 members. An individual member of the library differs from other members of the library at least in the guide sequence, i.e., the DNA targeting segment of the gRNA. On the other hand, in certain embodiments, each individual member of a library can contain the same or substantially the same nucleotide sequence for the tracrRNA segment as all the other members of the library. In this way, the library can comprise members that target different polynucleotides or different sequences in one or more polynucleotides.

In certain embodiments, the library comprises at least 102 unique guide sequences. In certain embodiments, the library comprises at least 103 unique guide sequences. In certain embodiments, the library comprises at least 104 unique guide sequences. In certain embodiments, the library comprises at least 105 unique guide sequences. In certain embodiments, the library comprises at least 106 unique guide sequences. In certain embodiments, the library comprises at least 107 unique guide sequences. In certain embodiments, the library targets at least 10 different polynucleotides. In certain embodiments, the library targets at least 102 different polynucleotides. In certain embodiments, the library targets at least 103 different polynucleotides. In certain embodiments, the library targets at least 104 different polynucleotides. In certain embodiments, the library targets at least 105 different polynucleotides. In certain embodiments, the library targets at least 106 different polynucleotides. In certain embodiments, the library targets at least 107 different polynucleotides.

In certain embodiments, the library comprises a collection of guide RNAs having the same sequence and the same modifications in a progressively shifted window that moves across the sequence of the members in the library. In certain embodiments, the windows collectively cover the entire length of the RNA.

In certain embodiments, the library allows one to conduct high-throughput, multi-target genomic manipulations and analyses. In certain embodiments, only the DNA-targeting segments of the guide RNAs are varied, while the Cas protein-binding segment is the same. In certain embodiments, a first portion of the library comprises guide RNAs possessing a Cas-binding segment that recognizes, binds and directs a particular Cas protein and a second portion of the library comprises a different Cas-binding segment that recognizes, binds and directs a different Cas protein (e.g., a Cas protein from a different species), thereby allowing the library to function with two or more orthogonal Cas proteins. In certain embodiments, induced expression of a first orthogonal Cas protein utilizes the portion of the library which interacts with the first orthogonal Cas protein. In certain embodiments, induced expression of a first and second orthogonal Cas protein utilizes the portions of the library which interact with the first and second orthogonal Cas proteins, respectively. In certain embodiments, induced expression of the first and second orthogonal Cas proteins occur at different times. Accordingly, one can carry out large-scale gene editing or gene regulation by specifically manipulating or modifying multiple targets as specified in the library.

In certain embodiments, the library is an “arrayed” library, namely a collection of different features or pools of features in an addressable arrangement. For example, features of an array can be selectively cleaved and transferred to a microtiter plate such that each well in the plate contains a known feature or a known pool of features. In some other embodiments, the library is synthesized in a 48-columns or in a 96-columns microtiter plate format or in a 384-columns plate.

In certain embodiments, synthesis of the guide RNA of this invention may be conducted on a solid support having a surface to which chemical entities may bind. In some embodiments, guide RNAs being synthesized are attached, directly or indirectly, to the same solid support and may form part of an array. An “array” is a collection of separate molecules of known monomeric sequence each arranged in a spatially defined and a physically addressable manner, such that the location of each sequence is known. An “array,” or “microarray’ used interchangeably herein includes any one-dimensional, two-dimensional or substantially two-dimensional (as well as a three-dimensional) arrangement of addressable regions bearing a particular chemical moiety or moieties (such as ligands, e.g., biopolymers such as polynucleotide or oligonucleotide sequences (nucleic acids), polypeptides (e.g., proteins), carbohydrates, lipids, etc.) associated with that region. An array is “addressable” when it has multiple regions of different moieties (e.g., different polynucleotide sequences) such that a region (i.e., a “feature” of the array) at a particular predetermined location (i.e., an “address”) on the array will detect a particular target or class of targets (although a feature may incidentally detect non-targets of that feature). Array features are typically, but need not be, separated by intervening spaces. The number of features that can be contained on an array will largely be determined by the surface area of the substrate, the size of a feature and the spacing between features. Arrays can have densities of up to several hundred thousand or more features per cm2, such as 2,500 to 200,000 features/cm2. The features may or may not be covalently bonded to the substrate.

Suitable solid supports may have a variety of forms and compositions and derive from naturally occurring materials, naturally occurring materials that have been synthetically modified, or synthetic materials. Examples of suitable support materials include, but are not limited to, silicas, silicon and silicon oxides, teflons, glasses, polysaccharides such as agarose (e.g., Sepharose® from Pharmacia) and dextran (e.g., Sephadex® and Sephacyl®, also from Pharmacia), polyacrylamides, polystyrenes, polyvinyl alcohols, copolymers of hydroxyethyl methacrylate and methyl methacrylate, and the like. In some embodiments, the solid support is a plurality of beads.

The initial monomer of the guide RNAs to be synthesized on the substrate surface can be bound to a linker which in turn is bound to a surface hydrophilic group, e.g., a surface hydroxyl moiety present on a silica substrate. In some embodiments, a universal linker is used. In some other embodiments, the initial monomer is reacted directly with, e.g., a surface hydroxyl moiety. Alternatively, guide RNAs can be synthesized first according to the present invention, and attached to a solid substrate post-synthesis by any method known in the art. Thus, the present invention can be used to prepare arrays of guide RNAs wherein the oligonucleotides are either synthesized on the array, or attached to the array substrate post-synthesis. Subsequently, the guide RNAs or a pool or a plurality of pools of guide RNAs can optionally and selectively be cleaved from the array substrate and be used as a library or libraries.

IV. Cas Proteins

As mentioned above, a functional CRISPR-Cas system also requires a protein component (e.g., a Cas protein, which may be a Cas nuclease) that provides a desired activity, such as target binding or target nicking/cleaving. In certain embodiments, the desired activity is target binding. In certain embodiments, the desired activity is target nicking or target cleaving. In certain embodiments, the desired activity also includes a function provided by a polypeptide that is covalently fused to a Cas protein, as disclosed herein. In certain embodiments, the desired activity also includes a function provided by a polypeptide that is covalently fused to a nuclease-deficient Cas protein, as disclosed herein. Examples of such a desired activity include a transcription regulation activity (either activation or repression), an epigenetic modification activity, or a target visualization/identification activity, as described below. The Cas protein can be introduced into an in vitro or in vivo system as a purified or non-purified (i) Cas protein or (ii) mRNA encoded for expression of the Cas protein or (iii) linear or circular DNA encoded for expression of the protein. Any of these 3 methods of providing the Cas protein are well known in the art and are implied interchangeably when mention is made herein of a Cas protein or use of a Cas protein. In certain embodiments, the Cas protein is constitutively expressed from mRNA or DNA. In certain embodiments, the expression of Cas protein from mRNA or DNA is inducible or induced.

In certain embodiments, the Cas protein is chemically synthesized (see e.g., Creighton, “Proteins: Structures and Molecular Principles,” W.H. Freeman & Co., NY, 1983), or produced by recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Frederick M. Ausubel et al., “Current Protocols in Molecular Biology,” John Wiley & Sons, 2003; and Sambrook et al., “Molecular Cloning, A Laboratory Manual,” Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 2001).

In certain embodiments, the Cas protein is provided in purified or isolated form. In certain embodiments, the Cas protein is provided at about 80%, about 90%, about 95%, or about 99% purity. In certain embodiments, the Cas protein is provided as part of a composition. In certain embodiments, the Cas protein is provided in aqueous compositions suitable for use as, or inclusion in, a composition for an RNA-guided nuclease reaction. Those of skill in the art are well aware of the various substances that can be included in such nuclease reaction compositions.

In certain embodiments, a Cas protein is provided as a recombinant polypeptide. In certain examples, the recombinant polypeptide is prepared as a fusion protein. For example, in certain embodiments, a nucleic acid encoding the Cas protein is linked to another nucleic acid encoding a fusion partner, e.g., glutathione-s-transferase (GST), 6×-His epitope tag, or M13 Gene 3 protein. Suitable host cells can be used to expresses the fusion protein. In certain embodiments, the fusion protein is isolated by methods known in the art. In certain embodiments, the fusion protein can be further treated, e.g., by enzymatic digestion, to remove the fusion partner and obtain the Cas protein. Alternatively, Cas protein:guide RNA complexes can be made with recombinant technology using a host cell system or an in vitro translation-transcription system known in the art. Details of such systems and technology can be found in e.g., WO2014144761 WO2014144592, WO2013176772, US20140273226, and US20140273233, the contents of which are incorporated herein by reference in their entireties.

Wild Type Cas Proteins

In certain embodiments, a Cas protein comprises a protein derived from a CRISPR-Cas type I, type II, or type III system, which has an RNA-guided polynucleotide binding and/or nuclease activity. Non-limiting examples of suitable Cas proteins include Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966. See e.g., WO2014144761 WO2014144592, WO2013176772, US20140273226, and US20140273233, the contents of which are incorporated herein by reference in their entireties.

In certain embodiments, the Cas protein is derived from a type II CRISPR-Cas system. In certain embodiments, the Cas protein is or is derived from a Cas9 protein. In certain embodiments, the Cas protein is or is derived from a bacterial Cas9 protein, including those identified in WO2014144761. In certain embodiments, the Cas protein is or is derived from a Streptococcus sp. or Staphylococcus sp. Cas9 protein. In certain embodiments, the Cas protein is or is derived from the Streptococcus thermophilus Cas9 protein. In certain embodiments, the Cas protein is or is derived from a the Streptococcus pyogenes Cas9 protein. In certain embodiments, the Cas protein is or is derived from the Staphylococcus aureus Cas9 protein. In certain embodiments, the Cas protein is or is derived from the Streptococcus thermophilus Cas9 protein.

In certain embodiments, the wild type Cas protein is a Cas9 protein. In certain embodiments, the wild type Cas9 protein is the Cas9 protein from S. pyogenes (SEQ ID NO: 1). In certain embodiments, the protein or polypeptide can comprise, consist of, or consist essentially of a fragment of SEQ ID NO: 1.

In general, a Cas protein includes at least one RNA binding domain, which interacts with the guide RNA. In certain embodiments, the Cas protein is modified to increase nucleic acid binding affinity and/or specificity, alter an enzymatic activity, and/or change another property of the protein. For example, nuclease (i.e., DNase, RNase) domains of the Cas protein can be modified, mutated, deleted, or inactivated. Alternatively, the Cas protein can be truncated to remove domains that are not essential for the function of the protein. In certain embodiments, the Cas protein is truncated or modified to optimize the activity of the effector domain. In certain embodiments, the Cas protein includes a nuclear localization sequence (NLS) that effects importation of the NLS-tagged Cas protein into the nucleus of a living cell. In certain embodiments, the Cas protein includes two or more modifications.

Mutant Cas Proteins

In some embodiments, the Cas protein can be a mutant of a wild type Cas protein (such as Cas9) or a fragment thereof. In other embodiments, the Cas protein can be derived from a mutant Cas protein. For example, the amino acid sequence of the Cas9 protein can be modified to alter one or more properties (e.g., nuclease activity, binding affinity, stability to proteases, etc.) of the protein. Alternatively, domains of the Cas9 protein not involved in RNA-guided cleavage can be eliminated from the protein such that the modified Cas9 protein is smaller than the wild type Cas9 protein. For example, reducing the size of the Cas9 coding sequence can allow it to fit within a transfection vector that otherwise cannot accommodate the wild type sequence, such as the AAV vector among others. In some embodiments, the present systemutilizes the Cas9 protein from S. pyogenes, either as encoded in bacteria or codon-optimized for expression in eukaryotic cells. Shown below is the amino acid sequence of wild type S. pyogenes Cas9 protein sequence (SEQ ID No. 1, Uniprot No. Q99ZW2).

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK LNREDLLRKQRTFDNGSIPHQIHLGELHATLRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKK GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI EEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL SDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINN YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEI GKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEK NPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQIS EFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

A Cas9 protein generally has at least two nuclease (e.g., DNase) domains. For example, a Cas9 protein can have a RuvC-like nuclease domain and an HNH-like nuclease domain. The RuvC and HNH domains work together to cut both strands in a target site to make a double-stranded break in the target polynucleotide. (Jinek et al., Science, 337: 816-821). In certain embodiments, a mutant Cas9 protein is modified to contain only one functional nuclease domain (either a RuvC-like or an HNH-like nuclease domain). For example, in certain embodiments, the mutant Cas9 protein is modified such that one of the nuclease domains is deleted or mutated such that it is no longer functional (i.e., the nuclease activity is absent). In some embodiments where one of the nuclease domains is inactive, the mutant is able to introduce a nick into a double-stranded polynucleotide (such protein is termed a “nickase”) but not able to cleave the double-stranded polynucleotide. For example, an aspartate to alanine (D10A) conversion in a RuvC-like domain converts the Cas9-derived protein into a nickase. Likewise, a histidine to alanine (H840A) conversion in a HNH domain converts the Cas9-derived protein into a nickase. Likewise, an arsparagine to alanine (N863A) conversion in a HNH domain converts the Cas9-derived protein into a nickase.

In certain embodiments, both the RuvC-like nuclease domain and the HNH-like nuclease domain are modified or eliminated such that the mutant Cas9 protein is unable to nick or cleave the target polynucleotide. In certain embodiments, all nuclease domains of the Cas9-derived protein are modified or eliminated such that the Cas9-derived protein lacks all nuclease activity. In certain embodiments, a Cas9 protein that lacks some or all nuclease activity relative to a wild-type counterpart, nevertheless, maintains target recognition activity to a greater or lesser extent.

In any of the above-described embodiments, any or all of the nuclease domains can be inactivated by one or more deletion mutations, insertion mutations, and/or substitution mutations using well-known methods, such as site-directed mutagenesis, PCR-mediated mutagenesis, and total gene synthesis, as well as other methods known in the art.

In certain embodiments, the “Cas mutant” or “Cas variant” is at least 50% (e.g., any number between 50% and 100%, inclusive, e.g., 50%, 60%, 70%, 80%, 90%, 95%, 98%, and 99%) identical to SEQ ID NO: 1. In certain embodiments, the “Cas mutant” or “Cas variant” binds to an RNA molecule (e.g., a sgRNA). In certain embodiments, the “Cas mutant” or “Cas variant” is targeted to a specific polynucleotide sequence via the RNA molecule.

Fusion Proteins

In certain embodiments, the Cas protein is fused to another protein or polypeptide heterologous to the Cas protein to create a fusion protein. In certain embodiments, the heterologous sequence includes one or more effector domains, such as a cleavage domain, a transcriptional activation domain, a transcriptional repressor domain, or an epigenetic modification domain. Additional examples of the effector domain include a nuclear localization signal, cell-penetrating or translocation domain, or a marker domain. In certain embodiments, the effector domain is located at the N-terminal, the C-terminal, or in an internal location of the fusion protein. In certain embodiments, the Cas protein of the fusion protein is or is derived from a Cas9 protein. In certain embodiments, the Cas protein of the fusion protein is or is derived from a modified or mutated Cas protein in which all the nuclease domains have been inactivated or deleted. In certain embodiments, the Cas protein of the fusion protein is or is derived from a modified or mutated Cas protein that lacks nuclease activity. In certain embodiments, the RuvC and/or HNH domains of the Cas protein are modified or mutated such that they no longer possess nuclease activity.

Cleavage Domains

In certain embodiments, the effector domain of the fusion protein is a cleavage domain. As used herein, a “cleavage domain” refers to a domain that cleaves DNA. The cleavage domain can be obtained from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which a cleavage domain can be derived include restriction endonucleases and homing endonucleases. See, for example, New England Biolabs Catalog or Belfort et al. (1997) Nucleic Acids Res. 25, 3379-88. Additional enzymes that cleave DNA are known (e.g., 51 Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease). See also Linn et al. (eds.) “Nucleases,” Cold Spring Harbor Laboratory Press, 1993. One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains.

In certain embodiments, the cleavage domain can be derived from a type II-S endonuclease. Type II-S endonucleases cleave DNA specifically at sites that are typically several base pairs away from the DNA recognition site of the endonuclease and, as such, have separable recognition and cleavage domains. These enzymes generally are monomers that transiently associate to form dimers to cleave each strand of DNA at staggered locations. Non-limiting examples of suitable type II-S endonucleases include BfiI, BpmI, BsaI, BsgI, BsmBI, Bsm, BspMI, FokI, MbolI, and SapI. In certain embodiments, the cleavage domain of the fusion protein is a FokI cleavage domain or a fragment or derivative thereof. See Miller et al. (2007) Nat. Biotechnol. 25, 778-85; Szczpek et al. (2007) Nat. Biotechnol. 25, 786-93; Doyon et al. (2011) Nat. Methods, 8, 74-81.

Transcriptional Activation Domains

In certain embodiments, the effector domain of the fusion protein is a transcriptional activation domain. In general, a transcriptional activation domain interacts with transcriptional control elements and/or transcriptional regulatory proteins (i.e., transcription factors, RNA polymerases, etc.) to increase and/or activate transcription of a gene. In certain embodiments, the transcriptional activation domain is a herpes simplex virus VP16 activation domain, VP64 (which is a tetrameric derivative of VP16), a NFκB p65 activation domain, p53 activation domains 1 and 2, a CREB (cAMP response element binding protein) activation domain, an E2A activation domain, or an NFAT (nuclear factor of activated T-cells) activation domain. In certain embodiments, the transcriptional activation domain is Gal4, Gcn4, MLL, Rtg3, Gln3, Oafl, Pip2, Pdrl, Pdr3, Pho4, or Leu3. The transcriptional activation domain may be wild type, or it may be a modified or truncated version of the original transcriptional activation domain.

Transcriptional Repressor Domains

In certain embodiments, the effector domain of the fusion protein is a transcriptional repressor domain. In general, a transcriptional repressor domain interacts with transcriptional control elements and/or transcriptional regulatory proteins (i.e., transcription factors, RNA polymerases, etc.) to decrease and/or prohibit transcription of a gene. In certain embodiments, the transcriptional repressor domains is inducible cAMP early repressor (ICER) domains, Kruppel-associated box A (KRAB-A) repressor domains, YY1 glycine rich repressor domains, Sp1-like repressors, E(spI) repressors, IκB repressor, or MeCP2.

Epigenetic Modification Domains

In certain embodiments, the effector domain of the fusion protein is an epigenetic modification domain. In general, epigenetic modification domains alter gene expression by modifying the histone structure and/or chromosomal structure. In certain embodiments, the epigenetic modification domains is a histone acetyltransferase domain, a histone deacetylase domain, a histone methyltransferase domain, a histone demethylase domain, a DNA methyltransferase domain, or a DNA demethylase domain.

Additional Domains

In certain embodiments, the fusion protein further comprises at least one additional domain. Non-limiting examples of suitable additional domains include nuclear localization signals (NLSs), cell-penetrating or translocation domains, and marker domains. An NLS generally comprises a stretch of basic amino acids. See, e.g., Lange et al. (2007) J. Biol. Chem., 282, 5101-5. For example, in certain embodiments, the NLS is a monopartite sequence, such as PKKKRKV (SEQ ID NO: 2) or PKKKRRV (SEQ ID NO: 3). In certain embodiments, the NLS is a bipartite sequence. In certain embodiments, the NLS is KRPAATKKAGQAKKKK (SEQ ID NO: 4).

In certain embodiments, the fusion protein comprises at least one cell-penetrating domain. In certain embodiments, the cell-penetrating domain is a cell-penetrating peptide sequence derived from the HIV-1 TAT protein. As an example, the TAT cell-penetrating sequence can be GRKKRRQRRRPPQPKKKRKV (SEQ ID NO: 5). In certain embodiments, the cell-penetrating domain is TLM (PLSSIFSRIGDPPKKKRKV; SEQ ID NO: 6), a cell-penetrating peptide sequence derived from the human hepatitis B virus. In certain embodiments, the cell-penetrating domain is MPG (GALFLGWLGAAGSTMGAPKKKRKV; SEQ ID NO: 7 or GALFLGFLGAAGSTMGAWSQPKKKRKV; SEQ ID NO: 8). In certain embodiments, the cell-penetrating domain is Pep-1 (KETWWETWWTEWSQPKKKRKV; SEQ ID NO: 9), VP22, a cell penetrating peptide from Herpes simplex virus, or a polyarginine peptide sequence.

In certain embodiments, the fusion protein comprises at least one marker domain. Non-limiting examples of marker domains include fluorescent proteins, purification tags, and epitope tags. In certain embodiments, the marker domain is a fluorescent protein. Non limiting examples of suitable fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g. YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellow1,), blue fluorescent proteins (e.g. EBFP, EBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire,), cyan fluorescent proteins (e.g. ECFP, Cerulean, CyPet, AmCyan1, Midoriishi-Cyan), red fluorescent proteins (mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRasberry, mStrawberry, Jred), orange fluorescent proteins (mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato) and any other suitable fluorescent protein. In certain embodiments, the marker domain is a purification tag and/or an epitope tag. Exemplary tags include, but are not limited to, glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, HA, nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, 6×His, biotin carboxyl carrier protein (BCCP), and calmodulin.

V. Uses and Methods

In one aspect, the present invention provides a method for cleaving a target polynucleotide with a Cas protein. The method comprises contacting the target polynucleotide with (i) a guide RNA or a set of guide RNA molecules described herein, and (ii) a Cas protein. In certain embodiments, the method results in a double-strand break in the target polynucleotide. In certain embodiments, the Cas protein is a Cas protein having a single-strand nicking activity. In certain embodiments, the method results in a single-strand break in the target polynucleotide. In certain embodiments, a complex comprising a guide RNA and Cas protein having a single-strand nicking activity is used for sequence-targeted single-stranded DNA cleavage, i.e., nicking.

In one aspect, the present invention provides a method for cleaving two or more target polynucleotides with a Cas protein. The method comprises contacting the target polynucleotides with (i) a set of guide RNA molecules described herein, and (ii) a Cas protein. In certain embodiments, the method results in double-strand breaks in the target polynucleotides. In certain embodiments, the Cas protein is a Cas protein having a single-strand nicking activity. In certain embodiments, the method results in single-strand breaks in the target polynucleotides. In certain embodiments, a complex comprising a guide RNA and Cas protein having a single-strand nicking activity is used for sequence-targeted single-stranded DNA cleavage, i.e., nicking.

In one aspect, the present invention provides a method for binding a target polynucleotide with a Cas protein. The method comprises contacting the target polynucleotide with (i) a guide RNA or a set of guide RNA molecules described herein and (ii) a Cas protein, to result in binding of the target polynucleotide with the Cas protein. In certain embodiments, the Cas protein is a Cas variant. In certain embodiments, the Cas variant lacks some or all nuclease activity relative to a counterpart wild-type Cas protein.

In one aspect, the present invention provides a method for binding two or more target polynucleotides with a Cas protein. The method comprises contacting the target polynucleotides with (i) a set of RNA molecules described herein and (ii) a Cas protein, to result in binding of the target polynucleotides with the Cas protein. In certain embodiments, the Cas protein is a Cas variant. In certain embodiments, the Cas variant lacks some or all nuclease activity relative to a counterpart wild-type Cas protein.

In one aspect, the present invention provides a method for targeting a Cas protein to a target polynucleotide. The method comprises contacting the Cas protein with a guide RNA or a set of guide RNA molecules described herein. In certain embodiments, the method results in formation of a guide RNA:Cas protein complex. In certain embodiments, the Cas protein is a wild type Cas9 protein. In certain embodiments, the Cas protein is a mutant or variant of a Cas9 protein. In certain embodiments, the Cas protein is a Cas protein having a single-strand nicking activity. In certain embodiments, the Cas protein is a Cas protein lacking nuclease activity (e.g., a nuclease-deficient mutant of Cas protein). In certain embodiments, the Cas protein is part of a fusion protein (e.g., a fusion protein comprising (i) the Cas protein and (ii) a heterologous polypeptide).

In one aspect, the present invention provides a method for targeting a Cas protein to two or more target polynucleotides. The method comprises contacting the Cas protein with a set of guide RNA molecules described herein. In certain embodiments, the method results in formation of a guide RNA:Cas protein complex. In certain embodiments, the Cas protein is a wild type Cas9 protein. In certain embodiments, the Cas protein is a mutant or variant of a Cas9 protein. In certain embodiments, the Cas protein is a Cas protein having a single-strand nicking activity. In certain embodiments, the Cas protein is a Cas protein lacking nuclease activity (e.g., a nuclease-deficient mutant of Cas protein). In certain embodiments, the Cas protein is part of a fusion protein (e.g., a fusion protein comprising (i) the Cas protein or and (ii) a heterologous polypeptide).

In certain embodiments, the guide RNA is introduced into a cell by transfection. Techniques for RNA transfection are known in the art and include electroporation and lipofection. Effective techniques for RNA transfection depend mostly on cell type. See, e.g., Lujambio et al. (Spanish National Cancer Centre) Cancer Res. February 2007, which describes transfection of HTC-116 colon cancer cells and uses Oligofectamine (Invitrogen) for transfection of commercially obtained, modified miRNA or precursor miRNA. See also, Cho et al. (Seoul National Univ.) Nat. Biotechnol. March 2013, which describes transfection of K562 cells and uses 4D Nucleofection™ (Lonza) electroporation for transfection of transcribed sgRNAs (about 60 nts long). Techniques for transfection of RNA are also known in the art. For example, therapeutic RNA has been delivered in non-pathogenic E. coli coated with Invasin protein (to facilitate uptake into cells expressing β-1 integrin protein) and with the E. coli encoded to express lysteriolysin O pore-forming protein to permit the shRNA to pass from the E. coli into the cytoplasm. See also Cho et al. (Seoul National Univ.) Nat. Biotechnol. March 2013.

In certain embodiments, the guide RNA is introduced or delivered into cells. Technologies that can be used for delivery of guide RNA include those that utilize encapsulation by biodegradable polymers, liposomes, or nanoparticles. Such polymers, liposomes, and nanoparticles can be delivered intravenously. In certain embodiments, for in vivo delivery, guide RNA can be injected into a tissue site or administered systemically. In vivo delivery can also be effected by a beta-glucan delivery system, such as those described in U.S. Pat. Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781, which are hereby incorporated by reference in their entirety. In certain embodiments, guide RNA or a delivery vehicle containing guide RNA is targeted to a particular tissue or body compartment. For example, in certain embodiments, to target exogenous RNA to other tissues, synthetic carriers are decorated with cell-specific ligands or aptamers for receptor uptake, e.g., RNA encased in cyclodextrin nanoparticles coated with PEG and functionalized with human transferrin protein for uptake via the transferrin receptor which is highly expressed in tumor cells. Further approaches are described herein below or known in the art.

The present invention has been tested in human cells as described in Hendel et al., Nat. Biotechnol. (2015) 33:9, 985-9 (which is incorporated in this application in its entirety). In the cited work, modified guide RNA was introduced into K562 cells, human primary T cells, and CD34+ hematopoietic stem and progenitor cells (HSPCs). The modified guide RNA significantly enhanced genome editing efficiencies in human cells, including human primary T cells and CD34+ HSPCs as compared to unmodified guide RNA.

FIGS. 11A and 11B illustrate experimental results showing that gene disruption in human cell lines can be achieved by high frequencies of indels or by cleavage-stimulated homologous recombination using synthesized and chemically modified sgRNAs disclosed herein. Gene disruption by mutagenic NHEJ was measured by deep sequencing of PCR amplicons (FIG. 12A) or gene addition by HR at the three loci IL2RG, HBB and CCR5 in K562 cells induced by Cas9 in combination with synthetic sgRNAs (FIG. 12B). The synthetic sgRNAs were delivered at 1 μg (light shade) or 20 μg (dark shade) per 1 million cells. Cas9 was expressed from a plasmid (2 g) and for HR experiments 5 μg of GFP-encoding donor plasmid was included. As a positive control, 2 μg of sgRNA plasmid encoding both the sgRNA and the Cas9 protein was used (gray bars). Bars represent average values+s.e.m., n=3.

FIGS. 12A, 12B, 12C and 12D illustrate experimental results showing that chemically modified sgRNAs as described herein can be used to achieve high frequencies of gene disruption or targeted genome editing in stimulated primary human T cells and CD34+ hematopoietic stem and progenitor cells (HSPCs).

FIG. 12A illustrates results from primary human T cells nucleofected with 10 μg of a synthetic CCR5 sgRNAs and either 15 μg Cas9 mRNA or 1 μg Cas9-encoding plasmid. 1 μg sgRNA plasmid encoding both the sgRNA and Cas9 protein was included for comparison. The bars represent average indel frequencies for three different donors+s.e.m., n=6, as measured by TIDE (tracking of indels by decomposition) analysis of PCR amplicons spanning the sgRNA target site, and using a mock-treated sample as control reference. Delivery of Cas9 mRNA with the unmodified or the M-modified sgRNA, and nucleofection of the plasmid encoding both the sgRNA and Cas9, did not give rise to allele modification frequencies above background. Co-transfection of the MSP-modified sgRNA with DNA expression plasmid for Cas9 generated 9.3% indel frequency. Cas9 mRNA with either the MS- or MSP-modified sgRNA generated 48.7% and 47.9% indel frequencies, respectively.

FIG. 12B illustrates results from stimulated T cells. The cells were nucleofected as above, but with 15 μg Cas9 protein complexed with a 2.5 molar excess of the indicated synthetic CCR5 sgRNAs. Indel frequencies were measured by TIDE analysis. The bars represent average indel frequencies for three different donors+s.e.m., n=6. A 2.4-fold improvement in indel frequencies of the MS-modified sgRNA over the unmodified sgRNA (30.7% vs. 12.8%) was observed for chemically modified sgRNAs when delivered complexed with Cas9 protein. These results establish that chemically modified sgRNAs can be used for genome editing of stimulated T cells when delivered complexed with Cas9 protein.

FIG. 12C illustrates results from human peripheral blood CD34+ HSPCs. 500,000 mobilized cells were nucleofected with 10 μg of the indicated synthetic sgRNAs targeting IL2RG or HBB and either 15 μg Cas9 mRNA or 1 μg Cas9 plasmid. 1 μg of sgRNA plasmid encoding both the sgRNA and Cas9 protein was included for comparison. Bars represent average indel frequencies+s.e.m., n=3, as measured by T7 endonuclease cleavage assay. Indels were not detected at either locus using the unmodified or M-modified sgRNAs when co-transfected with Cas9 mRNA. However, the IL2RG MS- and MSP-modified sgRNAs showed 17.5% and 17.7% indel frequencies, respectively, and 23.4% and 22.0%, respectively, for the HBB MS- and MSP-modified sgRNAs.

FIG. 12D illustrates results from stimulated T cells or mobilized human peripheral blood CD34+ HSPCs. One million cells were nucleofected with 15 μg Cas9 mRNA and 10 μg of the indicated synthetic CCR5 sgRNAs. A recent study showed that the simultaneous use of two sgRNAs could improve gene disruption in human primary T cells and in CD34+ HSPCs. See, e.g., Mandal et al. (2014) Cell Stem Cell, 15, 643-52. MS- and MSP-modified CCR5 sgRNAs were chemically synthesized with the sequences reported in Mandal study (termed ‘D’ and ‘Q’), which cut 205 base pairs apart. When used in combination, the amount of each sgRNA was 5 g. Indel frequencies for samples with single sgRNAs were measured by TIDE analysis as above and allele disruption frequencies for samples with two sgRNAs were measured by sequencing of cloned PCR products. The bars represent average indel frequencies+s.e.m., n=3. In T cells, the ‘D’ sgRNA alone gave rise to 56.0% and 56.3% indels for the MS- and MSP-modified sgRNA, respectively, and the ‘Q’ sgRNA gave rise to 62.6% and 69.6% indels, respectively. When used in combination, the frequencies of allele modification increased, as we observed 73.9% and 93.1% indels for the MS- and MSP-modified sgRNAs, respectively, of which the majority of the modification events were deletions between the two sgRNA target sites. In CD34+ HSPCs, observations were similar though the overall frequencies were lower. For the ‘D’ sgRNA, allele modification frequencies of 9.8% and 11.2% were observed for the MS- and MSP-modified sgRNA, respectively, and 17.8% and 19.2% for the ‘Q’ sgRNA. When used in combination the frequencies increased to 37.8% and 43.0% for the MS- and MSP-modified sgRNAs, respectively. This shows that the use of two chemically modified sgRNAs is a highly effective way to facilitate gene disruption in primary human T cells and CD34+ HSPCs.

Examples of other uses include genomic editing and gene expression regulation as described below.

Genomic Editing

In one aspect, the present invention provides a method for genomic editing to modify a DNA sequence in vivo or in vitro (“in vitro” includes, without being limited to, a cell-free system, a cell lysate, an isolated component of a cell, and a cell outside of a living organism). The DNA sequence may comprise a chromosomal sequence, an episomal sequence, a plasmid, a mitochondrial DNA sequence, or a functional intergenic sequence, such as an enhancer sequence or a DNA sequence for a non-coding RNA. The method comprises contacting the DNA sequence with (i) a guide RNA or a set of guide RNA molecules described herein, and (ii) a Cas protein. In certain embodiments, the DNA sequence is contacted outside of a cell. In certain embodiments, the DNA sequence is located in the genome within a cell and is contacted in vitro or in vivo. In certain embodiments, the cell is within an organism or tissue. In certain embodiments, the cell is a human cell, a non-human mammalian cell, a stem cell, a non-mammalian vertebrate cell, an invertebrate cell, a plant cell, a single cell organism, or an embryo. In certain embodiments, the guide RNA aids in targeting the Cas protein to a targeted site in the DNA sequence. In certain embodiments, the Cas protein cleaves at least one strand of the DNA sequence at the targeted site. In certain embodiments, the Cas protein cleaves both strands of the DNA sequence at the targeted site.

In certain embodiments, the method further comprises introducing the Cas protein into a cell or another system. In certain embodiments, the Cas protein is introduced as a purified or non-purified protein. In certain embodiments, the Cas protein is introduced via an mRNA encoding the Cas protein. In certain embodiments, the Cas protein is introduced via a linear or circular DNA encoding the Cas protein. In certain embodiments, the cell or system comprises a Cas protein or a nucleic acid encoding a Cas protein.

In certain embodiments, a double-stranded break can be repaired via an error-prone, non-homologous end-joining (“NHEJ”) repair process. In certain embodiments, a double-stranded break can be repaired by a homology-directed repair (HDR) process such that a donor sequence in a donor polynucleotide can be integrated into or exchanged with the targeted DNA sequence.

In certain embodiments, the method further comprises introducing at least one donor polynucleotide into the cell or system. In certain embodiments, the donor polynucleotide comprises at least one homologous sequence having substantial sequence identity with a sequence on either side of the targeted site in the DNA sequence. In certain embodiments, the donor polynucleotide comprises a donor sequence that can be integrated into or exchanged with the DNA sequence via homology-directed repair, such as homologous recombination.

In certain embodiments, the donor polynucleotide includes an upstream homologous sequence and a downstream homologous sequence, each of which have substantial sequence identity to sequences located upstream and downstream, respectively, of the targeted site in the DNA sequence. These sequence similarities permit, for example, homologous recombination between the donor polynucleotide and the targeted DNA sequence such that the donor sequence can be integrated into (or exchanged with) the DNA sequence targeted.

In certain embodiments, the target site(s) in the DNA sequence spans or is adjacent to a mutation, e.g., point mutation, a translocation or an inversion which may cause or be associated with a disorder. In certain embodiments, the method comprises correcting the mutation by introducing into the cell or system at least one donor polynucleotide comprising (i) a wild type counterpart of the mutation and (ii) at least one homologous sequence having substantial sequence identity with a sequence on one side of the targeted site in the DNA sequence. In certain embodiments, the donor polynucleotide comprises a homologous sequence having substantial sequence identity with a sequence on both sides of the targeted site in the DNA sequence.

In certain embodiments, the donor polynucleotide comprises an exogenous sequence that can be integrated into or exchanged with the targeted DNA sequence via a homology-directed repair process, such as homologous recombination. In certain embodiments, the exogenous sequence comprises a protein coding gene, which, optionally, is operably linked to an exogenous promoter control sequence. Thus, in certain embodiments, upon integration of the exogenous sequence, a cell can express a protein encoded by the integrated gene. In certain embodiments, the exogenous sequence is integrated into the targeted DNA sequence such that its expression in the recipient cell or system is regulated by the exogenous promoter control sequence. Integration of an exogenous gene into the targeted DNA sequence is termed a “knock in.” In other embodiments, the exogenous sequence can be a transcriptional control sequence, another expression control sequence, an RNA coding sequence, and the like.

In certain embodiments, the donor polynucleotide comprises a sequence that is essentially identical to a portion of the DNA sequence at or near the targeted site, but comprises at least one nucleotide change. For example, in certain embodiments, the donor sequence comprises a modified or mutated version of the DNA sequence at or near the targeted site such that, upon integration or exchange with the targeted site, the resulting sequence at the targeted site comprises at least one nucleotide change. In certain embodiments, the at least one nucleotide change is an insertion of one or more nucleotides, a deletion of one or more nucleotides, a substitution of one or more nucleotides, or combinations thereof. As a consequence of the integration of the modified sequence, the cell may produce a modified gene product from the targeted DNA sequence.

In certain embodiments, the methods are for multiplex applications. In certain embodiments, the methods comprise introducing a library of guide RNAs into the cell or system. In certain embodiments, the library comprises at least 100 unique guide sequences. In certain embodiments, the library comprises at least 1,000 unique guide sequences. In certain embodiments, the library comprises at least 10,000 unique guide sequences. In certain embodiments, the library comprises at least 100,000 unique guide sequences. In certain embodiments, the library comprises at least 1,000,000 unique guide sequences. In certain embodiments, the library targets at least 10 different polynucleotides or at least 10 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 100 different polynucleotides or at least 100 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 1,000 different polynucleotides or at least 1,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 10,000 different polynucleotides or at least 10,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 100,000 different polynucleotides or at least 100,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 1,000,000 different polynucleotides or at least 1,000,000 different sequences within one or more polynucleotides.

Genomic Editing in Human and Mammalian Cells

Embodiments of the present invention are useful in methods for genomic editing to modify a target polynucleotide, for example a DNA sequence, in a mammalian cell.

In certain embodiments, the DNA sequence is a chromosomal sequence. In certain embodiments, the DNA sequence is a protein-coding sequence. In certain embodiments, the DNA sequence is a functional intergenic sequence, such as an enhancer sequence or a non-coding sequence. In certain embodiments, the DNA is part of a human gene. In some such embodiments, the human gene is the clathrin light chain (CLTA1) gene, the human interleukin 2 receptor gamma (IL2RG) gene, the human cytotoxic T-lymphocyte-associated protein 4 (CLTA4) gene, the human protocadherin alpha 4 (PCDHA4) gene, the human engrailed homeobox 1 (EN1) gene), the human hemoglobin beta (HBB) gene, which can harbor mutations responsible for sickle cell anemia and thalassemias, or the human chemokine (C—C motif) receptor 5 (CCR5) gene which encodes a co-receptor of HIV.

In certain embodiments, the mammalian cell is a human cell. In some such embodiments, the human cell is a primary human cell. In further embodiments, the primary human cell is a human primary T cell. The human primary T cell may be stimulated or unstimulated. In certain embodiments, the human cell is a stem/progenitor cell, such as a CD34+ hematopoietic stem and progenitor cell (HSPC). In certain embodiments, the human cell is from a cultured cell line, for example such as can be obtained commercially. Exemplary cell lines include K562 cells, a human myelogenous leukemia line.

In certain embodiments, the cell is within a living organism. In certain other embodiments, the cell is outside of a living organism.

The method comprises contacting the DNA sequence with (i) a guide RNA or a set of guide RNA molecules described herein, and (ii) a Cas protein.

In certain embodiments, the method further comprises introducing or delivering the guide RNA into the cell. In some such embodiments, the guide RNA is introduced into a cell by transfection. Techniques for RNA transfection are known in the art and include electroporation and lipofection. In other embodiments, the guide RNA is introduced into a cell (and, more particularly, a cell nucleus) by nucleofection. Techniques for nucleofection are known in the art and may utilize nucleofection devices such as the Lonza Nucleofector 2b or the Lonza 4D-Nucleofector and associated reagents.

In certain embodiments, the method further comprises introducing or delivering the Cas protein into the cell. In some such embodiments, the Cas protein is introduced as a purified or non-purified protein. In other embodiments, the Cas protein is introduced via an mRNA encoding the Cas protein. In some such embodiments, the mRNA encoding the Cas protein is introduced into the cell by transfection. In other embodiments, the mRNA encoding the Cas protein is introduced into a cell (and, more particularly, a cell nucleus) by nucleofection.

In certain embodiments, the method employs ribonucleoprotein (RNP)-based delivery such that the Cas protein is introduced into the cell in a complex with the guide RNA. For example, a Cas9 protein may be complexed with a guide RNA in a Cas9:gRNA complex, which allows for co-delivery of the gRNA and Cas protein. For example, the Cas:gRNA complex may be nucleofected into cells.

In certain embodiments, the method employs an all-RNA delivery platform. For example, in some such embodiments, the guide RNA and the mRNA encoding the Cas protein are introduced into the cell simultaneously or substantially simultaneously (e.g., by co-transfection or co-nucleofection). In certain embodiments, co-delivery of Cas mRNA and modified gRNA results in higher editing frequencies as compared to co-delivery of Cas mRNA and unmodified gRNA. In particular, gRNA having 2′-O-methyl-3′-phosphorothioate (MS), or 2′-O-methyl-3′-thioPACE (MSP) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, provide higher editing frequencies as compared to unmodified gRNA.

In certain embodiments, the guide RNA and the mRNA encoding the Cas protein are introduced into the cell sequentially; that is, the guide RNA and the mRNA encoding the Cas protein are introduced into the cell at different times. The time period between the introduction of each agent may range from a few minutes (or less) to several hours or days. For example, in some such embodiments, gRNA is delivered first, followed by delivery of Cas mRNA 4, 8, 12 or 24 hours later. In other such embodiments, Cas mRNA is delivered first, followed by delivery of gRNA 4, 8, 12 or 24 hours later. In some particular embodiments, delivery of modified gRNA first, followed by delivery of Cas mRNA results in higher editing frequencies as compared to delivery of unmodified gRNA followed by delivery of Cas mRNA.

In certain embodiments, the gRNA is introduced into the cell together with a DNA plasmid encoding the Cas protein. In some such embodiments, the gRNA and the DNA plasmid encoding the Cas protein are introduced into the cell by nucleofection. In some particular embodiments, an RNP-based delivery platform or an all-RNA delivery platform provides lower cytotoxicity in primary cells than a DNA plasmid-based delivery system.

In certain embodiments, the method provides significantly enhanced genome editing efficiencies in human cells, including human primary T cells and CD34+ HSPCs.

In certain embodiments, modified gRNA increases the frequency of insertions or deletions (indels), which may be indicative of mutagenic NHEJ and gene disruption, relative to unmodified gRNA. In particular, modified gRNA having 2′-O-methyl-3′-phosphorothioate (MS) or 2′-O-methyl-3′-thioPACE (MSP) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, increases the frequency of indels relative to unmodified gRNA.

In certain embodiments, co-delivery of modified gRNA and Cas mRNA to human primary T cells increases the frequency of indels as compared to co-delivery of unmodified gRNA and Cas mRNA. In particular, modified gRNA having 2′-O-methyl-3′-phosphorothioate (MS) or 2′-O-methyl-3′-thioPACE (MSP) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, increases the frequency of indels in human primary T cells relative to unmodified gRNA.

In certain embodiments, modified gRNA improves gRNA stability relative to unmodified gRNA. As one example, gRNA having 2′-O-methyl (M) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, modestly improves stability against nucleases and also improves base pairing thermostability over unmodified gRNA. As another example, gRNA having 2′-O-methyl-3′-phosphorothioate (MS) or 2′-O-methyl-3′-thioPACE (MSP) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, dramatically improves stability against nucleases relative to unmodified gRNA. It is contemplated that gRNA end modifications enhance intracellular stability against exonucleases, thus enabling increased efficacy of genome editing when Cas mRNA and gRNA are co-delivered or sequentially delivered into human cells.

In certain embodiments, modified gRNA stimulates gene targeting, which, in turn, allows for gene editing by, for example, homologous recombination or NHEJ. In particular, gRNA having 2′-O-methyl-3′-phosphorothioate (MS), or 2′-O-methyl-3′-thioPACE (MSP) incorporated at three terminal nucleotides at both the 5′ and 3′ ends, stimulates higher levels of homologous recombination than unmodified gRNA.

In certain embodiments, modified gRNA retains high specificity. In certain embodiments, the ratio of on-target to off-target indel frequencies is improved with modified gRNA as compared to unmodified gRNA. In certain embodiments, modified gRNA delivered in an RNP complex with a Cas protein provides significantly better on-target:off-target ratios compared to a DNA plasmid-based delivery system.

Gene Expression Regulation

In certain embodiments, the guide RNA described herein is used for regulating transcription or expression of a gene of interest. For example, in certain embodiments, a fusion protein comprising a Cas protein (e.g., a nuclease-deficient Cas9) and a transcription activator polypeptide is used to increase transcription of a gene. Similarly, in certain embodiments, a fusion protein comprising a Cas protein (e.g., a nuclease-deficient Cas9) and a repressor polypeptide is used to knock-down gene expression by interfering with transcription of the gene.

In at least one aspect, the present invention provides a method for regulating the expression of a gene of interest in vivo or in vitro. The method comprises introducing into a cell or another system (i) a synthetic guide RNA described herein, and (ii) a fusion protein. In certain embodiments, the fusion protein comprises a Cas protein and an effector domain, such as a transcriptional activation domain, a transcriptional repressor domain, or an epigenetic modification domain. In certain embodiments, the fusion protein comprises a mutated Cas protein, such as a Cas9 protein that is a null nuclease. In certain embodiments, the Cas protein contains one or more mutations, such as D10A, H840A and/or N863A.

In certain embodiments, the fusion protein is introduced into the cell or system as a purified or non-purified protein. In certain embodiments, the fusion protein is introduced into the cell or system via an mRNA encoding the fusion protein. In certain embodiments, the fusion protein is introduced into the cell or system via a linear or circular DNA encoding the fusion protein.

In certain embodiments, the guide RNA aids in directing the fusion protein to a specific target polynucleotide comprising a chromosomal sequence, an episomal sequence, a plasmid, a mitochondrial DNA sequence, or a functional intergenic sequence, such as an enhancer or the DNA sequence for a non-coding RNA. In certain embodiments, the effector domain regulates expression of a sequence in the target polynucleotide. A guide RNA for modulating gene expression can be designed to target any desired endogenous gene or sequence encoding a functional RNA. A genomic target sequence can be selected in proximity of the transcription start site of the endogenous gene, or alternatively, in proximity of the translation initiation site of the endogenous gene. In certain embodiments, the target sequence is in a region of the DNA that is traditionally termed the “promoter proximal” region of a gene. In certain embodiments, the target sequence lies in a region from about 1,000 base pairs upstream of the transcription start site to about 1,000 base pairs downstream of the transcription start site. In certain embodiments, the target sequence is remote from the start site for transcription of the gene (e.g., on another chromosome).

In certain embodiments, the methods are for multiplex applications. In certain embodiments, the methods comprise introducing a library of guide RNAs into the cell or system. In certain embodiments, the library comprises at least 100, at least 1,000, at least 10,000, at least 100,000, or at least 1,000,000 unique guide sequences. In certain embodiments, the library targets at least 10 different polynucleotides or at least 10 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 100 different polynucleotides or at least 100 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 1,000 different polynucleotides or at least 1,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 10,000 different polynucleotides or at least 10,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 100,000 different polynucleotides or at least 100,000 different sequences within one or more polynucleotides. In certain embodiments, the library targets at least 1,000,000 different polynucleotides or at least 1,000,000 different sequences within one or more polynucleotides.

Kits

In one aspect, the present invention provides kits containing reagents for performing the above-described methods, including producing gRNA:Cas protein complex and/or supporting its activity for binding, nicking or cleaving target polynucleotide. In certain embodiments, one or more of the reaction components, e.g., one or more guide RNAs and Cas proteins, for the methods disclosed herein, can be supplied in the form of a kit for use. In certain embodiments, the kit comprises a Cas protein or a nucleic acid encoding the Cas protein, and one or more guide RNAs described herein or a set or library of guide RNAs. In certain embodiments, the kit includes one or more other reaction components. In certain embodiments, an appropriate amount of one or more reaction components is provided in one or more containers or held on a substrate.

Examples of additional components of the kits include, but are not limited to, one or more different polymerases, one or more host cells, one or more reagents for introducing foreign nucleic acid into host cells, one or more reagents (e.g., probes or PCR primers) for detecting expression of the guide RNA and/or the Cas mRNA or protein or for verifying the status of the target nucleic acid, and buffers, transfection reagents or culture media for the reactions (in 1× or more concentrated forms). In certain embodiments, the kit includes one or more of the following components: biochemical and physical supports; terminating, modifying and/or digesting reagents; osmolytes; and apparati for reaction, transfection and/or detection.

The reaction components used can be provided in a variety of forms. For example, the components (e.g., enzymes, RNAs, probes and/or primers) can be suspended in an aqueous solution or bound to a bead or as a freeze-dried or lyophilized powder or pellet. In the latter case, the components, when reconstituted, form a complete mixture of components for use in an assay. The kits of the invention can be provided at any suitable temperature. For example, for storage of kits containing protein components or complexes thereof in a liquid, it is preferred that they are provided and maintained below 0° C., preferably at about −20° C., possibly in a freeze-resistant solution containing glycerol or other suitable antifreeze.

A kit or system may contain, in an amount sufficient for at least one assay, any combination of the components described herein. In some applications, one or more reaction components may be provided in pre-measured single use amounts in individual, typically disposable, tubes or equivalent containers. With such an arrangement, a RNA-guided nuclease reaction can be performed by adding a target nucleic acid, or a sample or cell containing the target nucleic acid, to the individual tubes directly. The amount of a component supplied in the kit can be any appropriate amount and may depend on the market to which the product is directed. The container(s) in which the components are supplied can be any conventional container that is capable of holding the supplied form, for instance, microfuge tubes, microtiter plates, ampoules, bottles, or integral testing devices, such as fluidic devices, cartridges, lateral flow, or other similar devices.

The kits can also include packaging materials for holding the container or combination of containers. Typical packaging materials for such kits and systems include solid matrices (e.g., glass, plastic, paper, foil, micro-particles and the like) that hold the reaction components or detection probes in any of a variety of configurations (e.g., in a vial, microtiter plate well, microarray, and the like). The kits may further include instructions recorded in a tangible form for use of the components.

EXAMPLES Example 1

To evaluate the ability of the chemically synthesized guide RNAs to target and cleave a DNA target sequence, an in vitro cleavage assay was developed. Briefly, as shown in FIG. 3, ˜4-kb PAM-addressable DNA targets were prepared by preparative PCR amplification of plasmid-borne human sequences (here, a sequence from the human clathrin light chain CLTA gene). In a 20-uL reaction volume, 50 fmoles of linearized DNA target in the presence of 50 nM sgRNA, 39 nM recombinant purified Cas9 protein (S. pyogenes; Agilent) and 10 mM MgCl2 at pH 7.6 was incubated at 37° C. for 30 min. Upon completion, 0.5 uL of RNace It (Agilent) was added, and incubation was continued at 37° C. for 5 min and then at 70° C. for 15 min. Subsequently 0.5 μL of Proteinase K (Mol. Bio. grade, NEB) was added and incubated at 37° C. for 15 min. Aliquots were loaded into a DNA 7500 LabChip and were analyzed on a Bioanalyzer 2200. The workup steps served to release Cas9 from binding to target DNA, which were assayed for cleavage.

A series of guide RNAs as listed in FIG. 4 were chemically synthesized. Briefly, individual RNA strands were synthesized and HPLC purified. All oligonucleotides were quality control approved on the basis of chemical purity by HPLC analysis and full-length strand purity by mass spectrometry analysis. Each of these guide RNAs was designed to target the human CLTA gene.

The results are shown in FIG. 4. As shown in the Table 1 of FIG. 4, all but one of the chemically synthesized guide RNAs targeted and cleaved the CLTA-encoded DNA target sequence with significant cleavage rates. The one exception was “CLTA_37_Deoxy” guide RNA, which had a contiguous sequence of 37 deoxyribonucleotides at its 5′ end.

As disclosed herein, a variety of chemical modifications were tested at specific positions in the sequence of a guide RNA. Surprisingly, the tested positions in the guide sequence of the guide RNA (a.k.a. the spacer sequence in the guide RNA) tolerated most of the modifications tested, including combinations of multiple modifications within single nucleotides in the guide RNA, even when modifications were instantiated in the target-binding sequences.

The results revealed that guide RNAs containing modifications at specific positions were tolerated by active Cas protein and gRNA:Cas protein complexes, as the modifications did not prevent target-specific cleavage of the target polynucleotide. In all the guide RNA sequences listed in the Table 1 of FIG. 4, the first 20 nucleotides at the 5′ end are complementary to the target sequence in target DNA. The modifications that were tested and found to be tolerated at specific positions include 2′-O-methylribonucleotide (=2′OMe), 2′-deoxyribonucleotide, racemic phosphorothioate internucleotide linkage(s) (=P(S)), 3′-phosphonoacetate (=PACE), 3′-thiophosphonoacetates (=thioPACE), Z nucleotides, and combinations of these.

It is contemplated that the chemical modifications disclosed and tested herein, particularly at the tested positions (as listed in the Table 1 of FIG. 4), will be tolerated at equivalent positions in a variety of guide RNAs. In certain embodiments, the chemical modifications disclosed and tested herein are tolerated in any position in a guide RNA.

As disclosed herein, chemically modified nucleotides were incorporated into guide RNAs in an effort to improve certain properties. Such properties include improved nuclease resistance of the guide RNA, reduced off-target effects of a gRNA:Cas protein complex (also known as improved specificity), improved efficacy of gRNA:Cas protein complex when cleaving, nicking or binding a target polynucleotide, improved transfection efficiency, and/or improved organelle localization such as nuclear localization.

While the use of modified RNA is known (e.g., to block nucleotlytic degradation in certain applications), it is widely known that one cannot simply incorporate modifications at any or all positions in an RNA sequence and expect it to function, particularly when the RNA sequence needs to complex with a protein or an enzyme to exert certain functions. Thus, it was not predictable whether these guide RNAs could tolerate chemical modifications at a variety of nucleotide positions while performing sufficient or improved function in a CRISPR-Cas system. In fact, it was unexpected that the guide RNA can tolerate specific modifications to the extent instantiated and tested, especially at several of the positions tested.

Example 2

To evaluate the ability of the chemically synthesized guide RNAs to target and cleave a DNA target sequence, an in vitro cleavage assay similar to that described in Example 1 was used. Target DNA constructs were for human DNA targets (sequences from the human clathrin light chain (CLTA1) gene, the human Interleukin 2 Receptor Gamma (IL2RG) gene, the human cytotoxic T-lymphocyte-associated protein 4 (CLTA4) gene, the human protocadherin alpha 4 (PCDHA4) gene, and the human engrailed homeobox 1 (EN1) gene), along with off-target DNA constructs differing from the target DNA by one or more nucleotides.

Table 3 sets forth the guide RNA constructs and their sequences, along with DNA constructs used for assessing the ability of those guide RNA constructs to target and cleave. In all the guide RNA sequences listed in the Table 3, the first 20 nucleotides at the 5′ end are complementary to the target sequence in target DNA. ON target constructs comprise the 20 nt target sequence. OFF target constructs comprise most of the same 20 nucleotides as the target DNA, with 1, 2 or 3 nucleotide differences. Accordingly, the guide RNA is mostly, but not completely, complementary to the sequence of the OFF target constructs. The OFF target constructs are based on gene sequences known to occur in the human genome.

TABLE 3 Entry Target DNA RNA # Guide RNA Construct Construct RNA sequence (5′ → 3′) length 2-piece dual-guide scaffold Unmodified dual-guide RNA (dgRNA)   1 CLTA1 crRNA + tracrRNA CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   2 CLTA1 crRNA + tracrRNA CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   3 CLTA1 crRNA + tracrRNA CLTA1 OFF1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   4 CLTA1 crRNA + tracrRNA CLTA1 OFF1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC + (SEQ ID NO: 25) GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   5 CLTA1 crRNA + tracrRNA CLTA1 OFF2- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   6 CLTA1 crRNA + tracrRNA CLTA1 OFF2- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   7 CLTA1 crRNA + tracrRNA CLTA1 OFF3- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   8 CLTA1 crRNA + tracrRNA CLTA1 OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 target CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)   9 CLTA1 crRNA + tracrRNA CLTA1 target AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 CAAAAC (SEQ ID NO: 25) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  10 IL2RG_crRNA + tracrRNA IL2RGmg ON-  UGGUAAUGAUGGCUUCAACAGUUUUAGAGCUAUGCUGUUUUGAAUGGUC 56 + 86 target CCAAAAC (SEQ ID NO: 27) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 28) Fluorophore-coupled dgRNA  11 CLTA1 crRNA + CLTA1 ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGUCC 56 + 86 tracrRNA_aminoallyl- target CAAAAC (SEQ ID NO: 29) + U57 + Cy5 GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUG(aminoallylU + Cy5)AAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 30) 2′OMethyl-modified dgRNA  12 IL2RG_crRNA_5′,3′- IL2RGmg ON-  UGG UAAUGAUGGCUUCAACAGUUUUAGAGCUAUGCUGUUUUGAAUGGUC 56 + 86 3x(2′OMe) + target CCA AAA C (SEQ ID NO: 31) + tracrRNA_5′,3′- GGA ACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA 3x(2′OMe) ACUUGUAAAAGUGGCACCGAGUCGGUGCUUU UUU U (SEQ ID NO: 32) 2′OMethyl,3′Phosphorothioate-modified dgRNA  13 IL2RG_crRNA_5′,3′- IL2RGmg ON-  U s G s G sUAAUGAUGGCUUCAACAGUUUUAGAGCUAUGCUGUUUUGAAUGG 56 + 86 3x(2′OMe,3′P(S)) + target UCCCA A s A s A sC (SEQ ID NO: 33) + tracrRNA_5′,3′- G s G s A sACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAU 3x(2′OMe,3′P(S)) CAACUUGUAAAAGUGGCACCGAGUCGGUGCUUU U s U s U sU  (SEQ ID NO: 34) 2′OMethyl,3′PhosphorothioPACE-modified dgRNA  14 IL2RG_crRNA_5′,3′- IL2RGmg ON-  U *s G *s G *sUAAUGAUGGCUUCAACAGUUUUAGAGCUAUGCUGUUUUGAAU 56 + 86 3x(2′OMe, 3′thioPACE) + target GGUCCCA A *s A *s A *sC (SEQ ID NO: 35) + tracrRNA_5′,3′- G *s G *s A *sACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGU 3x(2′OMe, 3′thioPACE) UAUCAACUUGUAAAAGUGGCACCGAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 36)  15 IL2RG_crRNA_5′,3′- IL2RGmg ON- U *sGGUAAUGAUGGCUUCAACAGUUUUAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 1x(2′OMe, 3′thioPACE) + target CCCAAA A *sC (SEQ ID NO: 37) + tracrRNA_5′,3′- G *sGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAU 1x(2′OMe, 3′thioPACE) CAACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUU U *sU  (SEQ ID NO: 38) 2-thioU-modified dgRNA  16 CLTA1_2thioU + 3 crRNA + CLTA1 ON1-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  17 CLTA1_2thioU + 3 crRNA + CLTA1 ON1-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  18 CLTA1_2thioU + 3 crRNA + CLTA1 OFF1-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  19 CLTA1_2thioU + 3 crRNA + CLTA1 OFF1-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  20 CLTA1_2thioU + 3 crRNA + CLTA1 OFF2-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  21 CLTA1_2thioU + 3 crRNA + CLTA1 OFF2-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  22 CLTA1_2thioU + 3 crRNA + CLTA1 OFF3-  AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  23 CLTA1_2thioU + 3 crRNA + CLTA1 OFF3- AG(2sU)CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 39) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  24 CLTA1_2thioU + 9 crRNA + CLTA1 ON1- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  25 CLTA1_2thioU + 9 crRNA + CLTA1 ON1- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  26 CLTA1_2thioU + 9 crRNA + CLTA1 OFF1- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  27 CLTA1_2thioU + 9 crRNA + CLTA1 OFF1- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  28 CLTA1_2thioU + 9 crRNA + CLTA1 OFF2- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  29 CLTA1_2thioU + 9 crRNA + CLTA1 OFF2- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  30 CLTA1_2thioU + 9 crRNA + CLTA1 OFF3- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  31 CLTA1_2thioU + 9 crRNA + CLTA1 OFF3- AGUCCUCA(2sU)CUCCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 40) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  32 CLTA1_2thioU + 11 crRNA + CLTA1 ON1- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  33 CLTA1_2thioU + 11 crRNA + CLTA1 ON1- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  34 CLTA1_2thioU + 11 crRNA + CLTA1 OFF1- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  35 CLTA1_2thioU + 11 crRNA + CLTA1 OFF1- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  36 CLTA1_2thioU + 11 crRNA + CLTA1 OFF2- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  37 CLTA1_2thioU + 11 crRNA + ″ AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  38 CLTA1_2thioU + 11 crRNA + CLTA1 OFF3- AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA target CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26)  39 CLTA1_2thioU + 11 crRNA + ″ AGUCCUCAUC(2sU)CCCUCAAGCGUUUAAGAGCUAUGCUGUUUUGAAUGGU 56 + 86 tracrRNA CCCAAAAC (SEQ ID NO: 41) + GGAACCAUUCAAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCA ACUUGUAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 26) Single-guide scaffold Unmodified single-guide RNA (sgRNA)  40 CLTA1 sgRNA (Batch #1) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  41 CLTA1 sgRNA (Batch #1) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  42 CLTA1 sgRNA (Batch #2) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  43 CLTA1 sgRNA (Batch #2) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  44 CLTA1 sgRNA (Batch #3) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  45 CLTA1 sgRNA (Batch #3) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  46 CLTA1 sgRNA (Batch #3) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  47 CLTA1 sgRNA (Batch #3) CLTA1mg ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  48 CLTA1 sgRNA (Batch #3) CLTA1mg ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  49 CLTA1 sgRNA (Batch #3) CLTA1mg ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  50 CLTA1 sgRNA (Batch #3) CLTA1mg OFF1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  51 CLTA1 sgRNA (Batch #3) CLTA1mg OFF3- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  52 CLTA1 sgRNA (crude) CLTA1 ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 42)  53 CLTA1_Bos sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 43)  54 CLTA1_Bos sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 43)  55 CLTA1_Bos sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 43)  56 CLTA1_Bos sgRNA CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 43)  57 CLTA1_Bos sgRNA CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 43)  58 CLTA4 sgRNA CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  59 CLTA4 sgRNA CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  60 CLTA4 sgRNA CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  61 CLTA4 sgRNA CLTA4mg ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  62 CLTA4 sgRNA CLTA4mg ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  63 CLTA4 sgRNA CLTA4mg OFF5-  GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 44)  64 CLTA1_Truncated_18 mer CLTA1mg ON1-  UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAG 111 target UUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGG UGCUUUUUUU (SEQ ID NO: 45)  65 CLTA1_Truncated_18 mer CLTA1mg ON1-  UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAG 111 target UUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGG UGCUUUUUUU (SEQ ID NO: 45)  66 CLTA1_Truncated_18 mer CLTA1mg OFF1-  UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAG 111 target UUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGG UGCUUUUUUU (SEQ ID NO: 45)  67 CLTA1_Truncated_18 mer CLTA1mg OFF3-  UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAG 111 target UUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGG UGCUUUUUUU (SEQ ID NO: 45)  68 CLTA1_Truncated_17 mer CLTA1mg ON1-  CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGU 110 target UUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUUUUUUU (SEQ ID NO: 46)  69 CLTA1_Truncated_17 mer CLTA1mg ON1-  CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGU 110 target UUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUUUUUUU (SEQ ID NO: 46)  70 CLTA1_Truncated_17 mer CLTA1mg OFF1-  CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGU 110 target UUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUUUUUUU (SEQ ID NO: 46)  71 CLTA1_Truncated_17 mer CLTA1mg OFF3-  CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGU 110 target UUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUUUUUUU (SEQ ID NO: 46)  72 CLTA1_1xExtraG CLTA1mg ON1-  GAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 114 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 47)  73 CLTA1_1xExtraG CLTA1mg ON1-  GAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 114 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 47)  74 CLTA1_1xExtraG CLTA1mg OFF1-  GAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 114 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 47)  75 CLTA1_1xExtraG CLTA1mg OFF3-  GAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 114 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 47)  76 CLTA1_2xExtraG CLTA1mg ON1-  GGAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 115 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 48)  77 CLTA1_2xExtraG CLTA1mg ON1-  GGAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 115 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 48)  78 CLTA1_2xExtraG CLTA1mg OFF1-  GGAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 115 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 48)  79 CLTA1_2xExtraG CLTA1mg OFF3-  GGAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 115 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 48)  80 CLTA1_63U,64U CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAUUCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 49)  81 CLTA1_63A,64A CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAAACUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 50)  82 CLTA1_63A,64A,70U,71U CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAAACUAGUUUGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 51)  83 CLTA1_cis-block(1- CLTA1mg ON1-  GGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 5)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 52)  84 CLTA1_cis-block(1- CLTA1mg ON1-  GGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 5)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 52)  85 CLTA1_cis-block(1- CLTA1mg OFF1-  GGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 5)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 52)  86 CLTA1_cis-block(1- CLTA1mg OFF3-  GGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 5)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 52)  87 CLTA1_cis-block(1- CLTA1mg ON1-  GAUGAGGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGA 116 10)_polyU_sgRNA target AAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 53)  88 CLTA1_cis-block(1- CLTA1mg ON1-  GAUGAGGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGA 116 10)_polyU_sgRNA target AAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 53)  89 CLTA1_cis-block(1- CLTA1mg OFF1-  GAUGAGGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGA 116 10)_polyU_sgRNA target AAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 53)  90 CLTA1_cis-block(1- CLTA1mg OFF3-  GAUGAGGACUUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGA 116 10)_polyU_sgRNA target AAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 53)  91 CLTA1_cis-block(16-  CLTA1mg ON1- GCUUGUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 20)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 54)  92 CLTA1_cis-block(16-  CLTA1mg ON1- GCUUGUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 20)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 54)  93 CLTA1_cis-block(16-  CLTA1mg OFF1- GCUUGUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 20)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 54)  94 CLTA1_cis-block(16- CLTA1mg OFF3- GCUUGUUUUUUAGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGAAAUAG 111 20)_polyU_sgRNA target CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU (SEQ ID NO: 54) DMT-modified sgRNA  95 CLTA1_DMT-ON sgRNA CLTA1 ON1-  (dmt)AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 113 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUUUUUU (SEQ ID NO: 55)  96 CLTA1_DMT-ON/OFF CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 56) Fluorophore-modified sgRNA  97 CLTA1_IntFl_sgLoop CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 57)  98 CLTA1_IntFl_sgLoop CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 57)  99 CLTA1_IntFl_sgLoop CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 57) 100 CLTA1_IntFl_sgLoop CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 57) 101 CLTA1_IntFl_sgLoop CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 57) 102 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  AGU CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 3′-3x(2′OMe) target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 58) 103 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  AGU CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 3′-3x(2′OMe) target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 58) 104 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF1-  AGU CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 3′-3x(2′OMe) target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 58) 105 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF3-  AGU CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCAUAGC 113 3′-3x(2′OMe) target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 58) 106 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCA 113 3′-3x(2′OMe, 3′P(S)) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 59) 107 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCA 113 3′-3x(2′OMe, 3′P(S)) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 59) 108 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCA 113 3′-3x(2′OMe, 3′P(S)) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 59) 109 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF3-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACAGCA 113 3′-3x(2′OMe, 3′P(S)) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 59) 110 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACA 113 3′-3x(2′OMe,  target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAC 3′thioPACE) CGAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 60) 111 CLTA1_IntFl_sgLoop_5′, CLTA1mg ON1-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACA 113 3′-3x(2′OMe,  target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAC 3′thioPACE) CGAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 60) 112 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF1-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACA 113 3′-3x(2′OMe,  target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAC 3′thioPACE) CGAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 60) 113 CLTA1_IntFl_sgLoop_5′, CLTA1mg OFF3-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGG(Fl)AACA 113 3′-3x(2′OMe,  target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAC 3′thioPACE) CGAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 60) 114 CLTA4_3xFl- CLTA4mg ON- U _(o) *s(Fl _(o) )GCAGAUGUAGUGUUUCCACAGUUUaAGAGCUAGUAAUAGCAAGU 102 Int_3x(2′OMe, target UuAAAUAAGGCUAGUCCGUUA(Fl)CAACUUGAAAAAGUGGCACCGAGUCGG 3′thioPACE) UGCU(Fl) U *sU (SEQ ID NO: 61) 115 CLTA4_3xFl- CLTA4mg OFF5-  U _(o) *s(Fl _(o) )GCAGAUGUAGUGUUUCCACAGUUUaAGAGCUAGUAAUAGCAAGU 102 Int_3x(2′OMe, target UuAAAUAAGGCUAGUCCGUUA(Fl)CAACUUGAAAAAGUGGCACCGAGUCGG 3′thioPACE) UGCU(Fl) U *sU (SEQ ID NO: 61) 116 CLTA4_3xFl- CLTA4mg ON- G *sCAGAUGUAGUGUUUCCACAGUUUaAGAGCUAG(Fl)AAUAGCAAGUUuAA 100 Loops_3x(2′OMe, target AUAAGGCUAGUCCGUUAUCAACUUG(Fl)AAAAGUGGCACCGAG(Fl)CGGUG 3′thioPACE) CUU U *sU (SEQ ID NO: 62) 117 CLTA4_3xFl- CLTA4mg OFF5-  G *sCAGAUGUAGUGUUUCCACAGUUUaAGAGCUAG(Fl)AAUAGCAAGUUuAA 100 Loops_3x(2′OMe, target AUAAGGCUAGUCCGUUAUCAACUUG(Fl)AAAAGUGGCACCGAG(Fl)CGGUG 3′thioPACE) CUU U *sU (SEQ ID NO: 62) 3′Phosphorothioate-modified sgRNA 118 CLTA1_5′-2xP(S) sgRNA CLTA1 ON1- AsGsUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 63) 119 CLTA1_5′-3xP(S) sgRNA CLTA1 ON1- AsGsUsCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGAAACAGCAUAG 113 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 64) 120 CLTA1_5′-4xP(S) sgRNA CLTA1 ON1- AsGsUsCsCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUUUUUU (SEQ ID NO: 65) 121 CLTA1_3′-4xP(S) sgRNA CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGAAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUsUsUsUsU (SEQ ID NO: 66) 2′OMethyl-modified sgRNA 122 CLTA1_2′OMe + 20 sgRNA CLTA1 ON1- AGUCCUCAUCUCCCUCAAG C GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 67) 123 CLTA1_2′OMe + 19 sgRNA CLTA1 ON1- AGUCCUCAUCUCCCUCAA G CGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 68) 124 CLTA1_2′OMe + 19 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCAA G CGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 68) 125 CLTA1_2′OMe + 19 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCAA G CGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 68) 126 CLTA1_2′OMe + 19 sgRNA CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAA G CGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 68) 127 CLTA1_2′OMe + 19 sgRNA CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAA G CGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 68) 128 CLTA1_2′OMe + 18 sgRNA CLTA1 ON1- AGUCCUCAUCUCCCUCA A GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 69) 129 CLTA1_2′OMe + 18 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCA A GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU  (SEQ ID NO: 69) 130 CLTA1_2′OMe + 18 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUCA A GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 69) 131 CLTA1_2′OMe + 18 sgRNA CLTA1mg OFF1-  AGUCCUCAUCUCCCUCA A GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 69) 132 CLTA1_2′OMe + 18 sgRNA CLTA1mg OFF3-  AGUCCUCAUCUCCCUCA A GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 69) 133 CLTA1_2′OMe + 17 sgRNA CLTA1 ON1- AGUCCUCAUCUCCCUC A AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 70) 134 CLTA1_2′OMe + 17 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUC A AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 70) 135 CLTA1_2′OMe + 17 sgRNA CLTA1mg ON1-  AGUCCUCAUCUCCCUC A AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 70) 136 CLTA1_2′OMe + 17 sgRNA CLTA1mg OFF1-  AGUCCUCAUCUCCCUC A AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 70) 137 CLTA1_2′OMe + 17 sgRNA CLTA1mg OFF3-  AGUCCUCAUCUCCCUC A AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 70) 138 CLTA1_2′OMe + 17,18 CLTA1 ON1-  AGUCCUCAUCUCCCUC AA GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 71) 139 CLTA1_2′OMe + 17,18 CLTA1mg ON1-  AGUCCUCAUCUCCCUC AA GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 71) 140 CLTA1_2′OMe + 17,18 CLTA1mg ON1-  AGUCCUCAUCUCCCUC AA GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 71) 141 CLTA1_2′OMe + 17,18 CLTA1mg OFF1-  AGUCCUCAUCUCCCUC AA GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 71) 142 CLTA1_2′OMe + 17,18 CLTA1mg OFF3-  AGUCCUCAUCUCCCUC AA GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 71) 143 CLTA1_5′,3′-3x(2′OMe) CLTA1 ON1-  AGU CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU UUU U (SEQ ID NO: 72) 144 CLTA4_5′,3′-3x(2′OMe) CLTA4mg ON- GCA GAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 73) 145 CLTA4_5′,3′-3x(2′OMe) CLTA4mg OFF5-  GCA GAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 73) 146 CLTA1_5′-20x(2′OMe) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGC GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 74) 147 CLTA1_5′-20x(2′OMe) CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGC GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 74) 148 CLTA1_5′-20x(2′OMe) CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGC GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 74) 149 CLTA1_5′-20x(2′OMe) CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGC GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 74) 150 CLTA1_5′-20x(2′OMe) CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGC GUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 74) 151 CLTA1_5′-26x(2′OMe) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAA GAGCUAUGCUGGUAACAGCAUAGC 113 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 75) 152 CLTA1_5′-37x(2′OMe) CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUG GUAACAGCAUAGC 113 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 76) 153 CLTA1_41x(2′OMeC/U)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 77) 154 CLTA1_47x(2′OMeC/U)_ CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 78) 155 CLTA1_47x(2′OMeC/U)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 79) 156 CLTA1_47x(2′OMeC/U)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 79) 157 CLTA1_47x(2′OMeC/U)_ CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 79) 158 CLTA1_47x(2′OMeC/U)_ CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 79) 159 CLTA1_47x(2′OMeG/A)_ CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 80) 160 CLTA1_47x(2′OMeG/A)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGA)AAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 80) 161 CLTA1_47x(2′OMeG/A)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 80) 162 CLTA1_47x(2′OMeG/A)_ CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 80) 163 CLTA1_47x(2′OMeG/A)_ CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 QB3 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 80) 164 CLTA1_43x(2′OMeG/A)_ CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 Bos target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 81) 165 CLTA1_43x(2′OMeG/A)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 Bos target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 81) 166 CLTA1_43x(2′OMeG/A)_ CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 Bos target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 81) 167 CLTA1_43x(2′OMeG/A)_ CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 Bos target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 81) 168 CLTA1_43x(2′OMeG/A)_ CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUA 100 Bos target AGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 81) 169 CLTA4 sgRNA_5′,3′- CLTA4 ON- GCA GAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 3x(2′OMe) target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 82) 170 CLTA4 sgRNA_5′,3′- CLTA4 ON- GCA GAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGC 113 3x(2′OMe) target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUU UUU U (SEQ ID NO: 82) 171 CLTA4_47x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 QB3 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 83) 172 CLTA4_47x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 QB3 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 83) 173 CLTA4_47x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 QB3 target  AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 83) 174 CLTA4_49x(2′OMeG/A)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 84) 175 CLTA4_49x(2′OMeG/A)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 84) 176 CLTA4_49x(2′OMeG/A)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 84) 177 CLTA4_39x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 85) 178 CLTA4_39x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 85) 179 CLTA4_39x(2′OMeC/U)_ CLTA4 ON- GCAGAUGUAGUGUUUCCACAGUUUUAGAGCUAGUAAUAGCAAGUUAAAAU 100 Bos target  AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 85) 2′Deoxy-modified sgRNA 180 CLTA1_5′-20x(2′deoxy) CLTA1 ON1-

GUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCG GUGCUUUUUUU (SEQ ID NO: 86) 181 CLTA1_5′-26x(2′deoxy) CLTA1 ON1-

GAGCUAUGCUGGUAACAG 113 target CAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUUUUU (SEQ ID NO: 87) 182 CLTA1_5′-37x(2′deoxy) CLTA1 ON1-

GUAACAGCA 113 target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUUUUU (SEQ ID NO: 88) 2′Deoxy,3′PACE-modified sgRNA 183 CLTA4_2′deoxy3′PACE +  CLTA4mg ON- GCAGAUGUAGUGUU

*CCACAGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 15 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 89) 184 CLTA4_2′deoxy3′PACE + CLTA4mg OFF5-  GCAGAUGUAGUGUU

*CCACAGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 15 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 89) 2′OMethyl,3′PACE-modified sgRNA 185 5′- CLTA1mg ON1-  A*GUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 1x(2′OMe,3′PACE)_CLTA1 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU sgRNA CGGUGCUUUUUUU (SEQ ID NO: 90) 186 5′- CLTA1mg ON1-  A*GUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 1x(2′OMe,3′PACE)_CLTA1 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU sgRNA CGGUGCUUUUUUU (SEQ ID NO: 90) 187 5′- CLTA1 ON1- A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 2x(2′OMe,3′PACE)_CLTA1 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG sgRNA UCGGUGCUUUUUUU (SEQ ID NO: 91) 188 5′- CLTA1 ON1- A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 2x(2′OMe,3′PACE)_CLTA1 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG sgRNA UCGGUGCUUUUUUU (SEQ ID NO: 91) 189 5′- CLTA1mg ON1-  A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 2x(2′OMe,3′PACE)_CLTA1 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG sgRNA UCGGUGCUUUUUUU (SEQ ID NO: 91) 190 5′- CLTA1mg ON1-  A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 2x(2′OMe,3′PACE)_CLTA1 target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG sgRNA UCGGUGCUUUUUUU (SEQ ID NO: 91) 191 5′- CLTA1mg ON1-  G*G*A*GUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 115 3x(2′OMe,3′PACE)_CLTA1 target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC sgRNA GAGUCGGUGCUUUUUUU (SEQ ID NO: 92) 192 5′- CLTA1mg ON1-  G*G*A*GUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 115 3x(2′OMe,3′PACE)_CLTA1 target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC sgRNA GAGUCGGUGCUUUUUUU (SEQ ID NO: 92) 193 5′- CLTA1 ON1- A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 113 4x(2′OMe,3′PACE)_CLTA1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG sgRNA AGUCGGUGCUUUUUUU (SEQ ID NO: 93) 194 5′- CLTA1mg ON1-  A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 113 4x(2′OMe,3′PACE)_CLTA1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG sgRNA AGUCGGUGCUUUUUUU (SEQ ID NO: 93) 195 5′- CLTA1mg ON1-  A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 113 4x(2′OMe,3′PACE)_CLTA1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG sgRNA AGUCGGUGCUUUUUUU (SEQ ID NO: 93) 196 5′- CLTA1mg ON1-  G*G*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAG 115 5x(2′OMe,3′PACE)_CLTA1 target CAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA sgRNA CCGAGUCGGUGCUUUUUUU (SEQ ID NO: 94) 197 5′- CLTA1mg ON1-  G*G*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAG 115 5x(2′OMe,3′PACE)_CLTA1 target CAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA sgRNA CCGAGUCGGUGCUUUUUUU (SEQ ID NO: 94) 198 CLTA1_3′- CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 4x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU*U*U*U*U (SEQ ID NO: 95) 199 CLTA1_3′- CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 4x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU*U*U*U*U (SEQ ID NO: 95) 200 CLTA1_3′- CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 4x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU*U*U*U*U (SEQ ID NO: 95) 201 CLTA1_3′- CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 4x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU*U*U*U*U (SEQ ID NO: 95) 202 CLTA1_3′- CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 5x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUU*U*U*U*U*U (SEQ ID NO: 96) 203 CLTA1_3′- CLTA1 ON1- AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 5x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUU*U*U*U*U*U (SEQ ID NO: 96) 204 CLTA1_3′- CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 5x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUU*U*U*U*U*U (SEQ ID NO: 96) 205 CLTA1_3′- CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 5x(2′OMe,3′PACE) sgRNA target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUU*U*U*U*U*U (SEQ ID NO: 96) 206 5′- CLTA1 ON1- C _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: 97) 207 5′- CLTA1mg ON1-  C _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: 97) 208 5′- CLTA1mg ON1-  C _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: 97) 209 5′- CLTA1 ON1- G _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG NC_overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: 98 210 5′- CLTA1mg ON1-  G _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG NC_overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: (SEQ ID NO: 98) 211 5′- CLTA1mg ON1-  G _(o)*A*G*UCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAU 114 3x(2′OMe,3′PACE)_plus1 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG NC_overhg_CLTA1 AGUCGGUGCUUUUUUU (SEQ ID NO: 98) 212 5′- CLTA1 ON1- U _(o)*C _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 99) 213 5′- CLTA1mg ON1-  U _(o)*C _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 99) 214 5′- CLTA1mg ON1-  U _(o)*C _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 99) 215 5′- CLTA1 ON1- A _(o)*G _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC NC_overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 100) 216 5′- CLTA1mg ON1-  A _(o)*G _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC NC_overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 100) 217 5′- CLTA1mg ON1-  A _(o)*G _(o)*A*G*U*CCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACA 115 5x(2′OMe,3′PACE)_plus2 target GCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC NC_overhg_CLTA1 ACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 100) 218 5′- CLTA1 ON1- C _(o)*U _(o)*C _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 219 5′- CLTA1mg ON1-  C _(o)*U _(o)*C _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 220 5′- CLTA1mg ON1-  C _(o)*U _(o)*C _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 221 5′- CLTA1 ON1- G _(o)*A _(o)*G _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU NC_overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 222 5′- CLTA1mg ON1-  G _(o)*A _(o)*G _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU NC_overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 223 5′- CLTA1mg ON1-  G _(o)*A _(o)*G _(o)*A*G*U*C*CUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUA 116 7x(2′OMe,3′PACE)_plus3 target ACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGU NC_overhg_CLTA1_3′- GGCACCGAGUCGGUGCUUU*U*U*U*U (SEQ ID NO: 101) 4x(2′OMe,3′PACE) 224 CLTA1_2′OMe,3′PACE + CLTA1 ON1- AGUCCUCAUCUCCCUCAAGC*GUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 20 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 102 225 CLTA1_2′OMe,3′PACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGC*GUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 20 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 102) 226 CLTA1_2′OMe,3′PACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAGC*GUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 20 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 102) 227 CLTA1_2′OMePACE + CLTA1 ON1- AGUCCUCAUCUCCCUCAAG*CGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 19 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 103) 228 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAG*CGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 19 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 103) 229 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAAG*CGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 19 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 103) 230 CLTA1_2′OMePACE + CLTA1mg OFF1-  AGUCCUCAUCUCCCUCAAG*CGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 19 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 103) 231 CLTA1_2′OMePACE + CLTA1mg OFF3-  AGUCCUCAUCUCCCUCAAG*CGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 19 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 103) 232 CLTA1_2′OMePACE + CLTA1 ON1- AGUCCUCAUCUCCCUCAA*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 18 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 104) 233 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAA*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 18 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 104) 234 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCAA*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 18 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 104) 235 CLTA1_2′OMePACE + CLTA1 ON1- AGUCCUCAUCUCCCUCA*AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 17 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 105) 236 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCA*AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 17 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 105) 237 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCA*AGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 17 sgRNA target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 105) 238 CLTA1_2′OMePACE + CLTA1 ON1- AGUCCUCAUCUCCCUCA*A*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 17,18 sgRNA target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 106) 239 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCA*A*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 17,18 sgRNA target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 106) 240 CLTA1_2′OMePACE + CLTA1mg ON1-  AGUCCUCAUCUCCCUCA*A*GCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 17,18 sgRNA target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUUU (SEQ ID NO: 106) 2′OMethyl,3′Phosphorothioate-modified sgRNA 241 CLTA1_5′,3′-3x(2′OMe, CLTA1 ON1- A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′P(S)) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 242 CLTA1_5′,3′-3x(2′OMe, CLTA1mg ON1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′P(S)) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 243 CLTA1_5′,3′-3x(2′OMe, CLTA1mg ON1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′P(S)) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 244 CLTA1_5′,3′-3x(2′OMe, CLTA1mg OFF1-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′P(S)) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 245 CLTA1_5′,3′-3x(2′OMe, CLTA1mg OFF3-  A s G s U sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′P(S)) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 246 CLTA4_5′,3′-3x(2′OMe, CLTA4 target G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 247 CLTA4_5′,3′-3x(2′OMe, CLTA4 target G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 248 CLTA4_5′,3′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 249 CLTA4_5′,3′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 250 CLTA4_5′,3′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 251 CLTA4_5′,3′-3x(2′OMe, CLTA4mg OFF5-  G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)) target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGCUUU U s U s U sU (SEQ ID NO: 107) 252 CLTA4_5′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)),3′-5x(2′OMe, target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA 3′P(S)) GUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 108) 253 CLTA4_5′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)),3′-5x(2′OMe, target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA 3′P(S)) GUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 108) 254 CLTA4_5′-3x(2′OMe, CLTA4mg ON- G s C s A sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUA 113 3′P(S)),3′-5x(2′OMe, target GCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA 3′P(S)) GUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 108) 255 CLTA4_5′,3′-5x(2′OMe, CLTA4mg ON- G s C s A s G s A sUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAU 113 3′P(S)) target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 109) 256 CLTA4_5′,3′-5x(2′OMe, CLTA4mg ON- G s C s A s G s A sUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAU 113 3′P(S)) target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 109) 257 CLTA4_5′,3′-5x(2′OMe, CLTA4mg OFF5- G s C s A s G s A sUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAU 113 3′P(S)) target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCU U s U s U s U s U sU (SEQ ID NO: 109) 2′OMethyl,3′PhosphorothioPACE-modified sgRNA 258 CLTA1_5′,3′-3x(2′OMe, CLTA1 ON1-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 110) 259 CLTA1_5′,3′-3x(2′OMe, CLTA1mg ON1- A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 110) 260 CLTA1_5′,3′-3x(2′OMe, CLTA1mg ON1- A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 110) 261 CLTA1_5′,3′-3x(2′OMe, CLTA1mg OFF1- A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 110) 262 CLTA1_5′,3′-3x(2′OMe, CLTA1mg OFF3- A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 110) 263 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1- A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 111) 264 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1- A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 111) 265 CLTA1_5′,3′-1x(2′OMe, CLTA1mg OFF1- A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 111) 266 CLTA1_5′,3′-1x(2′OMe, CLTA1mg OFF3-  A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 111) 267 CLTA1_5′,3′-3x(2′OMe, CLTA1 ON1-  A *s G *s U *sCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCA  75 3′thioPACE)_75 mer target UAGCAAGUUUAAAUAAGGCUAGUCC G *s U *s U *sU (SEQ ID NO: 112) 268 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1-  A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG  74 3′thioPACE)_74 mer target CAAGUUUAAAUAAGGCUAGUCCG U *sU (SEQ ID NO: 112) 269 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1-  A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG  75 3′thioPACE)_75 mer target CAAGUUUAAAUAAGGCUAGUCCGU U *sA (SEQ ID NO: 112) 270 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1-  A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG  77 3′thioPACE)_77 mer target CAAGUUUAAAUAAGGCUAGUCCGUUA U *sC (SEQ ID NO: 113) 271 CLTA1_5′,3′-1x(2′OMe, CLTA1mg ON1-  G *sAGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUA  78 3′thioPACE)_77 mer + G target GCAAGUUUAAAUAAGGCUAGUCCGUUA U *sC (SEQ ID NO: 114) 272 CLTA4_5′,3′-3x(2′OMe, CLTA4 ON- G *s C *s A *sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 115) 273 CLTA4_5′,3′-3x(2′OMe, CLTA4 ON- G *s C *s A *sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 115) 274 CLTA4_5′,3′-3x(2′OMe, CLTA4 ON- G *s C *s A *sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUU U *s U *s U *sU (SEQ ID NO: 115) 275 CLTA4_5′,3′-3x(2′OMe, CLTA4mg OFF5-  G*sC*sA*sGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCA 113 3′thioPACE) target UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACC GAGUCGGUGCUUUU*sU*sU*sU (SEQ ID NO: 115) 276 CLTA4_5′,3′-1x(2′OMe, CLTA4mg ON-  G*sCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUU*sU (SEQ ID NO: 116) 277 CLTA4_5′,3′-1x(2′OMe, CLTA4mg ON-  G *sCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 116) 278 CLTA4_5′,3′-1x(2′OMe, CLTA4mg ON-  G*sCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUUU*sU (SEQ ID NO: 116) 279 CLTA4_5′,3′-1x(2′OMe, CLTA4mg OFF5- G *sCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAG 113 3′thioPACE) target CAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAG UCGGUGCUUUUU U *sU (SEQ ID NO: 116) 2-aminoA-modified sgRNA (including unmodified controls) 280 EN1 EN1mg ON- GAUGUUGUCGAUGAAAAAGUGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 117) 281 EN1 EN1mg OFF- GAUGUUGUCGAUGAAAAAGUGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 117) 282 EN1_2aminoA + 16 EN1mg ON- GAUGUUGUCGAUGAA(2aA)AAGUGUUUAAGAGCUAUGCUGGUAACAGCAU 113 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUUUUUU (SEQ ID NO: 118) 283 EN1_2aminoA + 16 EN1mg OFF- GAUGUUGUCGAUGAA(2aA)AAGUGUUUAAGAGCUAUGCUGGUAACAGCAU 113 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUUUUUU (SEQ ID NO: 118) 284 PCDHA4 PCDHA4mg ON-  GAUUUAGACGAAGGAUUGAAGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 119) 285 PCDHA4 PCDHA4mg OFF-  GAUUUAGACGAAGGAUUGAAGUUUAAGAGCUAUGCUGGUAACAGCAUAGC 113 target AAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUUUUU (SEQ ID NO: 119) 286 PCDHA4_2aminoA + 15 PCDHA4mg ON-  GAUUUAGACGAAGG(2aA)UUGAAGUUUAAGAGCUAUGCUGGUAACAGCAU 113 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUUUUUU (SEQ ID NO: 120) 287 PCDHA4_2aminoA + 15 PCDHA4mg OFF-  GAUUUAGACGAAGG(2aA)UUGAAGUUUAAGAGCUAUGCUGGUAACAGCAU 113 target AGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUUUUUU (SEQ ID NO: 120) 5-methylU-modified sgRNA 288 CLTA4_21x(5-MeU) CLTA4mg ON-  GCAGA(5mU)G(5mU)AG(5mU)G(5mU)(5mU)(5mU)CCACAGUUUAAG 113 target AGC(5mU)A(5mU)GC(5mU)GG(5mU)AACAGCA(5mU)AGCAAGUUUAA AUAAGGCUAGUCCGUUAUCAAC(5mU)(5mU)GAAAAAG(5mU)GGCACCG AGUCGG(5mU)GC(5mU)(5mU)(5mU)(5mU)(5mU)(5mU)U  (SEQ ID NO: 121) 289 CLTA4_21x(5-MeU) CLTA4mg OFF5- GCAGA(5mU)G(5mU)AG(5mU)G(5mU)(5mU)(5mU)CCACAGUUUAAG 113 target AGC(5mU)A(5mU)GC(5mU)GG(5mU)AACAGCA(5mU)AGCAAGUUUAA AUAAGGCUAGUCCGUUAUCAAC(5mU)(5mU)GAAAAAG(5mU)GGCACCG AGUCGG(5mU)GC(5mU)(5mU)(5mU)(5mU)(5mU)(5mU)U  (SEQ ID NO: 121) Z base-modified sgRNA 290 CLTA1_ZZ_70,71 CLTA1 ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUZZGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUUUUUU (SEQ ID NO: 122) 291 CLTA1_ZZ_95,96 CLTA1 ON1-  AGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCA 113 target AGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAZZGAGUC GGUGCUUUUUUU (SEQ ID NO: 122) sgRNA modified to disfavor misfolding 292 CLTA1_opti_short_5′, CLTA1mg ON1- A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAGUAAUAGCAAGUUUAAA 100 3′-1x(2′OMe, target UAAGG U UA A UCCGUUAUCAACAAGAAAUUGUGGCACCGAGUCGGUGCUU U *sU 3′thioPACE)_2′OMe_54, (SEQ ID NO: 123) 57 293 CLTA1_opti_short_ 5′, CLTA1mg ON1- A *sGUCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAG 113 3′-1x(2′OMe, target CAAGUUUAAAUAAGG U UA A UCCGUUAUCAACAAGAAAUUGUGGCACCGAG 3′thioPACE)_2′OMe_64, UCGGUGCUUUUU U *sU (SEQ ID NO: 124) 67 N = 2′OMe N = 2′deoxy Ns = 3′P(S) N* = 3′-PACE N*s = 3′-thioPACE N* = 2′OMe,3′-PACE N*s = 2′OMe,3′-thioPACE Ns = 2′OMe, 3′P(S) N_(o) = 5′-overhang (5′ to the 20-nt guide sequence); ‘“NC” means the overhang is not complementary to protospacer-adjacent sequence (2sU) = 2-thioU (2aA) = 2-aminoA (5mU) = 5-methylU Z = Z base IntFl = Fluorophore incorporated at an internal position in the RNA sequence

The DNA target constructs in Table 3 had the following sequences:

CLTA1 ON1- AGAATTTAACTGTGGTCACATTTGCTTTATCGACTGGCTTCATCTCACAGCTCATC target: TTACGCAAGTTCGATGAGTATGCCAGTCACTTTCAATTTGGTTGAATGTTCCCGTG ACATGCGAGTTCTGTCGACCATGTGCCGCGGATTGAATTCCTCAAGGGTGGTGATA GATGCTACGGTGGTGATGCGCATGCGCTCAGTCCTCATCTCCCTCAAGC AGG CCCC GCTGGTGGGTCGGAGTCCCTAGTGAAGCCACCAATATAGTGGTCGTGTCAAGCAAC TGTCCACGCTCCACCCTCGAGGTCGTAACATAAACGTACTAAGGCACGAGTAAACA AGATCGATAGCAAGAACATGGTATAGACTGACGGAGAGCTCGCCATTAGTCTGA (SEQ ID NO: 10) CLTA1 OFF1- AGAATTTAACTGTGGTCACATTTGCTTTATCGACTGGCTTCATCTCACAGCTCATC target: TTACGCAAGTTCGATGAGTATGCCAGTCACTTTCAATTTGGTTGAATGTTCCCGTG ACATGCGAGTTCTGTCGACCATGTGCCGCGGATTGAATTCCTCAAGGGTGGTGATA GATGCTACGGTGGTGATGCGTATGCACTCAGTCCTCAACTCCCTCAAGC AGG CGAC CCCTGGGGGTCGGAGTCCCTAGTGAAGCCACCAATATAGTGGTCGTGTCAAGCAAC TGTCCACGCTCCACCCTCGAGGTCGTAACATAAACGTACTAAGGCACGAGTAAACA AGATCGATAGCAAGAACATGGTATAGACTGACGGAGAGCTCGCCATTAGTCTGA (SEQ ID NO: 11) CLTA1 OFF2- AGAATTTAACTGTGGTCACATTTGCTTTATCGACTGGCTTCATCTCACAGCTCATC target: TTACGCAAGTTCGATGAGTATGCCAGTCACTTTCAATTTGGTTGAATGTTCCCGTG ACATGCGAGTTCTGTCGACCATGTGCCGCGGATTGAATTCCTCAAGGGTGGTGATA GATGCTACGGTGGTGATGCAATAAATTTCAGCCCTCATTTCCCTCAAGC AGG GGTT ACTTTAGGGTCGGAGTCCCTAGTGAAGCCACCAATATAGTGGTCGTGTCAAGCAAC TGTCCACGCTCCACCCTCGAGGTCGTAACATAAACGTACTAAGGCACGAGTAAACA AGATCGATAGCAAGAACATGGTATAGACTGACGGAGAGCTCGCCATTAGTCTGA (SEQ ID NO: 12) CLTA1 OFF3- AGAATTTAACTGTGGTCACATTTGCTTTATCGACTGGCTTCATCTCACAGCTCATC target: TTACGCAAGTTCGATGAGTATGCCAGTCACTTTCAATTTGGTTGAATGTTCCCGTG ACATGCGAGTTCTGTCGACCATGTGCCGCGGATTGAATTCCTCAAGGGTGGTGATA GATGCTACGGTGGTGATGCTCTCCAGCCCACTCCTCATCCCCCTCAAGC CGG TCCC AGGCTGGGGTCGGAGTCCCTAGTGAAGCCACCAATATAGTGGTCGTGTCAAGCAAC TGTCCACGCTCCACCCTCGAGGTCGTAACATAAACGTACTAAGGCACGAGTAAACA AGATCGATAGCAAGAACATGGTATAGACTGACGGAGAGCTCGCCATTAGTCTGA (SEQ ID NO: 13) CLTA1mg ON1- GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGCAGGCCAAAGATG TCTCCCGCATGCGCTCAGTCCTCATCTCCCTCAAGC AGG CCCTGCTGGTGCACTGA AGAGCCACCCTGTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 14) CLTA1mg OFF1- GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGCAGGGCAAAGAGG TCTCCTGTATGCACTCAGTCCTCAACTCCCTCAAGC AGG CGACCCTTGGTGCACTG ACAAACCGCTCCTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 15) CLTA1mg_OFF3 GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCAGGAGAGGGAGCCA TGCTCATCTCCAGCCCACTCCTCATCCCCCTCAAGC CGG TCCCAGGCTGAGAGGCT AAAGCTTGTCTTTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 16) CLTA4 ON- GCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGA target: GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTAT GCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACG ATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAAC TCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTG ACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAA CTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGT TGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAAT CTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGT AAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGT CAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTT AAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACG TGAGTTTTCGTTCCACtGaGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTT GAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTA CCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAC TGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAG GCCACCACTTCAAGAACTCTGTAGCACCGCCACATACCTCGCTCTGCTAATCCTGT TACCAGTGGCTGCTTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAG ACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACAC AGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA TGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGC TCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTT CCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGA ACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAA ACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTC CCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCAT TAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGT GAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCGCG CAATTAACCCTCACTAAAGGGAACAAAAGCTGGGTACCGGGCCCCCCCTCGACACC AGTTGCATTCGATTCCTGTTTGTAATTGTCCAATTCCTGCAGCCCGGGGGATCGGC AGATGTAGTGTTTCCACA GGG GATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTG GAGCTCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTT TACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCA CATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTC CCAACAGTTGCGCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTT AAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAA TCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTT CCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCG AAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTT TTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGA TTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGC GAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCA CCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGG GGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTA TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGA GTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGC CTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCA GTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTG AGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTA TGTGGCGCGGTATTATCCCGTATTGAC (SEQ ID NO: 17) CLTA4mg ON- GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCAAGAGCTTCACTGA GTAGGATTAAGATATTGCAGATGTAGTGTTTCCACA GGG TGGCTCTTCAGTGCACC AGCGGAACCTGCTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 18) CLTA4mg OFF5- GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCTCTGAATAGAGTTG GGAAGAGATGCATACAACATATGTAGTATTTCCACA GGG AATACAATGGACAAATG ACCTCAAGAGCAGGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 19) IL2RGmg_ON GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGGGCAGCTGCAGGA ATAAGAGGGATGTGAATGGTAATGATGGCTTCAACA TGG CGCTTGCTCTTCATTCC CTGGGTGTAGTCTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 20) EN1mg_ON GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCCTCCTTACTGCAGC CGAAGTCCGGCCTCAGGATGTTGTCGATGAAAAAGT TGG TGGTGCGGTGCAGCTGG GCCGCTGGCTGCGGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 21) EN1mg_OFF GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGTCCTTTCGCCGGC CGAACTCGGGCCGCAGGATGTTGTCGATGAAGAAGT TGG TGATGCGGTGCGGGTGC TGGTGGTTGCCGGGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 22) PCDHA4mg_ ON GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target: GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGGAACATTGGTAAT TAAACTTAACGCCTCAGATTTAGACGAAGGATTGAA TGG GGACATTGTTTATTCAT TCTCGAATGATACGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 23) PCDHA4mg_ OFF GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG target GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATA AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCG TTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG GTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGG AAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCA TTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACG CCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATA CGACTCACTATAGGGCGAATTGGGTACGATCGATGCGGCCTCGGAACGCTGGTGAT TCATCCCAATGCCTCAGATTTAGACGAAGGCTTGAA TGG GGATATTATTTACTCCT TCTCCAGTGATGTGCGCGTGATATGCAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTA TCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT GAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCG GCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC (SEQ ID NO: 24)

In a 20-uL reaction volume, 50 fmoles of linearized DNA target in the presence of 50 nM sgRNA, 39 nM recombinant purified Cas9 protein (S. pyogenes; Agilent) and 10 mM or 0.8 mM MgCl₂ at pH 7.6 was incubated at 37° C. for 30 min. Upon completion, 0.5 uL of RNace It (Agilent) was added, and incubation was continued at 37° C. for 5 min and then at 70° C. for 15 min. Subsequently 0.5 μL of Proteinase K (Mol. Bio. grade, NEB) was added and incubated at 37° C. for 15 min. Aliquots were loaded into a DNA 1000 or DNA 7500 LabChip and were analyzed on a Bioanalyzer 2200, or alternatively were loaded into a Genomic DNA ScreenTape and were analyzed on a TapeStation. The workup steps served to release Cas9 from binding of target DNA, which was assayed for cleavage. Cleavage yields were calculated by the formula: a/(a+b)×100 where a is the sum of the band intensities of the two cleavage products and b is the remaining uncleaved DNA if present. A cleavage percentage of 100% means that all of the target DNA construct was cleaved.

A series of guide RNAs were chemically synthesized. The guide RNA oligomers were synthesized on an ABI 394 Synthesizer (Life Technologies, Carlsbad, Calif., USA) using 2′-O-thionocarbamate-protected nucleoside phosphoramidites according to procedures described in Dellinger et al. (2011) J. Am. Chem. Soc., 133, 11540-56. 2′-O-methyl phosphoramidites were incorporated into RNA oligomers under the same conditions as the 2′-O-thionocarbamate protected phosphoramidites. The 2′-O-methyl-3′-O-(diisopropylamino)phosphinoacetic acid-1,1-dimethylcyanoethyl ester-5′-O-dimethoxytrityl nucleosides used for synthesis of thiophosphonoacetate (thioPACE)-modified RNAs were synthesized essentially according to published methods. See Dellinger et al. (2003) J. Am. Chem. Soc., 125, 940-50; and Threlfall et al. (2012) Org. Biomol. Chem., 10, 746-54. For phosphorothioate-containing oligomers, the iodine oxidation step after the coupling reaction was replaced by a sulfurization step using a 0.05 M solution of 3-((N,N-dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-5-thione in a pyridine-acetonitrile (3:2) mixture for 6 min.

All the oligonucleotides were purified using reversed-phase high-performance liquid chromatography (HPLC) and analyzed by liquid chromatography-mass spectrometry (LC-MS) using an Agilent 1290 Infinity series LC system coupled to an Agilent 6520 Q-TOF (time-of-flight) mass spectrometer (Agilent Technologies, Santa Clara, Calif., USA). The yields for the synthesis and purification of the sgRNAs were estimated using deconvolution of mass spectra obtained from LC-MS-derived total ion chromatograms. The chemical synthesis of the 100-mer sgRNAs typically yielded 25-35% full-length product from a nominal 1 micromole scale synthesis. Reversed-phase HPLC purification using ion pairing buffer conditions typically gave 20% yield from the crude product with an estimated purity of the final sgRNA in the range of 90% to 95%.

The results are shown in Table 4. “% Target cleaved” indicates the percentage of the target DNA construct which was cleaved. Experiments were run with and without addition of a molar excess of targetless competitor DNA (tcDNA) which potentially competes with the target DNA, so the potential impact of the added nonspecific DNA upon the assay could be seen.

TABLE 4 [Mg²⁺] % Target % Cleaved vs. % CV Entry # (mM) tcDNA cleaved % CV CONTROL CONTROL 2-piece dual-guide scaffold Unmodified dual-guide RNA (dgRNA) 1 0.8 N 99% — 2 0.8 Y 99% 5% 3 0.8 N 96% — 4 0.8 Y 100%  5% 5 0.8 N 96% — 6 0.8 Y  0% 5% 7 0.8 N 99% — 8 0.8 Y 100%  5% 9 10 N 94%, 93% — 10 0.8 Y 88% — Fluorophore-coupled dgRNA 11 10 N 92%, 93% — 94%, 93% — 2′OMethyl-modified dgRNA 12 0.8 Y 87% — 88% — 2′OMethyl, 3′Phosphorothioate-modified dgRNA 13 0.8 Y 87% — 88% — 2′OMethyl, 3′PhosphorothioPACE-modified dgRNA 14 0.8 Y 89% — 88% — 15 0.8 Y 86% — 88% — 2-thioU-modified dgRNA 16 0.8 N 96% — 99% — 17 0.8 Y 95% 5% 99% 5% 18 0.8 N 95% — 96% — 19 0.8 Y 100%  5% 100%  5% 20 0.8 N 97% — 96% — 21 0.8 Y  0% 5%  0% 5% 22 0.8 N 98% — 99% — 23 0.8 Y 99% 5% 100%  5% 24 0.8 N 94% — 99% — 25 0.8 Y 83% 5% 99% 5% 26 0.8 N 93% — 96% — 27 0.8 Y 94% 5% 100%  5% 28 0.8 N 90% — 96% — 29 0.8 Y  0% 5%  0% 5% 30 0.8 N 95% — 99% — 31 0.8 Y 94% 5% 100%  5% 32 0.8 N 92% — 99% — 33 0.8 Y 84% 5% 99% 5% 34 0.8 N 90% — 96% — 35 0.8 Y 94% 5% 100%  5% 36 0.8 N 70% — 96% — 37 0.8 Y  0% 5%  0% 5% 38 0.8 N 96% — 99% — 39 0.8 Y 59% 5% 100%  5% Single-guide scaffold Unmodified single-guide RNA (sgRNA) 40 10 N 93% — 41 10 N 94% — 42 10 N 94% — 43 10 N 92% — 44 10 N 90%, 92% — 45 10 N 92% — 46 10 N 93% — 47 0.8 N 86% — 48 0.8 N 87% — 49 0.8 Y 87% — 50 0.8 N 82% — 51 0.8 N 92% — 52 10 N 60% — 53 0.8 N 90% — 54 0.8 N 90% — 55 0.8 Y 79% — 56 0.8 N 79% — 57 0.8 N 94% — 58 10 N 73% — 59 0.8 N 84% — 60 0.8 Y ≥85%  — 61 0.8 Y 89% — 62 0.8 N 87%, 82% — 63 0.8 N 23%, 22% — 64 0.8 N 78% — 87% — 65 0.8 Y 76% — 87% — 66 0.8 N 65% — 87% — 67 0.8 N 81% — 87% — 68 0.8 N 85% — 87% — 69 0.8 Y 71% — 87% — 70 0.8 N 32% — 87% — 71 0.8 N 84% — 87% — 72 0.8 N 91% — 87% — 73 0.8 Y 79% — 87% — 74 0.8 N 88% — 87% — 75 0.8 N 93% — 87% — 76 0.8 N 87% — 87% — 77 0.8 Y 79% — 87% — 78 0.8 N 89% — 87% — 79 0.8 N 88% — 87% — 80 0.8 N  3% — 86% — 81 0.8 N  5% — 86% — 82 0.8 N 89% — 86% — 83 0.8 N 68% — 87% — 84 0.8 Y 50% — 87% — 85 0.8 N 69% — 87% — 86 0.8 N 69% — 87% — 87 0.8 N 76% — 87% — 88 0.8 Y 42% — 87% — 89 0.8 N 72% — 87% — 90 0.8 N 78% — 87% — 91 0.8 N 85% — 87% — 92 0.8 Y 51% — 87% — 93 0.8 N 82% — 87% — 94 0.8 ″ 83% — 87% — DMT-modified sgRNA 95 10 N 93% — 92% — 96 10 N 93% — 92% — Fluorophore-modified sgRNA 97 10 N 91%, 91% — 90%, 92% — 98 0.8 N 86% — 87% — 99 0.8 Y 77% — 87% — 100 0.8 N 87% — 87% — 101 0.8 N 86% — 87% — 102 0.8 N 91% — 87% — 103 0.8 Y 82% — 87% — 104 0.8 N 90% — 87% — 105 0.8 N 92% — 87% — 106 0.8 N 91% — 87% — 107 0.8 Y 82% — 87% — 108 0.8 N 90% — 87% — 109 0.8 N 91% — 87% — 110 0.8 N 92% — 87% — 111 0.8 Y 84% — 87% — 112 0.8 N 92% — 87% — 113 0.8 N 89% — 87% — 114 0.8 N 84%, 84% — 87%, 82% — 115 0.8 N 12%, 6%  — 23%, 22% — 116 0.8 N 93%, 90% — 87%, 82% — 117 0.8 N 8%, 9% — 23%, 22% — 3′Phosphorothioate-modified sgRNA 118 10 N 95% — 90%, 92% — 119 10 N 94% — 90%, 92% — 120 10 N 97% — 90%, 92% — 121 10 N 94% — 90%, 92% — 2′OMethyl-modified sgRNA 122 10 N 91% — 94% — 123 10 N 92% — 93% — 124 0.8 N 86% — 87% — 125 ″ Y 77% — 87% — 126 ″ N 85% — 87% — 127 0.8 N 88% — 87% — 128 10 N 92% — 94% — 129 0.8 N 83% — 87% — 130 0.8 Y 78% — 87% — 131 0.8 N 83% — 87% — 132 0.8 N 85% — 87% — 133 10 N 92% — 94% — 134 0.8 N 86% — 87% — 135 0.8 Y 78% — 87% — 136 0.8 N 83% — 87% — 137 0.8 N 88% — 87% — 138 10 N 91% — 94% — 139 0.8 N 84% — 87% — 140 0.8 Y 81% — 87% — 141 0.8 N 83% — 87% — 142 0.8 N 87% — 87% — 143 10 N 89% — 92% — 144 0.8 N 91%, 88% — 87%, 82% — 145 0.8 N 24%, 25% — 23%, 22% — 146 10 N 93%, 92% — 90%, 92% — 147 0.8 N 22% — 87% — 148 0.8 Y  3% — 87% — 149 0.8 N 12% — 87% — 150 0.8 N  5% — 87% — 151 10 N 0%, 0% — 90%, 92% — 152 10 N 0%, 0% — 90%, 92% — 153 0.8 N 85% — 86% — 154 0.8 N 87% — 86% — 155 0.8 N 89% — 87% — 156 0.8 Y 78% — 87% — 157 0.8 N 84% — 87% — 158 0.8 N 93% — 87% — 159 0.8 N 90% — 86% — 160 0.8 N 90% — 87% — 161 0.8 Y 86% — 87% — 162 0.8 N 90% — 87% — 163 0.8 N 91% — 87% — 164 0.8 N 92% — 90% — 165 0.8 N 89% — 87% — 166 0.8 Y 80% — 87% — 167 0.8 N 90% — 87% — 168 0.8 N 94% — 87% — 169 0.8 N 90% — 84% — 170 0.8 Y ≥85%  — ≥85%  — 171 0.8 N  7% — 84% — 172 0.8 Y  0% — ≥85%  — 173 10 N 15% — 73% — 174 0.8 N 85% — 84% — 175 0.8 Y 75% — ≥85%  — 176 10 N 86% — 73% — 177 0.8 ″  0% — 84% — 178 0.8 Y  0% — ≥85%  — 179 10 N 15% — 73% — 2′Deoxy-modified sgRNA 180 10 N 27%, 19% — 90%, 92% — 181 10 N 0%, 0% — 90%, 92% — 182 10 N 0%, 0% — 90%, 92% — 2′Deoxy, 3′PACE-modified sgRNA 183 0.8 N 72%, 77% — 87%, 82% — 184 0.8 N 8%, 9% — 23%, 22% — 2′OMethyl, 3′PACE-modified sgRNA 185 0.8 N 82% — 87% — 186 0.8 Y 72% — 87% — 187 10 Y 95% — 93% — 188 10 Y 95% — 94% — 189 0.8 Y 91% — 87% — 190 0.8 Y 84% — 87% — 191 0.8 Y 85% — 87% — 192 0.8 Y 77% — 87% — 193 10 Y 88% — 94% — 194 0.8 Y 70% — 87% — 195 0.8 Y 56% — 87% — 196 0.8 Y 40% — 87% — 197 0.8 Y 23% — 87% — 198 10 Y 88% — 93% — 199 10 Y 89% — 94% — 200 0.8 Y 84% — 87% — 201 0.8 Y 75% — 87% — 202 10 Y 90% — 93% — 203 10 Y 90% — 94% — 204 0.8 Y 86% — 87% — 205 0.8 Y 82% — 87% — 206 10 Y 88% — 93% — 207 0.8 Y 82% — 87% — 208 0.8 Y 78% — 87% — 209 10 Y 77% — 93% — 210 0.8 Y 71% — 87% — 211 ″ Y 69% — ″ — 212 10 N 80% — 93% — 213 0.8 N 56% — 87% — 214 0.8 Y 41% — ″ — 215 10 Y 78% — 93% — 216 0.8 Y 58% — 87% — 217 0.8 Y 44% — ″ — 218 10 Y 80% — 93% — 219 0.8 Y 39% — 87% — 220 0.8 Y 13% — ″ — 221 10 Y 74% — 93% — 222 0.8 Y 36% — 87% — 223 0.8 Y 19% — 87% — 224 10 Y 86% — 93% — 225 0.8 Y 84% — 87% — 226 0.8 Y 80% — ″ — 227 10 Y 88% — 93% — 228 0.8 Y 83% — 87% — 229 0.8 Y 82% — 87% — 230 0.8 N 80% — 87% — 231 0.8 N 84% — 87% — 232 10 N 88% — 93% — 233 0.8 N 85% — 87% — 234 0.8 Y 73% — 87% — 235 10 Y 82% — 93% — 236 0.8 Y 89% — 87% — 237 0.8 Y 76% — 87% — 238 10 Y 65% — 93% — 239 0.8 Y 84% — 87% — 240 0.8 Y 56% — 87% — 2′OMethyl, 3′Phosphorothioate-modified sgRNA 241 10 N 92% — 92% — 242 0.8 N 84% — 87% — 243 0.8 Y 88% — 87% — 244 0.8 N 85% — 87% — 245 0.8 N 91% — 87% — 246 0.8 N 91% — 84% — 247 0.8 Y ≥85%  — ≥85%  — 248 0.8 N 84% — 84% — 249 0.8 Y 90% — 89% — 250 0.8 N 90%, 87% — 87%, 82% — 251 0.8 N 16%, 19% — 23%, 22% — 252 0.8 N 93% — 89% — 253 0.8 N 90%, 90% — 87%, 82% — 254 0.8 N 17%, 22% — 23%, 22% — 255 0.8 N 93% — 89% — 256 0.8 N 91%, 91% — 87%, 82% — 257 0.8 N 13%, 16% — 23%, 22% — 2′OMethyl, 3′PhosphorothioPACE-modified sgRNA 258 10 N 89% — 92% — 259 0.8 N 84% — 87% — 260 0.8 Y 80% — 87% — 261 0.8 N 77% — 87% — 262 0.8 N 83% — 87% — 263 0.8 N 92% — 87% — 264 0.8 Y 79% — 87% — 265 0.8 N 88% — 87% — 266 0.8 N 94% — 87% — 267 10 N 74% — 93% — 268 0.8 N 11% — 86% — 269 0.8 N 15% — ″ — 270 0.8 N 49% — ″ — 271 0.8 N 31% — ” — 272 0.8 N 91% — 84% — 273 0.8 Y 77% — ≥85%  — 274 0.8 N 90%, 91% — 87%, 82% — 275 0.8 N 9%, 8% — 23%, 22% — 276 0.8 N 90% — 84% — 277 0.8 Y ≥85%  — ≥85%  — 278 0.8 N 86%, 88% — 87%, 82% — 279 0.8 N 11%, 7%  — 23%, 22% — 2-aminoA-modified sgRNA(including unmodified controls) 280 0.8 Y 88%, 88% — 281 0.8 Y 76%, 75% — 282 0.8 Y 87%, 91% — 88%, 88% — 283 0.8 Y 90%, 90% — 76%, 75% — 284 0.8 Y 85%, 87% — 285 0.8 Y 88%, 88% — 286 0.8 Y 93%, 96% — 85%, 87% — 287 0.8 Y 82%, 79% — 88%, 88% — 5-methylU-modified sgRNA 288 0.8 N 86%, 83% — 87%, 82% — 289 0.8 N 11%, 11% — 23%, 22% — Z base-modified sgRNA 290 10 N 19% — 92% — 291 10 N 93% — ″ — sgRNA modified to disfavor misfolding 292 0.8 N 93% — 90% — 293 0.8 N 93% — 86% —

The results revealed that guide RNAs containing modifications at specific positions were tolerated by active Cas protein and gRNA:Cas protein complexes, as the modifications did not prevent target-specific cleavage of the on-target polynucleotide. The modifications that were tested and found to be tolerated at specific positions include 2′-O-methyribonucleotide (=2′OMe), 2-deoxyribonucleotide, racemic phosphorothioate internucleotide linkage, 3′-phosphonoacetate (=PACE), 3′-thiophosphonoacetate (=thioPACE), Z nucleotide, 2-thiouracil, 2-aminoadenine, 5-methyluracil, 5-aminoallyluracil coupled to Cy5 fluorophore, 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker, and combinations of these.

It is contemplated that the chemical modifications disclosed and tested herein, particularly at the tested positions (as listed in Tables 3 and 4), will be tolerated at equivalent positions in a variety of guide RNAs.

As disclosed herein, chemically modified nucleotides were incorporated into guide RNAs in an effort to improve certain properties. Such properties include improved nuclease resistance of the guide RNA (also known as improved stability), reduced off-target effects of a gRNA:Cas protein complex (also known as improved specificity), improved efficacy of gRNA:Cas protein complex when cleaving, nicking or binding a target polynucleotide, improved transfection efficiency, and/or improved organelle localization.

The assay results in Tables 3 and 4 indicate that: (1) In guide RNAs, many positions can tolerate a variety of chemical modifications; (2) 5′ and 3′ ends of guide RNAs will tolerate a wide variety of end-protecting modifications, and such modifications are useful to inhibit exonucleolytic RNA degradation; (3) 2-ThioU can be used to deter off-target interactions involving G-U wobble pairings, thereby increasing the specificity of guide pairing by inhibiting off-target hybridization interactions; (4) 5′ Extensions are generally well-tolerated; (5) Surface exposed regions of the guide RNA (as inferred from published crystal structures) are tolerant of extensively modifying U's to 5-methylU's, which potentially make the modified RNA more likely to elude immune responses such as stimulated by unmodified RNA; and (6) For RNA folding, G-C pairs are stronger and more stable than A-U pairs. At least one guide RNA is tolerant of replacing some G-C pairs with 2′-O-methylA-2′-O-methylU pairs that are more stable thermodynamically than unmodified A-U pairs.

More particularly, the present example shows that 2′-O-methyl modifications are tolerated at the 5′ and 3′ ends of dual-guide RNAs (as shown by entry 12 in Tables 3 and 4) and single-guide RNAs (entries 143-146, 169-170), thus allowing end-protection to stabilize gRNAs against exonucleases. 2′-O-methyl modifications are tolerated at most but not all internal positions, thus allowing stabilization against various nucleases including endonucleases (entries 146, 153-168, 174-179). However, the present example also demonstrates that not every position in guide RNAs will tolerate 2′-O-methyls (as shown by entries 151-152 and 171-173), suggesting that too many consecutive 2′-O-methyl modifications at the 5′ end (e.g., 26 or more consecutive 2′-O-methyl-modified nucleotides), or too many 2′-O-methyl modifications of C and U nucleotides downstream (3′) of the 5′-terminal 20mer guide sequence is not well tolerated (e.g., the inhibitory effect of one or both 2′-O-methyluracils at sequence positions+56 and +69 in entries 171-173 as revealed by the positions tested in entries 154-156).

The present example shows that 2′-O-methyl modifications throughout the 20mer guide sequence are tolerated during in vitro uses in buffer containing 10 mM Mg2+(entry 146), but such extensive modification is not well tolerated under physiological conditions (entries 147-150) as present in cells. Thus, in some embodiments, a gRNA comprising 15 or more, alternatively 17 or more, alternatively 18 or more, alternatively 20 2′-O-methyl modifications throughout the 20mer guide sequence is used for in vitro methods as described herein, such as genomic editing to modify a DNA sequence in vitro, regulating the expression of a gene of interest in vitro, cleaving a DNA target sequence in vitro, and other uses.

The present example shows that extensive incorporation of 2′-deoxy modifications is not well tolerated and can be substantially completely inhibitory (entries 180-182). However, 2′-deoxy modifications can be well-tolerated at some locations (entry 183), therefore such modification can be useful for inhibiting nucleases.

The present example also shows that fluorophore or dye labels are tolerated in every loop of the three known stem-loops in CRISPR-Cas9 guide RNAs (entry 116). Such labels are also tolerated in a 5′ overhang on the guide sequence (entry 114), tolerated at additional locations in sgRNAs (entry 114), and tolerated in a loop in tracrRNA used in dual-guide applications (entry 11). In this example, two different types of fluorophores were tested: a phosphodiester-linked fluorophore (no ribose ring) that essentially takes the place of a nucleotide (entries 114 & 116), and a dye label (Cy5) covalently coupled to 5-aminoallylU incorporated in a guide RNA (entry 11).

The present example also shows that Z bases are tolerated in synthetic guide RNAs, particularly as modifications of synthetic guide RNAs in which some C's are replaced with Z bases (entries 290-291). The present example also shows that several other bases are tolerated at various positions, as shown in Tables 3 and 4.

The present example further shows that the 5′ and 3′ ends of guide RNAs can tolerate a wide variety of end-protecting modifications. Such modifications can be used to inhibit exonucleolytic RNA degradation. Support for the tolerance of such modifications can be found in Hendel et al., Nat. Biotechnol. (2015) 33:9, 985-9. Additional support for modifications at the 5′ and 3′ ends of guide RNAs is provided by entries 143-144, 185-223, 241-257, 258-266, and 272-279 in Tables 3 and 4. In some embodiments, the guide RNA comprises 7 or fewer modified nucleotides at a 5′ end or a 3′ end or at each of 5′ and 3′ ends, alternatively 6 or fewer, alternatively 5 or fewer, alternatively 4 or fewer, alternatively 3 or fewer, alternatively 2 or fewer, alternatively 1. Dual-guide RNAs can be protected similarly (entries 12-15).

The present example further shows that 2-thioU can be used to deter off-target interactions involving G-U wobble pairings, thereby increasing the specificity of guide sequence pairing by inhibiting off-target hybridization interactions (entries 16-39). One of the base pairs involved in hybridization between the guide RNA and CLTA1 OFF-target 3 (also referred to as “CLTA1 OFF3-target” or “CLTA1 OFF3”) is a G-U wobble pair. Replacing the corresponding U in the guide RNA with a 2-thioU reduces cleavage from 100% (entry 8) to 59% (entry 39). Replacing other U's with 2-thioU's (e.g., at sequence position+3 or +9, entries 23 and 31) does not have the same effect, presumably because those U's do not involve G-U wobble pairing when fully hybridized to each of the OFF-target sites tested. Accordingly, 2-thioU can increase target specificity of guide RNAs when off-target sites involve G-U wobble pairing.

The present example also shows that 5′-overhang sequences attached to the guide sequence are generally well-tolerated (see entries 83-95, 114, and 206-223). For example, a bulky dimethoxytrityl (dmt) group at the 5′ end was well tolerated (entry 95). The chromatographic properties of dmt can be used to facilitate purification of full-length synthetic RNAs from incompletely elongated byproducts which are generally produced during synthesis. Accordingly, in some embodiments, the synthetic guide RNA comprises a 5′-overhang sequence, for example, comprising a short polynucleotide sequence of 15 or fewer nucleotides which is complementary to the guide sequence and is covalently linked at its 3′ end to the 5′ end of the guide sequence by a polymeric linker such as a polynucleotide or similarphosphodiester-based linker, in which the linker can be 5 or more consecutive uridine nucleotides, alternatively 6 or 7.

The present example also shows that surface exposed regions of the guide RNA (as inferred from crystal structures published by others) are tolerant of extensively modifying uracils nucleotides to 5-methyluracils (5-methylU's) (entry 288), which can make the modified RNA more likely to elude immune responses such as stimulated by unmodified RNA. In particular, the 5′ and 3′ ends of a synthetic guide RNA are potentially immunostimulatory, and the present example shows that 5′ and 3′ ends are tolerant of 5-methylU modifications (entry 288).

The present example also shows that a synthetic guide RNA is tolerant of replacing some G-C pairs with 2′-O-methylA-2′-O-methylU pairs which are more stable thermodynamically than unmodified A-U pairs (see the non-terminal -2′-O-methylU and complementary -2′-O-methylA modifications in entries 292-293). This is advantageous because it is known that, for folded RNAs, G-C pairs are stronger and more stable than A-U pairs. Replacement of G-C pairs with such thermostabilized A-U pairs in synthetic guide RNAs allows for improved folding of active structures by preventing misfolded structures that involve unintended G-C pair(s), as can be predicted by RNA folding algorithms in common use.

EXEMPLARY EMBODIMENTS

Exemplary embodiments provided in accordance with the presently disclosed subject matter include, but are not limited to, the claims and the following embodiments:

A1. A synthetic guide RNA comprising:

-   -   a crRNA segment comprising (i) a guide sequence capable of         hybridizing to a target sequence, (ii) a stem sequence; and     -   a tracrRNA segment comprising a nucleotide sequence that is         partially or completely complementary to the stem sequence,         wherein the synthetic guide RNA comprises at least one modified         nucleotide, and wherein the synthetic guide RNA has gRNA         functionality.

A2. The synthetic guide RNA of embodiment A1, comprising a 2′-deoxy moiety.

A3. The synthetic guide RNA of embodiment A1 or A2, comprising a 2′-halo moiety selected from 2′-fluoro, 2′-chloro, 2′-bromo and 2′-iodo.

A4. The synthetic guide RNA of any one of the preceding embodiments, comprising a phosphorothioate group.

A5. The synthetic guide RNA of any one of the preceding embodiments, comprising a PACE group.

A6. The synthetic guide RNA of any one of the preceding embodiments, comprising a thioPACE group.

A7. The synthetic guide RNA of any one of embodiments A2-A6, comprising a 2′-O-methyl moiety.

A8. The synthetic guide RNA of any one of the preceding embodiments, comprising a 2-thiouracil.

A9. The synthetic guide RNA of any one of the preceding embodiments, comprising a 4-thiouracil.

A10. The synthetic guide RNA of any one of the preceding embodiments, comprising a 2-aminoadenine.

A11. The synthetic guide RNA of any one of the preceding embodiments, comprising a hypoxanthine.

A12. The synthetic guide RNA of any one of the preceding embodiments, comprising a 5-methylcytosine.

A13. The synthetic guide RNA of any one of the preceding embodiments, comprising a 5-methyluracil.

A14. The synthetic guide RNA of any one of the preceding embodiments, comprising a 5-aminoallyl-uracil.

A15. The synthetic guide RNA of any one of the preceding embodiments, comprising a Z ribonucleotide.

A16. The synthetic guide RNA of any one of the preceding embodiments, comprising a Z deoxyribonucleotide.

A17. The synthetic guide RNA of any one of the preceding embodiments, comprising a squarate conjugation.

A18. The synthetic guide RNA of any one of the preceding embodiments, comprising a dye linker.

A19. The synthetic guide RNA of embodiment A18, wherein the dye linker is 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker.

A20. The synthetic guide RNA of any one of the preceding embodiments, comprising a nucleotide with 2′-O-methyl and 3′-phosphorothioate.

A21. The synthetic guide RNA of any one of the preceding embodiments, comprising a nucleotide with 2′-O-methyl and 3″-PACE.

A22. The synthetic guide RNA of any one of the preceding embodiments, comprising a nucleotide with 2′-O-methyl and 3′-thioPACE.

A23. The synthetic guide RNA of any one of the preceding embodiments, comprising a nucleotide with 2′-deoxy and 3′-PACE.

A24. The synthetic guide RNA of any one of the preceding embodiments, comprising a 5-methylcytidine.

A25. The synthetic guide RNA of any one of the preceding embodiments, comprising a methylphosphonate.

A26. The synthetic guide RNA of any one of the preceding embodiments, comprising an ester of PACE, wherein the ester is optionally a methyl ester.

A27. The synthetic guide RNA of any one of the preceding embodiments, comprising a a single RNA strand comprising both the cr RNA segment and the tracr RNA segment.

A28. The synthetic guide RNA of any one of embodiments A1-A26, comprising two RNA strands, and the cr RNA segment and the tracr RNA segment are in different RNA strands.

A29. The synthetic guide RNA of any one of the preceding embodiments, comprising a modified nucleotide at a 5′ end, 3′ end, or both 5′ end and 3′ end of each RNA strand.

A30. The synthetic guide RNA of any one of the preceding embodiments, comprising a modified nucleotide in the guide sequence.

A31. The synthetic guide RNA of any one of the preceding embodiments, comprising a modified nucleotide 5′ to the guide sequence.

A32. The synthetic guide RNA of any one of the preceding embodiments, comprising a modified nucleotide in the stem sequence.

A33. The synthetic guide RNA of any one of the preceding embodiments, comprising a modified nucleotide in the scaffold region.

A34. The synthetic guide RNA of any one of the preceding embodiments, comprising at least one unnatural, orthogonal base pair in the scaffold region, wherein the base pair is independently selected from isoG-isoC and Z base-P base.

A35. The synthetic guide RNA of any one of the preceding embodiments, comprising a 2′-amino group.

A36. The synthetic guide RNA of any one of the preceding embodiments, comprising a phosphorodithioate linkage group.

A37. The synthetic guide RNA of any one of the preceding embodiments, comprising a boranophosphonate linkage group.

A38. The synthetic guide RNA of any one of the preceding embodiments, comprising an unlocked nucleic acid modification (ULNA).

A39. The synthetic guide RNA of any one of the preceding embodiments, comprising a locked nucleic acid modification (LNA).

A40. The synthetic guide RNA of any one of the preceding embodiments, comprising an unstructured nucleic acid modification (UNA).

A41. The synthetic guide RNA of any one of the preceding embodiments, comprising a pseudoU.

A42. The synthetic guide RNA of any one of the preceding embodiments, comprising a 2′-MOE.

A43. The synthetic guide RNA of any one of the preceding embodiments, comprising a 2′-arabino.

A44. The synthetic guide RNA of any one of the preceding embodiments, comprising a 4′-thioribose.

A45. The synthetic guide RNA of any one of the preceding embodiments, comprising a squarate linkage

A46. The synthetic guide RNA of any one of the preceding embodiments, comprising a triazaolo linkage.

A47. A method for cleaving or nicking a target polynucleotide comprising contacting the target polynucleotide with a CRISPR-associated protein and the synthetic guide RNA of any one of the preceding embodiments, and cleaving or nicking the target polynucleotide.

A48. The method of embodiment A47, wherein the cleaving or nicking takes place in vitro.

A49. The method of embodiment A47, wherein the cleaving or nicking takes place in a cell.

A50. The method of embodiment A47, wherein the cleaving or nicking takes place in vivo.

A51. The method of any one of embodiments A47-A50, wherein the CRISPR-associated protein is Cas9.

A52. The method of any one of embodiments A47-A51, wherein the cleaving or nicking results in gene editing.

A53. The method of any one of embodiments A47-A52, wherein the cleaving or nicking results in alteration of gene expression.

A54. A method for binding a target polynucleotide comprising contacting the target polynucleotide with a CRISPR-associated protein and the synthetic guide RNA of any one of the preceding embodiments,

A55. The method of embodiment A54, wherein the CRISPR-associated protein comprises a mutant which does not have a cleavage or nicking activity.

A56. The method of embodiment A54 or A55, wherein the CRISPR-associated protein is a fusion protein comprising a protein component not naturally existing in a CRISPR system.

A57. The method of any one of embodiments A54 to A56, resulting in a change of expression of the target polynucleotide.

A58. The method of any one of embodiments A54 to A57 useful to tag the target polynucleotide.

Further Exemplary Embodiments

B1. A synthetic guide RNA comprising:

-   -   (a) a crRNA segment comprising (i) a guide sequence capable of         hybridizing to a target sequence in a polynucleotide, (ii) a         stem sequence; and     -   (b) a tracrRNA segment comprising a nucleotide sequence that is         partially or completely complementary to the stem sequence,         wherein the synthetic guide RNA comprises one or more         modifications, and wherein the synthetic guide RNA has gRNA         functionality.

B2. The synthetic guide RNA of embodiment 1, comprising a 2′-O-methyl moiety, a 2′-deoxy moiety, a Z base, a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a thiophosphonoacetate internucleotide linkage, or combinations thereof.

B3. The synthetic guide RNA of embodiment 1 or 2, comprising one or more modifications selected from the group consisting of a 2′-O-methyl nucleotide with a 3′-phosphorothioate group, a 2′-O-methyl nucleotide with a 3′-phosphonocarboxylate group, a 2′-O-methyl nucleotide with a 3′-phosphonoacetate group, a 2′-O-methyl nucleotide with a 3′-thiophosphonocarboxylate group, a 2′-O-methyl nucleotide with a 3′-thiophosphonoacetate group, a 2′-deoxy nucleotide with a 3′-phosphonoacetate group, a 2′-deoxy nucleotide with a 3′-thiophosphonoacetate group, and a Z base.

B4. The synthetic guide RNA of embodiment 1, 2 or 3, comprising one or more modifications selected from the group consisting of a 2′-fluororibosyl, a 2-thiouracil base, a 4-thiouracil base, a 2-aminoadenine base, an hypoxanthine base, a 5-methylcytosine base, a 5-methyluracil base, a methylphosphonate internucleotide linkage, a 5-aminoallyluracil base, a squarate linkage, a triazolo linkage, a dye conjugated to a nucleotide, and combinations thereof.

B5. The synthetic guide RNA of any of the preceding embodiments, comprising a modification selected from the group consisting of a 2′-MOE, 2′-amino, 2′-F-arabino, 2′-LNA, 2′-ULNA, 3′-methylphosphonate, 3′-boranophosphonate, 3′-phosphorodithioate, 2′-OMe-3′-P(S)₂, 2′-OMe-3′-P(CH₃), 2′-OMe-3′-P(BH₃), 4′-thioribosyl, L-sugar, 2-thiocytosine, 6-thioguanine, 2-aminopurine, pseudouracil, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allyluracil, 5-allylcytosine, 5-allylaminocytosine, P nucleobase, isocytosine (isoC), isoguanine (isoG),UNA, x(A,G,C,T), y(A,G,C,T), abasic nucleotide, PEG, hydrocarbon linker, halo-substituted hydrocarbon linker, heteroatom (O,N,S)-substituted hydrocarbon linker, (keto, carboxy, amido, thionyl, carbamoyl, or thionocarbamoyl)-containing hydrocarbon linker, spermine linker, and combinations thereof.

B6. The synthetic guide RNA of any one of the preceding embodiments, comprising a stability-enhancing modification.

B7. The synthetic guide RNA of any one of the preceding embodiments, comprising at least two modifications; wherein a first modification is a stability-enhancing modification and a second modification is a specificity-altering modification.

B8. The synthetic guide RNA of embodiment 6 or 7, wherein the stability-enhancing modification is located in the guide sequence.

B9. The synthetic guide RNA of embodiment 6 or 7, wherein the stability-enhancing modification is located upstream of the guide sequence.

B10. The synthetic guide RNA of embodiment 6 or 7, wherein the stability-enhancing modification is located within the first five and/or the last five nucleotides of the crRNA segment.

B11. The synthetic guide RNA of embodiment 6 or 7, wherein the stability-enhancing modification is located in the tracrRNA segment.

B12. The synthetic guide RNA of embodiment 6 or 7, wherein the stability-enhancing modification is located within the first five and/or the last five nucleotides of the tracrRNA segment.

B13. The synthetic guide RNA of any one of embodiments 6-12, wherein the stability-enhancing modification comprises a 2′-O-methyl moiety, a 2′-fluoro moiety, or a 2′-deoxy moiety.

B14. The synthetic guide RNA of any one of embodiments 6-13, wherein the stability-enhancing modification comprises a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a thiophosphonoacetate internucleotide linkage, a methylphosphonate internucleotide linkage, a boranophosphate internucleotide linkage, or a phosphorodithioate internucleotide linkage.

B15. The synthetic guide RNA of any one of embodiments 6-14, wherein the stability-enhancing modification comprises a 3′-phosphonoacetate or a 3′-thiophosphonoacetate.

B16. The synthetic guide RNA any one of embodiments 6-15, wherein the stability-enhancing modification comprises a 2′-O-methyl-3′-phosphorothioate nucleotide, a 2′-O-methyl-3′-phosphonoacetate nucleotide, or a 2′-O-methyl-3′-thiophosphonoacetate nucleotide.

B17. The synthetic guide RNA of any one of embodiments 6-16, wherein the stability-enhancing modification comprises a 2′-fluoro-3′-phosphorothioate nucleotide, a 2′-fluoro-3′-phosphonoacetate nucleotide, or a 2′-fluoro-3′-thiophosphonoacetate nucleotide.

B18. The synthetic guide RNA of any one of the preceding embodiments, comprising a specificity-altering modification.

B19. The synthetic guide RNA of embodiment 18, wherein the specificity-altering modification is located in the guide sequence.

B20. The synthetic guide RNA of any one of embodiment 18 or 19, wherein the specificity-altering modification comprises a 2-thiouracil, a 4-thiouracil or a 2-aminoadenine.

B21. The synthetic guide RNA of any one of embodiments 18-20, wherein the specificity-altering modification comprises a phosphorothioate internucleotide linkage, a phosphonoacetate internucleotide linkage, a thiophosphonoacetate internucleotide linkage, a methylphosphonate internucleotide linkage, a boranophosphate internucleotide linkage, or a phosphorodithioate internucleotide linkage.

B22. The synthetic guide RNA of any one of embodiments 18-21, wherein the specificity-altering modification comprises a 3-phosphonoacetate or a 3-thiophosphonoacetate.

B23. The synthetic guide RNA of any one of the preceding embodiments, comprising a fluorescent dye or a label.

B24. The synthetic guide RNA of any one of the preceding embodiments, comprising one or more isotopic labels.

B25. The synthetic guide RNA of any one of the preceding embodiments, wherein the guide RNA is conjugated to an oligonucleotide, an aptamer, an amino acid, a peptide, a protein, a steroid, a lipid, a folic acid, a vitamin, a sugar, or an oligosaccharide.

B26. The synthetic guide RNA of any one of the preceding embodiments, wherein the synthetic guide RNA is a single guide RNA, wherein the crRNA segment and the tracrRNA segment are linked through a loop L.

B27. The synthetic guide RNA of embodiment 26, wherein the loop L comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.

B28. The synthetic guide RNA of embodiment 26 or 27, wherein the loop L comprises a nucleotide sequence of GNRA, wherein N represents A, C, G, or U and R represents A or G.

B29. The synthetic guide RNA of embodiment 26, 27 or 28, wherein the loop L comprises a nucleotide sequence of GAAA.

B30. The synthetic guide RNA of any one of embodiments 26-29, wherein the loop L comprises one or more modified nucleotides.

B31. The synthetic guide RNA of embodiment 30, wherein the loop L comprises a fluorescent dye.

B32. The synthetic guide RNA of embodiment 31, wherein the dye is conjugated to a 2-(4-butylamido-dye)propane-1,3-diol bis(phosphodiester) linker.

B33. The synthetic guide RNA of any one of the preceding embodiments, wherein the crRNA segment is at the 5′ end of the guide RNA.

B34. The synthetic guide RNA of any one of the preceding embodiments, wherein the tracrRNA segment is at the 3′ end of the guide RNA.

B35. The synthetic guide RNA of any of the preceding embodiments, wherein the crRNA segment comprises from 25 to 70 nucleotides.

B36. The synthetic guide RNA of any of the preceding embodiments, wherein the guide sequence comprises from 15 to 30 nucleotides.

B37. The synthetic guide RNA of any of the preceding embodiments, wherein the stem sequence comprises from 10 to 50 nucleotides.

B38. The synthetic guide RNA of any of the preceding embodiments, comprising one or more triazolo linkage(s).

B39. The synthetic guide RNA of any of the preceding embodiments, comprising one or more squarate linkage(s).

B40. The synthetic guide RNA of any of the preceding embodiments, wherein the guide RNA comprises a nucleotide composition of:

M_(m)N_(n)

wherein each N independently represents an unmodified nucleotide and each M is selected from a 2′-O-methyl ribonucleotide, a 2′-O-methyl-3′-P(S) ribonucleotide, a 2′-O-methyl-3′-PACE ribonucleotide, a 2′-O-methyl-3′-thioPACE ribonucleotide, and a 2′-deoxynucleotide;

wherein each M is at any position in the sequence of the guide RNA; and

wherein m is an integer between 1 and 220, and n is an integer between 0 and 219, and 50<m+n≤220.

B41. The synthetic guide RNA of embodiment 38, wherein m+n<150, and each of m and n are independently selected from an integer between 0 and 150, provided that m is not 0.

B42. The synthetic guide RNA of any of the preceding embodiments, wherein the guide RNA comprises a nucleotide sequence of:

M_(m)N_(n)M′_(m′)N′_(n′)M″_(m″)

wherein each M, M′ and M″ independently represent a modified nucleotide and each N and N′ independently represent an unmodified ribonucleotide;

wherein any given M is the same or different from any other M, any given N is the same or different from any other N, any given M′ is the same or different from any other M′, any given N′ is the same or different from any other N′, any given M″ is the same or different from any other M″; and

wherein m is an integer between 0 and 40, n is an integer between 20 and 130, m′ is an integer between 0 and 10, n′ is an integer between 0 and 50, m″ is an integer between 0 and 10, provided that m+m′+m″ is greater than or equal to 1.

B43. The synthetic guide RNA of any of the preceding embodiments, wherein the crRNA segment comprises a nucleotide sequence of:

M_(m)N_(n)M′_(m′)N′_(n),

wherein M and M′ each represent a modified nucleotide and N and N′ each represent an unmodified ribonucleotide;

wherein any given M is the same or different from any other M, any given N is the same or different from any other N, any given M′ is the same or different from any other M′, any given N′ is the same or different from any other N′; and

wherein n and n′ are each independently selected from an integer between 0 and 50, and

wherein m and m′ are each independently selected from an integer between 0 and 25, provided that m+m′ is greater than or equal to 1.

B44. The synthetic guide RNA of any of the preceding embodiments, wherein the guide sequence comprises a nucleotide sequence of:

M_(m)N_(n)M′_(m′)N′_(n),

wherein M and M′ each represent a modified nucleotide and N and N′ each represent an unmodified ribonucleotide;

wherein any given M is the same or different from any other M, any given N is the same or different from any other N, any given M′ is the same or different from any other M′, any given N′ is the same or different from any other N′; and

wherein m, n, m′, and n′ are each independently selected from an integer between 0 and 40, provided that m+m′ is greater than or equal to 1.

B45. The synthetic guide RNA of any of the preceding embodiments, wherein the tracrRNA segment comprises a nucleotide sequence of:

N_(m)M_(m)N′_(n′)M′_(m′)

wherein M and M′ each represent a modified nucleotide and N and N′ each represent an unmodified ribonucleotide;

wherein any given M is the same or different from any other M, any given N is the same or different from any other N, any given M′ is the same or different from any other M′, any given N′ is the same or different from any other N′; and

wherein n is an integer between 0 and 130 m is an integer between 0 and 40, and n′ is an integer between 0 and 130, and m′ is an integer between 0 and 40, provided that m+m′ is greater than or equal to 1.

B46. The synthetic guide RNA of any one of embodiments 40-43, wherein m, m′, m+m′, or m+m+m″ is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

B47. The synthetic guide RNA of any one of embodiments 40-43, wherein m, m′, m+m′, or m+m′+m″ is 1, 2, 3, 4, 5, or 6.

B48. The synthetic guide RNA of any one of embodiments 40-45, wherein n is 16, 17, 18, or 19.

B49. The synthetic guide RNA of any one of embodiments 40-45, wherein n, n′, or n+n′ is an integer between 75 and 115.

B50. The synthetic guide RNA of any one of embodiments 40-47, wherein each M is independently selected from the group consisting of a 2′-modified nucleotide, a 3′-modified nucleotide, and combinations thereof.

B51. The synthetic guide RNA of embodiment 48, wherein the 2′-modified nucleotide is selected from the group consisting of a 2′-deoxy nucleotide, a 2′-O-methyl nucleotide, a 2′-fluoro nucleotide, and a 2′-O—C₁₋₃alkyl-O—C₁₋₃alkyl nucleotide.

B52. The synthetic guide RNA of embodiment 48, wherein the 3′-modified nucleotide is selected from the group consisting of a 3′-phosphonoacetate nucleotide and a 3′-thiophosphonoacetate nucleotide.

B53. The synthetic guide RNA of embodiment 48, wherein the combination of the 2′-modified nucleotide and the 3′-modified nucleotide comprises a 2′-O-methyl-3′-phosphorothioate nucleotide, a 2′-O-methyl-3′-phosphonoacetate nucleotide, or a 2′-O-methyl-3′-thiophosphonoacetate nucleotide.

B54. A method for cleaving a target polynucleotide comprising contacting the target polynucleotide with a CRISPR-associated protein and the synthetic guide RNA of any one of the preceding embodiments and cleaving the target polynucleotide.

B55. The method of embodiment 52, further comprising contacting the target polynucleotide with an exogenous CRISPR-associated protein.

B56. The method of embodiment 53, wherein the CRISPR-associated protein is Cas9.

B57. The method of any one of embodiments 52-54, wherein the cleavage results in a functional knockout of a target gene.

B58. The method of any one of embodiments 52-55, further comprising repairing the cleaved target polynucleotide by homology-directed repair with an exogenous or endogenous template polynucleotide.

B59. The method of embodiment 56, wherein the exogenous or endogenous template polynucleotide comprises at least one sequence having substantial sequence identity with a sequence on either side of the cleavage site.

B60. The method of any one of embodiments 52-57, further comprising repairing the cleaved target polynucleotide by non-homologous end joining.

B61. The method of any one of embodiments 56-58, wherein the repairing step produces an insertion, deletion, or substitution of one or more nucleotides of the target polynucleotide.

B62. The method of embodiment 59, wherein the insertion, deletion, or substitution results in one or more amino acid changes in a protein expressed from a gene comprising the target polynucleotide.

B63. The method of any one of embodiments 52-60, wherein the target polynucleotide is contacted with the CRISPR-associated protein and the synthetic guide RNA in vitro.

B64. The method of any one of embodiments 52-61, wherein the target polynucleotide contacted with the CRISPR-associated protein and the synthetic guide RNA is within the genome of a cell in vitro or in vivo.

B65. The method of embodiment 62, wherein the cell is isolated from a multicellular source prior to contacting the target polynucleotide with the CRISPR-associated protein and the synthetic guide RNA.

B66. The method of embodiment 63, wherein the source is a plant, an animal, a multicellular protist, or a fungus.

B67. The method of any one of embodiments 62-64, wherein the cell, or a cell derived therefrom, is returned to the source after contacting the target polynucleotide with the CRISPR-associated protein and the synthetic guide RNA.

B68. A method of modifying a target polynucleotide in a cell comprising introducing into the cell the synthetic guide RNA of any one of embodiments 1-51 and introducing into the cell a CRISPR-associated protein or a nucleic acid that expresses a CRISPR-associated protein in the cell.

B69. The method of embodiment 66, wherein the CRISPR-associated-protein is Cas9.

B70. A method of altering expression of at least one gene product in a cell comprising introducing into the cell the synthetic guide RNA of any one of embodiments 1-51 and further introducing into the cell a CRISPR-associated-protein or a nucleic acid that expresses a CRISPR-associated protein in the cell, wherein the cell contains and expresses a DNA molecule having a target sequence and encoding the gene product.

B71. The method of embodiment 68, wherein the CRISPR-associated-protein is Cas9.

B72. The method of embodiment 69, wherein the CRISPR-associated-protein cleaves the DNA molecule.

B73. A set or library of RNA molecules comprising two or more synthetic guide RNAs of any one of embodiments 1-51.

B74. A kit comprising the synthetic guide RNA of any one of embodiments 1-51 or the set or library of RNA molecules of embodiment 71.

B75. The kit of embodiment 72, further comprising a CRISPR-associated protein or a nucleic acid encoding the CRISPR-associated protein.

B76. The kit of embodiment 73, wherein the CRISPR-associated-protein is Cas9.

B77. The synthetic guide RNA, method or kit of any of the preceding embodiments, wherein the synthetic guide RNA comprises an end modification.

B78. The synthetic guide RNA of any of the preceding embodiments, having a single RNA strand or two separate complementary RNA strands, wherein the guide RNA comprises at least one stability-enhancing modification at both ends of each RNA strand.

C1. A synthetic guide RNA comprising:

-   -   (a) a crRNA segment comprising (i) a guide sequence capable of         hybridizing to a target sequence in a polynucleotide, (ii) a         stem sequence; and     -   (b) a tracrRNA segment comprising a nucleotide sequence that is         partially or completely complementary to the stem sequence,         wherein the synthetic guide RNA comprises one or more         modifications, and wherein the synthetic guide RNA has gRNA         functionality.

C2. The synthetic guide RNA of embodiment C1, wherein one or more of the modifications comprises a stability-enhancing modification.

C3. The synthetic guide RNA of embodiment C2, wherein one or more of the stability-enhancing modifications is located in the guide sequence.

C4. The synthetic guide RNA of embodiment C2, wherein the stability-enhancing modification comprises a 2′-O-methyl moiety, a Z base, a 2′-deoxy nucleotide, a phosphorothioate internucleotide linkage, a phosphonoacetate (PACE) internucleotide linkage, or a thiophosphonoacetate (thioPACE) internucleotide linkage, or combinations thereof.

C5. The synthetic guide RNA of any of the foregoing embodiments, comprising less than 26 consecutive 2′-O-methyl modified nucleotides at a 5′ end of the guide RNA.

C6. The synthetic guide RNA of any of the foregoing embodiments, comprising a Z base replacing a cytosine in the synthetic guide RNA.

C7. The synthetic guide RNA of any of the foregoing embodiments, comprising at least one 2-thiouracil at a position corresponding to a uridine that can engage in U-G wobble pairing with a potential off-target sequence.

C8. The synthetic guide RNA of any of the foregoing embodiments, comprising one or more modifications selected from the group consisting of a 2′-O-methyl nucleotide with a 3′-phosphorothioate group, a 2′-O-methyl nucleotide with a 3′-phosphonoacetate group, a 2′-O-methyl nucleotide with a 3′-thiophosphonoacetate group, and a 2′-deoxy nucleotide with a 3′-phosphonoacetate group.

C9. The synthetic guide RNA of any of the foregoing embodiments, comprising at least two modifications.

C10. The synthetic guide RNA any of the foregoing embodiments, comprising up to 50 modifications.

C11. The synthetic guide RNA of any of the foregoing embodiments, comprising a single RNA strand or two separate RNA strands, and one or more modifications at a 5′ end of each RNA strand, at a 3′ end of each RNA strand, or at both a 5′ end and a 3′ end of each RNA strand.

C12. The synthetic guide RNA of any of the foregoing embodiments, comprising 7 or fewer consecutive modified nucleotides at a 5′ end or at a 3′ end or at each of 5′ and 3′ ends.

C13. The synthetic guide RNA of any of the foregoing embodiments, comprising one or more 5-methyluridine nucleotides at one or more of a 5′ end, a 3′ end, or a stem-loop.

C14. The synthetic guide RNA of any of the foregoing embodiments, wherein one or more of the modifications alters base-pairing thermostability.

C15. The synthetic guide RNA of embodiment C14, wherein said one or more modifications enhances the base-pairing thermostability.

C16. The synthetic guide RNA of embodiment C15, wherein said one or more modifications is independently selected from a 2-thiouracil (2-thioU), a 4-thiouracil (4-thioU), a 2-aminoadenine, a 2′-O-methyl, a 2′-fluoro, a 5-methyluridine, a 5-methylcytidine, and a locked nucleic acid modification (LNA).

C17. The synthetic guide RNA of embodiment C15, wherein said one or more modifications decreases the base-pairing thermostability.

C18. The synthetic guide RNA of embodiment C17, wherein said one or more modifications is independently selected from a 2-thiouracil, a 2′-deoxy, a phosphorothioate linkage, a phosphorodithioate linkage, a boranophosphonate linkage, a phosphonoacetate linkage, a thiophosphonoacetate linkage, and an unlocked nucleic acid modification (ULNA).

C19. The synthetic guide RNA of any of the foregoing embodiments, comprising one or more 2′-O-methylA-2′-O-methylU base pairs.

C20. The synthetic guide RNA of any of the foregoing embodiments, wherein one or more of the modifications is a specificity-altering modification.

C21. The synthetic guide RNA of embodiment C20, wherein the specificity-altering modification is located in the guide sequence.

C22. The synthetic guide RNA of any of the foregoing embodiments, wherein the specificity-altering modification comprises a 2-thiouracil, a 4-thiouracil, a 2-aminoadenine, a 2′-O-methyl, a 2′-fluoro, a LNA, a phosphorothioate linkage, a phosphorodithioate linkage, a boranophosphonate linkage, a phosphonoacetate linkage, a thiophosphonoacetate linkage, an ULNA, a 2′-deoxy, a 5-methyluridine, a 5-methylcytidine, or combinations thereof.

C23. The synthetic guide RNA of any of the foregoing embodiments, comprising a fluorescent dye or a label.

C24. The synthetic guide RNA of embodiment C23, wherein the fluorescent dye or a label is bound to a stem-loop of the synthetic guide RNA.

C25. A method for genomic editing to modify a DNA sequence, or regulating the expression of a gene of interest, or cleaving a target polynucleotide comprising: contacting the DNA sequence, the gene of interest, or the target polynucleotide with a CRISPR-associated protein and the synthetic guide RNA of any of the foregoing embodiments, and editing, regulating or cleaving the DNA sequence, the gene of interest or the target polynucleotide.

C26. The method of embodiment C25, wherein the method is performed in vitro, and the synthetic guide RNA comprises 15 or more 2′-O-methyl modifications throughout the guide sequence.

C27. A set or library of RNA molecules comprising two or more synthetic guide RNAs of any of the foregoing embodiments.

C28. A kit comprising the synthetic guide RNA of any of the foregoing embodiments.

C29. An array of RNA molecules comprising two or more synthetic guide RNAs of any of the foregoing embodiments.

The foregoing description of exemplary or preferred embodiments should be taken as illustrating, rather than as limiting, the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the scope of the invention, and all such variations are intended to be included within the scope of the following claims. All references cited herein are incorporated by reference in their entireties. 

We claim:
 1. A synthetic guide RNA comprising: (c) a crRNA segment comprising (i) a guide sequence capable of hybridizing to a target sequence in a polynucleotide, (ii) a stem sequence; and (d) a tracrRNA segment comprising a nucleotide sequence that is partially or completely complementary to the stem sequence, wherein the synthetic guide RNA comprises one or more modifications, and wherein the synthetic guide RNA has gRNA functionality.
 2. The synthetic guide RNA of claim 1, wherein one or more of the modifications comprises a stability-enhancing modification.
 3. The synthetic guide RNA of claim 2, wherein one or more of the stability-enhancing modifications is located in the guide sequence.
 4. The synthetic guide RNA of claim 1, comprising less than 26 consecutive 2′-O-methyl modified nucleotides at a 5′ end of the guide RNA.
 5. The synthetic guide RNA of claim 1, comprising a Z base replacing a cytosine in the synthetic guide RNA.
 6. The synthetic guide RNA of claim 1, comprising at least one 2-thiouracil at a position corresponding to a uridine that can engage in U-G wobble pairing with a potential off-target sequence.
 7. The synthetic guide RNA of claim 1, comprising one or more modifications selected from the group consisting of a 2′-O-methyl nucleotide with a 3′-phosphorothioate group, a 2′-O-methyl nucleotide with a 3′-phosphonoacetate group, a 2′-O-methyl nucleotide with a 3′-thiophosphonoacetate group, and a 2′-deoxy nucleotide with a 3′-phosphonoacetate group.
 8. The synthetic guide RNA of claim 1, comprising at least two modifications.
 9. The synthetic guide RNA of claim 1, comprising up to 50 modifications.
 10. The synthetic guide RNA of claim 1, comprising a single RNA strand or two separate RNA strands, and one or more modifications at a 5′ end of each RNA strand, at a 3′ end of each RNA strand, or at both a 5′ end and a 3′ end of each RNA strand.
 11. The synthetic guide RNA of claim 1, wherein one or more of the modifications alters base-pairing thermostability.
 12. The synthetic guide RNA of claim 11, wherein said one or more modifications enhances the base-pairing thermostability.
 13. The synthetic guide RNA of claim 11, wherein said one or more modifications decreases the base-pairing thermostability.
 14. The synthetic guide RNA of claim 1, comprising one or more 2′-O-methylA-2′-O-methylU base pairs.
 15. The synthetic guide RNA of claim 1, wherein one or more of the modifications is a specificity-altering modification.
 16. A method for genomic editing to modify a DNA sequence, or regulating the expression of a gene of interest, or cleaving a target polynucleotide comprising: contacting the DNA sequence, the gene of interest, or the target polynucleotide with a CRISPR-associated protein and the synthetic guide RNA of any of the foregoing claims, and editing, regulating or cleaving the DNA sequence, the gene of interest or the target polynucleotide.
 17. The method of claim 16, wherein the method is performed in vitro, and the synthetic guide RNA comprises 15 or more 2′-O-methyl modifications throughout the guide sequence.
 18. A set or library of RNA molecules comprising two or more synthetic guide RNAs of claim
 1. 19. A kit comprising the synthetic guide RNA of claim
 1. 20. An array of RNA molecules comprising two or more synthetic guide RNAs of claim
 1. 